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Summary  
Summary 
 
The molecular biology of affective disorders is still poorly understood. Affective 
disorders like major depression or post-traumatic stress disorder are known to 
be heterogeneous disorders and are believed to arise from a complex interplay 
of multiple genes and environmental triggering factors. Due to the 
heterogeneous and polygenic nature of these disorders, they are also difficult 
to treat effectively. In the case of depression, only as few as 20% of the 
affected individuals show full remission with the current antidepressants. This 
might be related to the fact that ”biomedical research in the field of psychiatry 
has remained focused on treatment targets that were identified” more or less 
by chance “half a century ago. Almost all available drugs target primarily 
monoamine transporter and receptors, in various combinations, leading to 
slightly different profiles. However, these differences rarely have a clinically 
relevant impact in terms of efficacy or safety. Moreover, the targets have not 
to this day proven to be at the core of the pathophysiology of the major 
psychiatric disorders” (3). 
 
Thus, there is clearly a need to better understand the biological basis of the 
complex psychiatric disorders and to identify biomarkers that are related not 
only to monoamine transporters and receptors. “Biological markers were and 
still are focused on the brain, where the pathophysiology of affective disorders 
is thought only to occur. Although the brain certainly is a critical site to study 
the biology of mental disorders, there is increasing evidence for peripheral 
changes associated with” affective disorders. “Recently, multiple forms of blood 
markers as alternative to brain markers have received significant attention” 
(3), for instance in post-traumatic stress disorder, bipolar disorder, and major 
depression.  
 
A few years ago, Lundbeck Research USA initiated an exploratory study into 
whole blood biomarkers for affective disorders. What made this study of 
particular interest, apart from focusing on peripheral signatures, was that the 
same ~30 carefully selected genes were measured at the mRNA level in whole 
blood both in depressed patients, post-traumatic stress disorder patients, and 
borderline personality disorder patients as well as in various control groups in 
the US, Denmark, UK and Serbia.  
 
In close cooperation with first Lundbeck Research USA and later also Lundbeck 
A/S in Denmark, I investigated the usability of these gene expressions as 
whole blood biomarkers in both borderline personality disorder and post-
traumatic stress disorder through comparisons with healthy subjects. Among 
the major questions were: 
• Would the psychopathology of the examined disorders be reflected in the 
selected whole blood gene expression profiles?  
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Would there be any consistent expression differences between the 
various groups? 
• Which exploratory methods could be used to analyze such data, and 
what could be learnt from applying these methods? Would the different 
exploratory methods basically tell the same story or would they highlight 
different aspects of the disorders? 
 
In short, the overall aim of the present thesis was thus to better characterize 
the molecular biology of these affective disorders by the use of various 
exploratory analyses of gene expression profiles in whole blood. Exploratory 
analyses comprised bioinformatics, statistical and classification methods, and 
was used to generate hypotheses about the studied disorders.  
 
A main task was obviously to compare the expression profiles of controls to 
those of patients. Apart from the expression data, clinical data was also 
available for two control groups and from some of the borderline personality 
disorder patients. This enabled us to look into another more subtle task of 
trying to identify disease subtypes (phenotypes) and healthy subjects at risk 
for developing depression (intermediate phenotypes). 
 
 
Some of the main findings of this thesis include support for the possibility of 
using gene expressions in whole blood as biomarkers for affective disorders. It 
is shown that the expression profiles of various control groups are more similar 
to each other, although not identical, than to the expression profiles of 
different patient groups.  
 
A simulation study identifies the most promising classifiers and variable 
selection methods for separating the various control and patient groups. With 
these classifiers, predictions about a subject’s status (control vs patient) can 
be made solely on the basis of the gene expression profiles. In addition, gene 
expressions are listed that separate control and patient groups. The genes are 
linked to biological functions, networks and pathways.  
 
A range of promising statistical methods to analyse the expression data are 
identified as well. Each method offer new interpretations of the data like 
establishing hypotheses about gene expression – clinical variable relationships 
(generating hypotheses concerning both intermediate phenotypes and disease 
phenotypes), identifying possible gene expression disease subtypes or 
revealing the stability of the gene expressions measured in the UK control 
group at three different time points. Being an explorative study, validation is 
needed to confirm or rule out these findings.  
 
Bioinformatics is used to predict new possible biomarkers based on the 
selected genes. I have also attempted to predict altered gene expressions in a 
patient group – bipolar disorder patients that so far has not been analyzed.  
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In perspectives for further studies, I propose an experiment to confirm or rule 
out temporal gene expression oscillations as large oscillations for a gene 
expression might mean that the gene expression is less suitable as a 
biomarker or at least more complicated to use. I list requirements for 
constructing a Bayesian gene regulatory network. With a Bayesian network, it 
might be possible to predict gene regulatory behaviour in whole blood in 
various affective disorders.  
Also, suggestions are made for other classifier approaches and other ways of 
searching for blood biomarkers in affective disorders. Finally, I propose 
clustering simulations to identify the most promising clustering methods for 
disease subtyping. 
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Dansk resumé 
 
Vi har i dag kun begrænset viden om de psykiske lidelsers molekylærbiologi. 
Lidelser som depression eller posttraumatisk stresssyndrom betragtes som 
inhomogene lidelser og menes opstået som følge af et kompleks sammenspil af 
flere gener og udløsende faktorer i omgivelserne. Den inhomogene og 
polygene natur af disse lidelser gør det svært at behandle dem effektivt. I 
tilfældet af depression, er det kun omkring 20% af de berørte personer, som 
bliver helt raske med de nuværende antidepressiver. Dette kan skyldes, at den 
”biomedicinske forskning indenfor psykiatrien stadig fokuserer på behandlings-
targets, som blev identificeret mere eller mindre tilfældigt for et halvt 
århundrede siden. Næsten alle tilgængelige medikamenter går primært efter 
monoamin transportere og receptorer, i forskellige kombinationer, ledende til 
minimalt forskellige profiler. Desværre har disse forskelle sjældent en klinisk 
relevant sikkerheds- eller virkningseffekt. Til dags dato har disse targets 
desuden ikke vist sig at være kernen i de psykiske lidelsers sygdomsfysiologi” 
(oversat efter reference nr 3). 
 
Der er derfor klart et behov for bedre at forstå den biologiske basis af de 
komplekse psykiske lidelser og for at identificere biomarkører, som ikke kun er 
relaterede til monoamin transportere og receptorer. ”Biologiske markører var 
og er stadig fokuseret på hjernen, hvor psykiske lidelsers sygdomsfysiologi kun 
menes at finde sted. Selv om hjernen helt sikkert er et centralt område, når 
det drejer sig om at studere psykiske sygdommes biologi, så er der tiltagende 
beviser for perifere ændringer ved psykiske lidelser. For nyligt har flere typer 
af blodmarkører som et alternativ til hjernemarkører fået betydelig 
opmærksomhed” (oversat efter reference nr 3), for eksempel, i forbindelse 
med posttraumatisk stresssyndrom og med både bipolær og unipolær 
depression.  
 
For nogle få år siden påbegyndte Lundbeck Research USA et eksplorativt 
studium af blodmarkører (whole blood) for psykiske lidelser. Det, der gjorde 
dette studium særligt interessant, bortset fra at det fokuserede på perifere 
blodmarkører, var, at det var de samme ~30 særligt udvalgte gener, som blev 
målt på mRNA niveau i blod både i deprimerede patienter, patienter med 
posttraumatisk stresssyndrom og borderline-personlighedsforstyrrede 
(grænsepsykotiske) patienter såvel som i forskellige kontrolgrupper fra USA, 
Danmark, England og Serbien. 
 
I tæt samarbejde med først Lundbeck Research USA og siden også Lundbeck 
A/S i Danmark har jeg undersøgt anvendeligheden af disse genekspressioner 
som blodmarkører i både borderline-personlighedsforstyrrelse og 
posttraumatisk stresssyndrom ved sammenligninger med raske personer. 
Nogle af de store spørgsmål var: 
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• Ville de undersøgte lidelsers psykopatologi være reflekteret i de udvalgte 
genekspressionsprofiler i blod? 
Ville der være nogle konsistente ekspressionsforskelle mellem de 
forskellige grupper? 
• Hvilke eksplorative metoder kunne anvendes til at analysere sådanne 
data, og hvad kunne der læres af at anvende disse metoder? Ville 
forskellige eksplorative metoder basalt set fortælle den samme historie 
eller ville de belyse forskellige aspekter af disse lidelser? 
 
Kort fortalt er det overordnet mål med denne afhandling således at 
karakterisere forskellige psykiske lidelsers molekylærbiologi i større detaljer 
ved anvendelsen af forskellige eksplorative analyser af genekspressionsprofiler 
i blod. De anvendte eksplorative analyser omfattede bioinformatik, statistiske 
metoder og klassifikationsmetoder, og de blev benyttet til at opstille hypoteser 
om de undersøgte lidelser.  
 
Det var oplagt at sammenligne kontrolpersoners ekspressionsprofiler med 
patienters ekspressionsprofiler. Bortset fra ekspressionsdata, var kliniske data 
også tilgængelige for to kontrolgrupper og fra nogle af de borderline-
personlighedsforstyrrede patienter. Dette gjorde det muligt for os at se 
nærmere på en mere raffineret opgave, nemlig at forsøge at identificere 
sygdomsundertyper (fænotyper) og raske personer i fare for at udvikle en 
depression (mellemliggende fænotyper). 
 
 
Nogle af denne afhandlings hovedresultater understøtter muligheden for at 
anvende genekspressioner i blod som biomarkører for psykiske lidelser. Det 
bliver vist, at forskellige kontrolgruppers ekspressionsprofiler, selvom de ikke 
er identiske, ligner hinanden mere end de ligner forskellige patienters 
ekpressionsprofiler.  
 
Et simulationsstudie identificerer klassifikationsalgoritmer og variabel 
selektionsmetoder, som er mest lovende til at adskille de forskellige kontrol- 
og patientgrupper. Med disse klassifikationsalgoritmer kan der foretages 
forudsigelser om et individs status (såsom rask eller syg) alene på baggrund af 
genekspressionsprofilerne. Derudover angives de genekspressioner, som 
adskiller kontrol- og patientgrupper. Gener bliver koblet til biologiske 
funktioner, netværk og pathways.  
 
Ligeledes identificeres en række lovende statistiske metoder til at analysere 
ekspressionsdata. Hver metode byder på nye tolkninger af data såsom at 
opstille hypoteser om genekspression-kliniske variable forhold (opstille 
hypoteser vedrørende både mellemliggende fænotyper og 
sygdomsundertyper), identificere mulige sygdomsundertyper kun ved hjælp af 
genekspressioner eller afsløre stabiliteten af genekspressioner målt i den 
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engelske kontrolgruppe på tre forskellige tidspunkter. Siden det er et 
eksplorativt studie, er en efterfølgende validering nødvendig for at bekræfte 
eller afvise disse indledende resultater. 
 
Bioinformatik bliver anvendt til at forudsige mulige biomarkører på baggrund af 
de udvalgte gener. Jeg har også forsøgt at forudsige ændrede 
genekspressioner i en patientgruppe – maniodepressive (bipolær depression) 
patienter som endnu ikke er blevet analyseret.  
 
I en diskussion af de videre perspektiver foreslår jeg et eksperiment til at 
bekræfte eller afvise tidslige genekspressionsoscillationer fordi store 
oscillationer for en genekspression kan betyde, at den pågældende 
genekspression er mindre egnet som biomarkør, eller i det mindste er 
kompliceret at anvende. Jeg opstiller kravene for at konstruere et Bayersk 
genreguleret netværk. Med et Bayersk netværk vil det være muligt at 
forudsige genreguleret adfærd i blod i forskellige psykiske lidelser.  
 
Afhandlingen giver også forslag til andre klassifikationsmetoder og andre 
måder at søge efter blodmarkører på i psykiske lidelser. Endeligt foreslår jeg 
clustering simuleringer for at udvælge de mest lovende clustering metoder til 
at identificere sygdomsundertyper. 
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1. Introduction 
 
There is a growing need to understand the biological basis of affective 
disorders. For instance, only 20% (1) to 50% (2) of individuals with depression 
show full remission with the current antidepressants. However, given that 
affective disorders are believed to arise from interactions between 
environmental influences and the genetic makeup of an individual that is not 
an easy task.  
 
To put the extent of people suffering from affective disorders into perspective 
(3) “according to the National Institute of Mental Health (NIMH), mental 
disorders affect an estimated 26.2% of Americans aged 18 and older in a given 
year. Unlike many other chronic and disabling disorders, mental illnesses strike 
early in life”, with e.g. unipolar depression accounting for 28% “of the disability 
from all medical causes in people aged 15-44 years” (3) (4). “These data are 
in line with the Global Burden of Disease study, reporting that mental illness, 
including suicide, accounts for over 15% of the burden of disease in 
established market economies. This is more than the disease burden caused by 
all cancers combined” (3). 
Despite this bleak assessment, “biomedical research in the field of psychiatry 
has remained focused on treatment targets that were identified serendipitously 
more than half a century ago. Almost all available drugs target primarily 
monoamine transporter and receptors, in various combinations, leading to 
slightly different profiles. However, these differences rarely have a clinically 
relevant impact in terms of efficacy or safety. Moreover, the targets have not 
proven to be at the core of the pathophysiology of the major psychiatric 
disorders to this day, which may explain the modest efficacy of all available 
drugs when tested in poorly defined patient populations. This is in contrast to 
research into other major chronic diseases, such as cancer and heart disease, 
that has shed light on the biology and has resulted in the successful 
development of new treatment targets” (3). 
 
“Biomedical research that focuses on the disease rather than on treatment 
may improve our understanding of core biological alterations associated with 
psychiatric disorders” (3). “A better understanding of the disease biology, and 
the biological differences among patients, should advance the diagnostic 
classification, which today is entirely descriptive. In doing this, one would also 
expect to identify new biomarkers that may yield more efficacious treatments, 
at least for subgroups of patients that share core biological disturbances” (3) 
thus resulting in biological signatures of the various disorders.  
 
“Not surprisingly, the biological markers were and still are focused on the 
brain, where the pathophysiology of mental disorders is thought to occur. 
Although the brain certainly is a critical site to study the biology of mental 
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disorders, there is increasing evidence for peripheral changes associated with 
mental disorders” (3) (5). “Recently, multiple forms of blood markers as 
alternative to brain markers have received significant attention” (3), for 
instance in post-traumatic stress disorder (6), (7) bipolar disorder (8), (9) and 
major depression (10), (11).  
 
The rationale for studying affective disorders via peripheral blood can summed 
up as follows:  
a) a disease is caused by (and/or results in) gene expression changes 
b) diseases in one part of the body (brain) can result in gene expression 
changes elsewhere (blood)   
c) blood represents a minimally invasive sampling option in humans  
 
The overall aim of this thesis is to better understand the biology of different 
types of affective disorders by the use of various exploratory analyses of gene 
expression profiles in whole blood. Four psychiatric disorders are considered in 
the thesis: Borderline personality disorder, post-traumatic stress disorder 
(PTSD), depression and bipolar disorder. Gene expression profiles in borderline 
personality disorder and PTSD are analyzed together with the expression 
profiles from several cohorts of controls. Gene expressions are not analyzed 
from depressed patients or from bipolar disorder patients. However, as will be 
explained later, gene1 predictions will be made for depressed and bipolar 
disorder patients. The results of all these various analyses will be presented. 
 
What further makes this study very interesting is that the same 25-30 gene 
expressions are measured in different control and patient groups and hence, 
one important challenge is to see whether there are relative expression 
differences between the groups.  
 
Being an exploratory study, focus has been on exploratory / hypothesis 
generating statistical and classification approaches that will be described in 
later chapters. For each applied statistical method strengths and weaknesses 
will be mentioned as well as the reason for using that method. However, I do 
not consider this as a thesis in statistics, so in general I will not go into 
statistical details but refer to appropriate literature for further details.  
 
Overall, it can be said that the thesis is an intersection of the fields of biology 
of affective disorders and gene-environment interactions combined with 
statistical, machine learning and bioinformatics methods. 
 
1.1 Lundbeck 
During the entire thesis I have had a close cooperation with Lundbeck 
Research USA and towards the end of the thesis also with Lundbeck. Focus has 
                                                 
1 The words “gene” and ”gene expression” are used interchangeably.  
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been on solving relevant challenges as defined together with Dr Irina 
Antonijevic (MD), Director, Translational Research, Lundbeck Research USA, 
senior scientist Joseph Tamm, Lundbeck Research USA and mathematical 
modelling scientist at the clinical department of pharmacology Jan Vistisen, 
Lundbeck DK.  
 
In order to get access to relevant data gathered by Lundbeck and Lundbeck’s 
academic collaborators a contract has been signed. Parts of the thesis may be 
treated confidentially by Lundbeck and will be omitted from a public version2. 
After the contract was signed, the gene expression data was made available 
for analysis in portions as soon as Lundbeck had the data in-house and had 
obtained written consent from collaborators, if necessary. All data obtained 
came from controls and untreated patients that all had signed an informed 
consent stating the guidelines for handling the data.   
 
Portions of this thesis have appeared in a book chapter called “Perspectives for 
an Integrated Biomarker Approach to Drug Discovery and Development” by 
Irina Antonijevic, Joseph Tamm, Wiktor Mazin, et al. (in press).  
 
Furthermore, I have made a number of presentations at various BioSim 
conferences and workshops about the methods used and results obtained in an 
anonymous format.  
 
1.2 Main findings 
This study has shown that: 
 
• Gene expression profiles in whole blood have the potential to be used as 
biomarkers for affective disorders (further validation is required). 
o The expression profiles of various control groups are more similar 
to each other, although not identical, than to the expression 
profiles of different patient groups.  
o Controls can be separated from borderline personality disorder 
patients based on differential expression of four genes: Gi2, GR, 
MAPK14 and partly MR (see section 8.1) 
o Controls can be separated from acute post-traumatic stress 
disorder patients by differential expression levels of ARRB2, ERK2 
and RGS2. 
o Controls can not be separated from remitted post-traumatic stress 
disorder patients – a result that is in good agreement with the 
clinical diagnosis.  
 
 
                                                 
2 At the end of July 2008, the Lundbeck legal department has accepted the thesis with minor corrections that I have 
implemented. 
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o Controls may be separated from trauma patients without post-
traumatic stress disorder by differential expression levels of 
ARRB2, CREB1, ERK2, IL-6 and partly MAPK8, Gs, MKP1, and MR 
(see section 8.1). The performance measure PPV (positive 
predictive value) in this case is not great, suggesting that the 
separation between these groups is not strong. 
o Controls, borderline disorder patients and acute post-traumatic 
stress disorder patients can all be separated from each other based 
on differential expression of four genes: ERK1, ERK2, GR and 
MKP1. 
 
• A simulation study combined with results from actual data sets has 
shown that the most promising classifiers and variable selection methods 
for separating various control and patient groups are 
o support vector machines combined with variables selection based 
on random forests (both for 2-group and multiple group 
comparisons) 
o stepwise logistic regression (only for 2-group comparisons) 
o recursive partitioning (only for multiple group comparisons) 
 
• The most promising statistical methods to analyse the data are 
o The univariate parametric t-test and non-parametric Wilcoxon test 
in the 2-group case as well as the ANOVA and Kruskal-Wallis test 
in the multiple group case. 
o Spearman correlations for pair wise gene expression comparisons. 
o Repeated measures ANOVA for identifying differences between 
multiple time points measurements. 
o For gene expression disease subtyping: hierarchical clustering and 
heat maps (validation is needed). 
o Canonical correlation analysis for gene expression-clinical variable 
relationships supplemented by the univariate tests (validation is 
needed). 
 
• 20 hypotheses are constructed as gene expression predictions for 
depressed patients. These hypotheses are based on expression patterns 
from controls and identified possible intermediate phenotypes. The 
expression patterns observed in a small group of severely depressed 
patients confirms some of the hypotheses. 
 
• Possible disease subtypes / phenotypes on the gene expression level 
may be identified with heat maps and canonical correlation analysis 
(validation is needed).  
 
• Bioinformatics may be used to predict new possible biomarkers for 
depression such as Hsp90, PP2A, NFkB, Ras, MHC Class I, Mek, Akt and 
Ap1.  
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Finally, bioinformatics may be used to predict altered gene expressions 
in an as yet unanalyzed patient group – bipolar disorder patients - for: 
Gs, IL-1 beta, CREB1 and ERK1. 
 
• Expression differences of the considered genes do exist between the 
genders, but these differences do not seem as significant as one might 
think.  
 
• Three time point measurements (Day 0 at 8 am, Day 0 at 2 pm, and Day 
1 at 8 am) indicate significant expression differences for CD8 beta, IL-8, 
MKP1, MR and ODC1 between the time points. Validation is needed (see 
section 9.1). 
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2. Four psychiatric disorders – their symptoms, phenotypes 
and genetic background 
 
This chapter provides an introductory description of the four psychiatric 
disorders – depression, borderline personality disorder, post-traumatic stress 
disorder (PTSD) and bipolar disorder - that I consider in the present thesis. 
These heterogeneous disorders are discussed from both a symptom 
perspective based on the descriptions in ‘Diagnostic and Statistical Manual of 
Mental Disorders, 4th text revision’ (DSM-IV-TR) and a gene perspective, listing 
the genes that are assumed to be associated with each disorder according to 
the literature and the online database OMIM. All information in this chapter is 
collected from publicly available sources. In order to illustrate the potential of 
the gene expression approach used, I have included a ground-breaking 
example of using gene expressions in blood to differentiate between individuals 
who developed PTSD and those who did not following a traumatic event. This 
study was performed by Segman et al. from Israel and considers trauma 
survivors who were admitted to the emergency room immediately following a 
traumatic event (6). 
Three of the main depression hypotheses are described: The monoamine 
hypothesis involving a neurotransmitter such as serotonin, the hypothalamic-
pituitary-adrenal (HPA) axis hypothesis involving stress and the stress 
hormone cortisol, and the cytokine hypothesis involving the action of pro- and 
anti-inflammatory cytokines in cell signaling. The three hypotheses are 
considered as different aspects of a single broader hypothesis at the end of the 
chapter where I also describe possible shared biological mechanisms between 
the above disorders.  
Hereafter, common aspects of the psychiatric disorders are shortly described;  
• phenotype and intermediate phenotype challenges. A disease phenotype 
or disease subtype may be a specific symptom cluster that consists of 
parts of the symptoms present in a disorder. This aspect is very 
important as the psychiatric disorders are heterogeneous diseases with 
no single well-defined disease phenotype capturing all the various 
symptoms present.  
Intermediate phenotypes are here understood as appearing in normal 
subjects who are or may be at risk to develop a disorder. These 
phenotypes involve some of the symptoms observed in acutely ill 
patients. Examination of intermediate phenotypes may represent an 
important step towards an improved understanding of the biology of 
psychiatric disorders. 
• gene-environment interactions. The significance and complexity of such 
interactions are clearly witnessed by the facts that mental disorders have 
environmental causes and that people show significant variability in their 
response to those causes. Environmental risk factors such as substance 
abuse during pregnancy, premature parental loss, and exposure to 
2. Four psychiatric disorders – their symptoms, phenotypes and genetic background 
 
7
family conflict and violence are mentioned.  
Gene-environment factors are finally discussed in the context of 
constructing the ultimate goal - a ‘Mendeleyev table’ of (genetic and 
non-genetic) phenotypes to help understand the ‘atomic structure’ 
underlying these complex disorders. 
 
In order to obtain the personality traits of each disorder according to DSM-IV-
TR, I have used the renowned database eMedicine.com. This database contains 
one of the largest and most current clinical knowledge bases available to 
physicians and other healthcare professionals.  
DSM-IV-TR is the latest version of the “Diagnostic and Statistical Manual of 
Mental Disorders (DSM)” which is an American handbook for mental health 
professionals that lists different categories of mental disorders and the criteria 
for diagnosing them, according to the publishing organization the American 
Psychiatric Association (12).  
 
Each of the following four sections mentions genes3 associated with different 
affective disorders as listed in some of the literature (see the respective 
section for references) and in the online public available database OMIM – 
“Online Mendelian Inheritance in Man”. The database catalogues all known 
diseases with a genetic component, links them to the relevant genes in the 
human genome, whenever possible, and provides appropriate references. 
OMIM is developed for the World Wide Web by NCBI, the National Center for 
Biotechnology Information.  
 
Even though expression data from depressed patients was not analyzed 
directly in this thesis in accordance with our agreement with Lundbeck, the 
section on depression will be relatively more thorough than the other disorder 
sections. This is partly because treatment of depression is one of Lundbeck’s 
key focus areas, and partly because it was the original intention to compare 
expression levels of depressed patients with the expression levels of patients 
suffering from the other/related disorders. Thus, the other disorders can be 
said to be benchmarked against depression.  
 
2.1 Depression 
Depression is a broad term for a heterogeneous disease that comes in different 
forms. According to the National Institute for Mental Health - NIMH (13), the 
most common forms are dysthymia (a less severe type of depression, but 
chronic form with a typical duration of more than two years) and major 
depression, also known as unipolar depression. Other types include psychotic 
depression, postpartum depression, seasonal affective disorder (SAD) and 
                                                 
3 Listed genes will come from both genetic and gene expression studies. SNPs (single nucleotide polymorphisms - a 
variation in a gene caused by the change of a single base in DNA) in genes are believed to result in altered gene 
expressions.  
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bipolar disorder. Bipolar disorder will be treated separately later in this 
chapter. The focus in this section is on ‘major depression’.  
 
“Major depression is characterized by a combination of symptoms that 
interfere with a person's ability to work, sleep, study, eat, and enjoy once–
pleasurable activities. Major depression is disabling and prevents a person 
from functioning normally. An episode of major depression may occur only 
once in a person's lifetime, but more often, once experienced it recurs 
throughout a patient’s life.” (13) 
 
The DSM-IV-TR defines a major depressive episode (14) as a syndrome in 
which, during the same 2-week period, are at least 5 of the following 
symptoms present and manifest themselves as a change from a previous state 
of well-functioning (moreover, the symptoms “must include either (a) or (b)): 
 
(a) Depressed mood  
(b) Diminished interest or pleasure  
(c) Significant weight loss or gain  
(d) Insomnia or hypersomnia  
(e) Psychomotor agitation or retardation  
(f) Fatigue or loss of energy  
(g) Feelings of worthlessness  
(h) Diminished ability to think or concentrate; indecisiveness  
(i) Recurrent thoughts of death, suicidal ideation, suicide attempt, or 
specific plan for suicide”  
 
Depending upon the number and severity of the symptoms, a depressive 
episode may be specified as mild, moderate or severe. Women are twice as 
likely to experience depression as men.  
 
DSM-IV-TR further includes descriptions of symptoms that must be present in 
various subtypes of depression. Depression can be noted to be with or without 
psychotic symptoms and may have melancholic or catatonic features or be 
classified as an atypical depression. Here it is not important to go into the 
details of each subtype, but just to stress that we are dealing with a clinically 
very heterogeneous disease. We may expect the gene expression profiles of 
depressed patients to reflect this heterogeneity. If it will be possible to define 
these different profiles, they can be used to better classify patients and tailor 
the development of drugs to these subtypes.  
 
Listing the symptoms also plays an important role for some of the first 
analyses done in this thesis. Here clinical information from controls was 
combined with their gene expression profiles. This was done to predict 
expression response in depressed patients. For more details, see the results 
chapter.   
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2.1.1 Depression hypotheses 
According to NIMH, “there is no single cause of depression. Rather, likely to 
result from a combination of genetic, biochemical, environmental, and 
psychological factors” (15). “Some types of depression tend to run in families, 
suggesting a genetic link. However, depression can occur in people without 
family histories of depression as well. Genetics research indicates that risk for 
depression results from the influence of multiple genes acting together with 
environmental or other factors”. (15) 
“In addition, trauma, loss of a loved one, a difficult relationship, or a 
particularly stressful situation may trigger a depressive episode. Subsequent 
depressive episodes may occur with or without an obvious trigger” (15). 
 
Given the fact that no single gene causes depression and that it’s a 
heterogeneous disease, several depression hypotheses exist. Some of the most 
common are the monoamine, the HPA-axis and the cytokine hypothesis which 
will briefly be touched upon below. Other hypotheses, like the neurogenesis 
hypothesis, exist but will not be described in detail here. 
 
The monoamine hypothesis 
Serotonin is a monoamine neurotransmitter and the monoamine hypothesis 
claims that low levels of serotonin cause depression. In addition, the 
hypothesis explains why antidepressants take about 6-8 weeks to work.  
In order to relieve symptoms in depressed patients the levels of serotonin have 
to be raised. This can be done by e.g. SSRI antidepressants. They block the 
reuptake of serotonin thereby causing a temporary increase in the level of 
serotonin. However, because a negative feedback exists that counterworks the 
increased neurotransmitter level, see figure 1, it takes 6-8 weeks to normalize 
serotonin levels and relief symptoms. 
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Figure 1: Illustration of the monoamine hypothesis. Increase of serotonin causes a negative 
feedback mechanism that reduces serotonin firing and then long-term treatment desensitizes 
the inhibitory serotonin presynaptic autoreceptors and transmission is enhanced.  
 
 
HPA-axis (Hypothalamic-Pituitary-Adrenal) hypothesis 
Stress causes the elevation of cortisol and long-term elevation of cortisol may 
cause depression. More precisely, long term exposure to stress causes 
excitatory drive of the hypothalamus. Thereby, the level of CRH (corticotropin 
releasing hormone) is increased and causes a sustained release of ACTH 
(adrenocorticotropic hormone) from the pituitary. This, in turn, increases the 
level of cortisol from the adrenal gland. The negative feedback loop, see figure 
2, is impaired in depressed patients which causes a reduction of brain 
corticosteroid receptors. The end result is elevated levels of the stress 
hormone cortisol which, thus, may cause depression. 
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Reduction of brain gluco- 
and mineralocorticod 
receptors in depression 
Impaired negatitive 
feedback in 
depression 
Figure 2: Illustration of the HPA-axis hypothesis. “The hypothalamus is subject to abnormal 
excitatory drive from limbic system regions due to prolonged stress, resulting in sustained 
release of ACTH. Depression causes a reduction of brain corticosteroid receptors, resulting in 
subnormal negative feedback in this system and thus, elevated levels of the stress hormone 
cortisol”. Source: (16). 
 
Interactions have been demonstrated (17) between the serotonergic system 
and the HPA axis. Cortisol may lower serotonin levels and conversely, 
serotonin stimulates secretion of CRH and ACTH and may modulate negative 
feedback of the HPA axis by glucocorticoids. 
 
The cytokine hypothesis 
The cytokine hypothesis of depression posits that depression is caused by the 
actions of cytokines (18). Cytokines are proteins and peptides that are used for 
cell signaling. They are similar in action to hormones and neurotransmitters 
and are sometimes loosely described as immune system hormones (19). 
 
Some of the well-known (from the literature) pro-inflammatory cytokines are 
IL-1β (interleukin-1 beta), IL-6 and TNF-α (tumor necrosis factor-α), while 
some anti-inflammatory cytokines are IL-4, IL-10, and TNF-β (tumor necrosis 
factor-β).  
 
There are many pathways known to be involved in the pathophysiology of 
depression that are influenced by cytokines, like the IL-6 and the IL-10 
signaling pathways. Cytokines also influence neurotransmitter and HPA-axis 
function (20), thus creating a link to the two previous mentioned hypotheses. 
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2.1.2 Depression and genes 
Table 1 lists genes considered to be associated with major depression together 
with references from the literature and OMIM. The table is not based on an 
exhaustive literature search but reflects the literature I have dealt with at the 
beginning of the thesis work. The purpose of listing the genes is to note any 
possible overlap with the list of genes selected by Lundbeck, see next 
chapter4.  
eference 
 
Genes associated with major depression  R
Involved in the action of monoamine neurotransmitters5: 
into presynaptic neurons and has long 
oxygenase) catalyzes the rate-limiting step of 
2), (23) 
0) 
2) 
 
• SERT (serotonin transporter gene) encodes an integral membrane 
protein that transports the neurotransmitter serotonin (monoamine 
transporter) from synaptic spaces 
been associated with depression. 
• TPH1 (tryptophan hydroxylase-1)  
• TPH2 (tryptophan hydroxylase-2) 
• HTR1A (serotonin 5-HT-1A receptor) 
• HTR2A (serotonin 5-HT-2A receptor) 
• IDO (indoleamine 2,3-di
tryptophan conversion. 
• DRD4 (dopamine D4 receptor).  
 
 
(10), (21), 
(2
 
 
(22) 
(22) 
(24) 
(22) 
(2
 
(2
Involved in hypothalamic-pituitary-adrenal (HPA) axis regulation5: 
 protein 5) plays a role in the stress hormone-
n 1) 
 hormone gene) 
in kinase 14) 
2) 
(27) 
6), (27) 
 
• FKBP5 (fk506-binding
regulating HPA axis. 
• CREB1 (cAMP response element-binding protei
• CRH (corticotrophin-releasing
• GR (glucocorticoid receptor) 
• MAPK14 (mitogen-activated prote
• MR (mineralocorticoid receptor) 
 
 
(2
 
(22), (25) 
(20), (26) 
(26), 
(20) 
(2
Involved in cytokine / immune system regulation5: 
  
lso a pro-inflammatory cytokine. 
or alpha) is also a pro-inflammatory cytokine. 
(28) 
 
• IL-1β (interleukin-1 beta) is a pro-inflammatory cytokine.
• IL-6 (interleukin-6) is a
• IL-12 (interleukin-12) 
• TNF-α (tumor necrosis fact
 
 
(24), 
(24) 
(20) 
(20) 
BCR (breakpoint cluster region)  (22) 
CHRM2 (cholinergic receptor, muscarinic, 2) (22) 
DYT1 (dystonia 1, torsion, autosomal dominant) (22) 
ERK1 (extracellular signal-regulated kinase 1) (29) 
ERK2 (extracellular signal-regulated kinase 2) (29) 
MTHFR (methylenetetrahydrofolate reductase) (22) 
P2RX7 (purinergic receptor P2X, ligand-gated ion channel, 7) (30) 
Table 1: Genes associated with major depression 
 
                                                 
4 The next chapter will also state the direction of the gene expression changes, that is, whether the expression is up- or 
down regulated. 
5 Certainly, some genes can play a role in e.g. both HPA-axis, cytokine and monoamine activity. Here a split is made 
according to descriptions of each gene’s activity in OMIM and the literature and to highlight the three described 
depression hypotheses.  
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2.2 Borderline Personality Disorder (BPD) 
According to NIMH, Borderline Personality Disorder (BPD) (31), in short 
borderline, “is a serious mental illness characterized by pervasive instability in 
moods, interpersonal relationships, self-image, and behavior” often in 
combination with pronounced "black and white" thinking. “This instability often 
disrupts family and work life, long-term planning, and the individual's sense of 
self-identity. Originally thought to be at the "borderline" between psychosis (a 
major mental disorder characterized by gross impairment of a person's 
perception of reality and ability to communicate and relate to others) and 
neurosis (a mental disorder characterized primarily by anxiety), people with 
BPD suffer from a disorder of emotion regulation.”  
 
The DSM-IV-TR defines BPD (32)6 as "a pervasive pattern of instability of 
interpersonal relationships, self-image and affects, as well as marked 
impulsivity, beginning by early adulthood and present in a variety of contexts. 
A DSM diagnosis of BPD requires any five out of nine listed criteria to be 
present for a significant period of time. The criteria are: 
  
(a) Frantic efforts to avoid real or imagined abandonment. [Not including 
suicidal or self-mutilating behavior covered in Criterion (e)]  
(b) A pattern of unstable and intense interpersonal relationships 
characterized by alternating between extremes of idealization and 
devaluation.  
(c) Identity disturbance: markedly and persistently unstable self-image or 
sense of self.  
(d) Impulsivity in at least two areas that are potentially self-damaging 
(e.g., promiscuous sex, eating disorders, binge eating, substance 
abuse, reckless driving). [Again, not including suicidal or self-
mutilating behavior covered in Criterion (e)]  
(e) Recurrent suicidal behavior, gestures, threats, or self-mutilating 
behavior such as cutting, interfering with the healing of scars, or 
picking at oneself.  
(f) Affective instability due to a marked reactivity of mood (e.g., intense 
episodic dysphoria, irritability, or anxiety usually lasting a few hours 
and only rarely more than a few days).  
(g) Chronic feelings of emptiness, worthlessness.  
(h) Inappropriate anger or difficulty controlling anger (e.g., frequent 
displays of temper, constant anger, recurrent physical fights).  
(i) Transient, stress-related paranoid ideation or severe dissociative 
symptoms.” 
 
Worth noticing in the above list are points (a), (f) and (i) which indicate the 
presence of stress-related responses, and thus, the involvement of 
disturbances in the HPA-axis according the HPA-axis hypothesis. 
                                                 
6 eMedicine.com do not contain a specified list of BPD criteria. Wikipedia (includes references) does and is used here. 
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The most consistent finding in the search for causation in this disorder is a 
history of childhood trauma, although some researchers have suggested a 
genetic predisposition (32). Neurobiological research has highlighted some 
abnormalities in serotonin metabolism which indicates a link to the monoamine 
hypothesis. 
 
The incidence has been calculated as 1-2% of the population by NIMH (31), 
with women three times more likely to suffer the disorder. The expression data 
that was analyzed in this thesis from BPD patients came mainly from women. 
 
2.2.1 Borderline Personality Disorder and genes 
In general, the literature on genes associated with BPD is very sparse, and 
OMIM has no record dealing with borderline. Hence, I will not show the few 
results in a table format. The biological underpinning of BPD is complex and 
poorly understood. Previous studies have emphasized the aminergic 
neurotransmission with serotonin and dopamine (33), (34) and HPA-axis 
hyperactivity in relation to the pathophysiology of BPD (35). BPD does not 
consist of impairment in a single neurotransmitter system. Besides aminergic 
neurotransmission, glucocorticoid and NMDA neurotransmission may play a 
part of the pathophysiology of BPD (35).  
 
Finally, genes involved in the production of MAOA (monoamine oxidase-A) may 
also be involved in the development of BPD. The MAOA gene encodes for the 
enzyme MAOA, a potent metabolizer of serotonin and dopamine (34). 
 
To sum up, it seems like some of the same mechanisms with neurotransmitter 
and HPA-axis activity are present in BPD as is the case in major depression. In 
young women, depression is often comorbid with BPD and here cytokines play 
a role (36).  
 
2.3 Post-Traumatic Stress Disorder (PTSD) 
Post-traumatic stress disorder (PTSD) “was first brought to public attention in 
relation to war veterans, but it can result from a variety of traumatic incidents, 
such as mugging, rape, torture, being kidnapped or held captive, child abuse, 
car accidents, train wrecks, plane crashes, bombings, or natural disasters such 
as floods or earthquakes” (37). The last couple of years PTSD has received 
more attention in Denmark due to the wars in former Yugoslavia, and in 
Afghanistan and Iraq with both refugees and soldiers affected.  
   
NIMH (38) characterizes PTSD as “an anxiety disorder that some people 
develop after seeing or living through an event that caused or threatened 
serious harm or death. Symptoms usually begin within 3 months of the 
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incident but occasionally emerge years afterward. Symptoms include 
flashbacks or bad dreams, emotional numbness, intense guilt or worry, angry 
outbursts, feeling “on edge,” or avoiding thoughts and situations that remind 
of the trauma”, see the DSM-IV-TR description below. Not every traumatized 
person develops full-blown or even minor PTSD. The course of the illness 
varies. Some people recover within 6 months, while others have symptoms 
that last much longer. In some people, the condition becomes chronic. 
 
DSM-IV-TR (39) has six criteria that has to be met for a person to be 
diagnosed with PTSD. Summarized, they are (40): 
 
(a) “Exposure to a traumatic event (see below)  
(b) Persistent reexperience  
(c) Persistent avoidance of stimuli associated with the trauma  
(d) Persistent symptoms of increased arousal (e.g. difficulty falling or 
staying asleep)  
(e) Duration of symptoms more than 1 month  
(f) Significant impairment in social, occupational, or other important 
areas of functioning  
 
Criterion (a) (the "stressor") consists of two parts, both of which must apply 
for a diagnosis of PTSD. The first (a1) requires that "the person experienced, 
witnessed, or was confronted with an event or events that involved actual or 
threatened death or serious injury, or a threat to the physical integrity of self 
or others." The second (a2) requires that "the person’s response involved 
intense fear, helplessness, or horror."  
 
Almost all of the above criteria indicate a (severe) stress response and thus, 
the involvement of disturbances in the HPA-axis. 
 
As can be seen from this introductory description of PTSD, environmental 
factors play a large role in the development of PTSD. However, genetic 
components are also associated with PTSD (see next section) as it is known 
that PTSD runs in families (40).  
 
“The estimated lifetime prevalence of PTSD among adult Americans is 7.8%, 
with women (10.4%) twice as likely as men (5%) to have PTSD at some point 
in their lives” (40). The expression data that was analyzed in this thesis from 
PTSD patients were from men only and all related to war events.   
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2.3.1 PTSD and genes 
In general, the literature on PTSD and associated genes is not abundant7, and 
OMIM has no record dealing with this disorder either.  
 
The literature indicates that serotonin might be implicated in PTSD (41). The 
same is true for DRD2 (dopamine receptor D2) (42) and DAT (dopamine 
transporter gene) (43). A recent paper (44) also points to FKBP5 (FK binding 
protein 5), CRH (corticotropin-releasing hormone), NET1 (noradrenaline 
transporter), COMT (catechol-o-methyltransferase) and GRP (gastrin-releasing 
peptide receptor) . Another recent paper (45) presents a search of literature 
that has looked at association studies involving candidate genes in the 
serotonin (5-HTT), dopamine (DRD2, DAT), glucocorticoid (GR), GABA 
(GABRB), apolipoprotein systems (APOE2), brain-derived neurotrophic factor 
(BDNF) and neuropeptide Y (NPY). “The studies have produced inconsistent 
results, many of which may be attributable to methodological shortcomings 
and insufficient statistical power. They conclude that the complex etiology of 
PTSD, for which experiencing a traumatic event forms a necessary condition, 
makes it difficult to identify specific genes that substantially contribute to the 
disorder”. 
 
The same paper (45) mentions the possible involvement of the HPA-axis. Since 
increased HPA activity is a natural reaction to stress, researchers have 
extensively explored this in PTSD patients. “While traditional models of stress 
would predict overactivity of the HPA axis, paradoxically there is substantial 
evidence for decreased HPA-axis activity in patients with PTSD. It is unknown 
whether these HPA anomalies are caused by, or result from, PTSD” (46). 
Furthermore, several papers report links between PTSD and the cytokines IL-
1beta (interleukin 1-beta) (47) and IL-6 (interleukin 6) (48), (49). 
 
At the gene expression level, a recent study by Segman and colleagues (6), 
based on a microarray study, identifies several hundred promising genes 
associated with PTSD. These authors observed peripheral blood mononuclear 
cell gene expression profiles in individuals seen in the emergency department 
shortly after a traumatic event and followed one and four months later. They 
found that gene expression signatures differentiated between individuals who 
developed PTSD and those who did not. They found that several differentiating 
genes were previously described as having a role in immune activation like 
CD2 (cluster of differentiation 2) and IL-8 (interleukin-8), and stress 
response/HPA-axis activity like ADM (adrenomedullin) and FKBP5 (fk506-
binding protein 5). Many more genes are listed in the article.  
                                                 
7 “One reason for this lack of attention might have to do with the fact that PTSD it is a relatively new diagnosis and 
that, until the 1990s, it was commonly thought to be prevalent only among specific subpopulations (e.g., Vietnam War 
veterans) and rare in the general population. This misconception was corrected with the publication of several 
epidemiologic studies of trauma exposure and PTSD. These studies consistently demonstrated that both exposure to 
traumatic events and PTSD are common” (36). 
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Even due to inconsistent results, it may seem like some of the same 
mechanisms with HPA-axis activity and involvement of cytokines and 
neurotransmitters are present in PTSD as is the case in major depression and 
BPD. 
 
2.4 Bipolar Disorder (BD) 
As it is the case for depression and the other affective disorders I have 
described, bipolar disorder (BD) is not a homogenous disease and has been 
divided into several subcategories. They are called “bipolar I, bipolar II and 
cyclothymia based on the type and severity of mood episodes experienced” 
(50). 
 
According to NIMH (51), “bipolar disorder, also known as manic-depressive 
illness, is a brain disorder that causes unusual shifts in a person’s mood, 
energy, and ability to function. Different from the normal ups and downs that 
everyone goes through, the symptoms of bipolar disorder are severe. They can 
result in damaged relationships, poor job or school performance, and even 
suicide”.  
 
“Episodes of mania and depression typically recur across the life span. 
Between episodes, most people with bipolar disorder are free of symptoms, but 
as many as one-third of people have some residual symptoms” (51). 
 
According to DSM-IV-TR (52), “manic episodes are characterized by the 
following symptoms:  
 
(a) At least 1 week of profound mood disturbance is present, 
characterized by elation, irritability, or expansiveness.  
(b) Three or more of the following symptoms are present:  
a. Grandiosity  
b. Diminished need for sleep  
c. Excessive talking or pressured speech  
d. Racing thoughts or flight of ideas  
e. Clear evidence of distractibility  
f. Increased level of goal-focused activity at home, at work, or 
sexually  
g. Excessive pleasurable activities, often with painful consequences  
(c) The mood disturbance is sufficient to cause impairment at work or 
danger to the patient or others.  
(d) The mood is not the result of substance abuse or a medical condition.”  
 
DSM-IV-TR depressive episodes have already been described in a previous 
section of this chapter and apply to BD as well. 
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DSM-IV-TR further contains specifies hypomanic (a mild to moderate level of 
mania) and mixed episodes (symptoms of mania and depression occur 
simultaneously), however, they will not be described here. 
 
Based on the DSM symptoms described above it seems that disturbances in 
the HPA-axis are involved in BD, as it is also the case for depression.  
 
Studies suggest that genetics, early environment, neurobiology, and 
psychological and social processes are important contributory factors (50). 
 
“In any given year about 5.7 million American adults or about 2.6 percent of 
the population age 18 and older, have bipolar disorder” (51) 
 
2.4.1 Bipolar disorder and genes 
As with the other affective disorders, bipolar disorder is a genetically 
heterogeneous complex trait.  
 
Table 2 lists some of the genes associated with bipolar disorder together with 
references from recent literature and OMIM. 
 
Genes associated with bipolar disorder Reference 
Involved in the action of monoamine neurotransmitters8: 
 
• SERT (serotonin transporter) 
• HTR4 (serotonin 5-HT-4A receptor) 
• DAT1 (dopamine transporter gene) 
• DRD4 (dopamine D4 receptor) 
• COMT (catechol-O-methyltransferase) 
• GPR50 (G protein-coupled receptor 50) 
• TPH2 (tryptophan hydroxylase-2) 
 
 
(53) 
(53) 
(53) 
(53) 
(53) 
(53) 
(54) 
Involved in hypothalamic-pituitary-adrenal (HPA) axis regulation8: 
 
• CRHR2 (Corticotropin-releasing hormone receptor 2) 
• GR (glucocorticoid receptor) 
• SEF2-1B (transcription factor 4) 
 
 
(55) 
(56) 
(53) 
Involved in cytokine / immune system regulation8: 
 
• IL-4 (interleukin 4)  
• IL-6 (interleukin 6)  
• TNF-α (tumor necrosis factor alpha) 
 
 
(57) 
(57) 
(57) 
BDNF (brain-derived neurotrophic factor) (53) 
BCR (breakpoint cluster region) (53) 
CACNA1C (calcium channel, voltage-dependent, L-type, alpha 1C subunit) (58) 
CLOCK (circadian locomotor output cycles kaput) (52) 
                                                 
8 As with depression, some genes can play a role in e.g. both HPA-axis, cytokine and monoamine activity. Here a split 
is made according to descriptions of each gene’s activity in OMIM and the literature and to highlight the three described 
depression hypotheses.  
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CUX2 (cut-like 2) (53) 
DFNB31 (59) 
DGKH (diacylglycerol kinase eta) (59) 
DISC1 (distrupted in schizophrenia 1) (54) 
EGFR (epidermal growth factor receptor) (58) 
GRIN2B (NMDA glutamate receptor, subunit 2B) (54) 
MTHFR (5,10 methylenetetrahydrofolate reductase) (54) 
MTND1 (complex I, subunit ND1) (53) 
MYO5B (myosin VB) (58) 
NXN (encodes the protein nucleoredoxin) (59) 
SORCS2 (SORCS receptor 2) (59) 
TRPM2 (transient receptor potential cation channel, subfamily m, member 2)  (53) 
TSPAN8 (tetraspanin 8) (58) 
VGCNL1 (voltage gated channel like 1) (59) 
Table 2: Genes associated with bipolar disorder 
 
Additional genes can be found in two recent papers dealing with gene 
expression (microarray) analysis in BD (60) and molecular genetics in bipolar 
disorder and depression (61). 
  
Since BD contains depressive episodes, it is not surprising to find some of the 
same genes listed in table 2 as in table 1 (major depression). In particular, 
SERT, DRD4, TPH2, IL-6, TNF-α and BCR are mentioned in both tables. 
 
Last year, the Wellcome Trust Case Control Consortium (WTCC) performed 
genome-wide association studies to identify genes involved in common human 
diseases, among them, bipolar disorder. In the British population, they 
examined ~2000 bipolar patients and ~3000 controls (62). In the results 
chapter, bioinformatics approaches will be used to link the genes inferred from 
the WTCC SNP data to the genes selected by Lundbeck. 
 
 
2.5 Phenotypes and intermediate phenotypes  
A disease phenotype (also known as an endophenotype, see the next section, 
or disease subtype) may be defined as a specific symptom cluster that consists 
of parts of the symptoms present in each disorder or be present across current 
diagnostic boundaries (3).  
 
The DSM-IV-TR descriptions for the four affective disorders above clearly show 
that we are dealing with heterogeneous diseases and thus, no single well-
defined disease phenotype captures all the various symptoms present in a 
psychiatric disorder. More likely, each disorder consists of a number of or 
perhaps even a whole spectrum of disease phenotypes. This makes it difficult 
(and sometimes even impossible) not only to decide on the right treatment for 
the individual patient but also to replicate genetic and gene expression findings 
in different studies and trials. To complicate things further, an affected 
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individual may suffer from several psychiatric disorders (comorbidity). For 
instance, borderline personality disorder often occurs together with mood 
disorders like depression or bipolar disorder. Some features of borderline 
personality disorder may overlap with those of mood disorders, pointing to the 
relevance of disease phenotypes. 
 
In 2011, the American Psychiatric Association is planning to publish DSM-V 
with the aim to develop “an etiologically based, scientifically sound (diagnostic) 
classification system” (3). In order to achieve this goal, a better understanding 
of the biological basis of psychiatric disorders seems to be a necessary first 
step. Linking disease phenotypes rather than an entire disorder to biological 
findings like transcription profiles should be a viable approach and help to 
uncover the biology of distinct phenotypes. “This point may be of particular 
importance when one aims to address early onset of disorders or to initiate 
prophylactic treatments. As the specific symptoms an individual develops 
depend on the individual’s genetic makeup and the environmental context, 
objective markers that allow recognition of phenotypes associated with 
increased vulnerability will help select individuals for prophylactic treatment” 
(3). It is here the concept of intermediate phenotypes is useful. An 
intermediate phenotype as defined in this thesis appears in normal subjects 
who are or may be at risk to develop a disorder and consists of some of the 
symptoms observed in acutely ill patients. “It may be an important step 
towards an improved understanding of the biology of psychiatric disorders, 
since there is likely to be a continuum between completely healthy individuals 
and those with a clinically manifest psychiatric disorder” (3). One can further 
imagine that the number of intermediate phenotypes will be higher in patients 
than in controls at risk, and when adding up, will lead to the diagnosis. 
 
“The importance of intermediate phenotypes is emphasized by the discussion 
put forward in the DSM-V research agenda on a dimensional vs categorical 
classification system. The dimensional approach includes an aspect often 
disregarded in psychiatric biomedical research, namely the examination of 
control populations” (3). In the results chapter, results will be provided in 
support of the relevance of intermediate phenotypes by showing association 
between transcription patterns and psychiatrically relevant clinical variables in 
a control population.  
 
“Moreover, intermediate phenotypes seem particularly relevant for drug 
development, as examination of drug effects in such ‘control’ subjects could 
provide early signs for efficacy in a patient population” (3). 
 
“An extension of the above approach is to address the biology of distinct 
clinical features across the boundaries of current diagnoses. The analysis of 
such complex relationships should help to characterize multiple intermediate 
phenotypes, which in turn may predispose for the development of certain 
psychiatric diseases, e.g. when exposed to environmental stressors. Examples 
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in psychiatry include (3) impaired cognitive executive function, which can occur 
in schizophrenia, some forms of depression and in connection with substance 
abuse. Another example is fatigue that can occur in different psychiatric 
disorders such as depression and anxiety, but also in disorders associated with 
a high incidence of depressive disorders, such as Parkinson’s disease, multiple 
sclerosis and obesity” (3).  
 
Apart from the examples above, there are several suggestions in the literature 
as to how to define disease phenotypes. Hasler et al. (63) propose 
endophenotypes for major depression at two levels: Psychopathological 
endophenotypes comprising e.g. impaired learning and memory and impaired 
diurnal variation and biological endophenotypes like REM sleep abnormalities 
and functional and structural brain abnormalities. For bipolar disorder some of 
the same phenotypes are suggested plus additional ones, see (64), (65).  
 
 
2.6 Gene-environment interactions 
As evident from the DSM-IV-TR descriptions and genes associated with each 
disorder, much research goes into establishing a connection between clinical 
symptoms and putatively associated genes (33), (66), (67). As explained in 
(66), the gene-environment interaction approach has grown out of two 
observations: first, that mental disorders have environmental causes; second, 
that people show heterogeneity in their response to those causes.  
 
In the same paper (66), “environment risk factors for mental disorders defined 
up to 2006 include (but are not limited to) maternal stress during pregnancy, 
maternal substance abuse during pregnancy, low birth weight, birth 
complications, deprivation of normal parental care during infancy, childhood 
physical maltreatment, childhood neglect, premature parental loss, expose to 
family conflict and violence, stressful life events involving loss or threat, 
substance abuse, toxic exposures and head injury”. These environmental risk 
factors may then contribute to the various symptoms associated with 
psychiatric disorders.  
 
This section may be considered as an extension to the previous section on 
phenotypes and intermediate phenotypes here with an additional focus on the 
genetic aspect. In the previous section, endophenotypes were mentioned. 
“They provide a means for identifying the ‘downstream’ traits of clinical 
phenotypes resulting partly from environmental factors, as well as the 
‘upstream’ consequence of genes. To be more specific, in a gene-environment 
perspective, endophenotypes are also assumed to be simpler than an entire 
complex disorder from a genetic point of view. Instead of looking for genes 
coding complex disorders, endophenotypic research looks for genes for simple, 
ideally monogenic traits that accompany the disorder and probably contribute 
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to its pathophysiology” (64). “Decreasing the complexity of the marker should 
also decrease the complexity of its genetic basis. If phenotypes associated with 
a disorder are very specialized and represent more elementary phenomena, 
the number of genes required to produce variations in these traits may be 
fewer than those involved in producing a complex psychiatric diagnostic entity. 
Endophenotypes are a step towards simplifying very complex diseases” (64).  
 
The ultimate goal might be compared (68) to the ‘Mendeleyev periodic table’ 
known from the field of chemistry. Here is would be a ‘Mendeleyev table’ of 
endophenotypes (consisting of known genetic and non-genetic factors) 
relevant for psychiatric disorders that would have to be constructed to help 
understand the ‘atomic structure’ underlying these complex disorders. This 
‘Mendeleyev table’ can then be used to understand the ‘molecules’ or different 
symptoms present in a given psychiatric disorder. Only then will it be possible 
to understand the ‘macromolecular’ structure or the range of symptoms 
associated with a psychiatric disorder.  
 
Finally, it should be mentioned that “a focus on biological markers of distinct 
clinical features is in line with the DSM-V research agenda, which stresses the 
importance of studying complex relationships between biological and clinical 
variables” (3). As referred to in the previous section, the first part of the thesis 
work dealt with testing gene-environment (clinical features) interactions along 
the intermediate phenotype approach. The last part of the thesis work went 
into another kind of gene-environment analysis, namely the classification 
issue. Here it was examined whether it is possible to distinguish different 
patient groups on the basis of their gene expression profiles.  
 
 
2.7 Shared biological mechanisms  
In the sections on the described psychiatric disorders, genes are listed and are 
involved in several different pathways. To varying degree, it seems like 
biological changes take place in the immune system, the HPA axis and the 
monoamine function in each of the four disorders. Many more biological 
mechanisms are most probably perturbed, but here focus will be on these 
three. 
  
In figure 3 the three biological mechanisms are shown together. As explained 
in (69) the HPA axis is upregulated in e.g. depression “with a down-regulation 
of its negative feedback controls. CRF (corticotropin-releasing factor) is 
hypersecreted from the hypothalamus and induces the release of ACTH 
(adrenocorticotropin hormone) from the pituitary. ACTH interacts with 
receptors on adrenocortical cells and cortisol is released from the adrenal 
glands; adrenal hypertrophy can also occur. Release of cortisol into the 
circulation has a number of effects, including elevation of blood glucose. The 
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negative feedback of cortisol to the hypothalamus, pituitary and immune 
system is impaired. This leads to continual activation of the HPA axis and 
excess cortisol release. Cortisol receptors become desensitized leading to 
increased activity of the pro-inflammatory immune mediators and disturbances 
in neurotransmitter transmission”.  
  
 
Figure 3: See text above figure. Source: Adapted after (69). 
 
 
It may be hypothesized that monoamine function, HPA axis regulation and 
cytokine production changes are not just present in depression (24), (70), but 
may contribute to the pathophysiology of other psychiatric disorders (71) like 
PTSD (72), (73) bipolar disorder (71) and borderline personality disorder, the 
latter, however, perhaps to a less degree. It may also be hypothesized that the 
changes in these biological systems may be reflected and measured in gene 
expressions in whole blood, likely showing differences depending on the 
disorder or endophenotype compared to healthy subjects. In this thesis, for 
PTSD, borderline and partly depression this combined hypothesis will be 
investigated and it will be seen which biological systems seem perturbed in 
blood in each analyzed disorder. 
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In this chapter, I present the genes that were selected by Lundbeck for my 
study, in particular the 29 genes coding for the G protein coupled receptors 
ARRB1 and ARRB2, the cell surface proteins CD8 alpha and CD8 beta, the 
transcription factors CREB1 and CREB2, the kinases ERK1, ERK2, MAPK8 and 
MAPK14, the G proteins Gi2 and Gs, the receptors GR, MR, P2X7 and PBR, the 
pro-inflammatory cytokines IL-1β, IL-6 and IL-8, the regulator of G-protein 
signaling RGS2, the calcium binding protein S100A10, the serotonin 
transporter SERT, the monoamine transporter VMAT2, and the enzymes ADA, 
DPP4, IDO, MKP1, ODC1 and PREP. These proteins have many different 
functions. For example, ARRB1 uncouples G protein coupled receptors from G 
protein, and VMAT2 that pumps monoamine neurotransmitters from neuronal 
cytoplasm into synaptic vesicles.  
Eleven of the genes overlap with the genes identified from the small literature 
search in the previous chapter. 
This set of genes was chosen as the basis for studying and comparing controls 
and patients because of their supposed relationship to various psychiatric 
disorders. As listed in table 3, examples are ARRB2 that show reduced levels in 
leukocytes from depressed patients and GR that may be downregulated on 
immune cells during depression. In addition, the genes all showed good 
expression levels in whole blood. Whenever possible, expected up or down 
regulation of the gene expressions will be noted. 
The purpose of the chapter is also to collect biological information concerning 
the set of genes in order to better understand the molecular biology and the 
function of subsets of the genes. Using the renowned web application 
Ingenuity, the selected genes are grouped according to their location in the 
cell, that is, in the nucleus, cytoplasm, plasma membrane or extracellular 
space. Also, the genes are grouped into three biological networks whose main 
functions deal with hematological and immunological diseases, cellular growth 
and proliferation as well as cell death. The relation to cell death is expressed 
through the neurogenesis hypothesis which posits that depression is caused by 
neuronal death and that antidepressant drugs cause neuronal growth. The 
three networks include other genes involved in the same functions, which 
might give ideas to new possible biomarkers. Other significant functions of the 
selected genes are also described, like cancer, metabolic and cardiovascular 
diseases, indicating the possible links between these diseases and the 
relevance of checking subjects for these diseases prior to enrolling them into a 
clinical trial for studying psychiatric diseases.     
Various combinations of the above genes are involved in pathways such as 
glucocorticoid receptor signaling and G-protein coupled receptor signaling, the 
latter being a key focus area of Lundbeck.   
 
 
3. The genes selected by Lundbeck 
Prior to the start of this PhD, Lundbeck had chosen a set of genes as the basis 
for studying and comparing controls and patients with various psychiatric 
disorders like major depression (MDD), borderline personality disorder (BPD) 
and post-traumatic stress disorder (PTSD). The reader may consult the 
previous chapter for descriptions of these disorders.  
 
The set of genes is based a on literature search performed by Lundbeck. This 
set has been (slightly) modified throughout this thesis work due to weak 
expression of some genes or large expression variation of other genes. New 
genes were added to the list to replace those that were dropped. The most 
consistent sets of genes analyzed comprised of 25 or 29 gene expressions. For 
the Serbian group of controls and for PTSD patients with and without trauma 
(see next chapter on study design), six additional genes were tested. In this 
chapter, focus is on the 29 genes. 
 
It should be noted, that the genes selected come from both human and animal 
data, from both blood and brain tissue and from both RNA and protein 
expression data. Furthermore, Lundbeck had refined the list of selected genes 
based on whether they had good expression levels in blood. 
 
Table 3 contains the 29 genes, a short description, reasons for listing each 
gene according to material provided by Lundbeck and the literature, and an 
indication of the expected up- or down-regulation of each gene expression 
during various mental disorders.  
 
Gene  Reasons for including the gene 
ADA (adenosine deaminase) “Enzyme catalyzes the hydrolysis of adenosine to inosine”. 
“Adenosine is involved in learned helplessness pathway” 
(74). 
Lower levels in MDD subjects, possible correlation with 
DPP4 levels (75). 
ARRB1 (beta-arrestin 1) Uncouples GPCR (G protein coupled receptors) from G 
protein, involved in receptor internalization.  
Reduced in leukocytes from depressed patients (76) and 
correlated with the severity of symptoms, levels rise in rats 
upon antidepressant treatment (77). 
ARRB2 (beta-arrestin 2) See ARRB1 for rationale. Data do not show clear change in 
MDD. 
CD8 alpha (CD8 antigen alpha 
polypeptide) 
Identifies cytotoxic / suppressor T cells and is involved in T 
cell mediating killing. 
Lower CD8 expression in depressed patients. 
CD8 beta (T-cell surface 
glycoprotein CD8 beta chain) 
See CD8 alpha. 
CREB1 (cAMP responsive 
element binding protein 1) 
Transcription factor, cAMP pathways regulate T cell 
mediated immune responses; CREB1 stimulates 
neurogenesis (see text after the table) in dendrite gyrase. 
Associated with MDD” (78) with expected reduced levels 
(79), (80). 
CREB2 (cAMP responsive Transcription factor, cAMP pathways regulate T cell 
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element binding protein 2) mediated immune responses. 
DPP4 (dipeptidyl peptidase 4) “Cleaves X-proline dipeptides from the N-terminus of 
polypeptides” (81); binds ADA and serves to active T cells.  
Protein levels are downregulated in the blood of depressed 
(cancer) patients; serum activity higher in men than women 
(81); decreased enzyme activity may mean lower immune 
system function in MDD (75). 
ERK1 (extracellular signal-
related kinase 1) 
Kinase, reduced protein and mRNA in brain of depressed 
suicide subjects (29); In PBMC (peripheral blood 
mononuclear cells) balance between ERK1/2 and 
MAPK8/MAPK14 regulates anti- and pro-inflammatory 
cytokine secretion with ERK1/2 promoting neurogeneration 
and anti-inflammation. 
ERK2 (extracellular signal-
related kinase 2) 
See ERK1. 
Gi2 (G protein, alpha-inhibiting 
activity polypeptide 2) 
Increased in depressed patients’ platelets and normalized 
by antidepressant treatment (82); decreased in leukocytes 
of depressed patients and normalized by ECT (electroshock 
therapy) (83); increased in bipolar disorder, but not MDD 
(84). 
Gs (G protein, alpha-stimulating 
activity polypeptide 1) 
Increased in bipolar disorder, but not MDD (84); decreased 
in leukocytes of depressed patients and normalized by ECT 
(electro chock treatment) (83). 
GR (glucocorticoid receptor) Lower affinity for CORT than MR, may be downregulated on 
immune cells in depression (85); handling of neonatal rats 
increases GR/MR ratio in hippocampus and prevents 
depression (86); receptor level in dorsal hippocampus 
increased after 20 days of stress (87); interferon alpha 
regulates GR receptors in cell lines (88).  
INDO (indoleamine pyrrole 
2,3-dioxygenase) 
Reduces tryptophan levels, induced by pro-inflammatory 
cytokines and glucocorticoids and could cause tryptophan 
depletion (70) (perhaps leading to less serotonin synthesis) 
and/or kynurenine (tryptophan metabolite) increase which 
leads to neurontoxicity (89).  
May be expected to be increased in depressed patients.  
IL-1β (interleukin-1 beta) Pro-inflammatory cytokine, upregulated in depressed 
patients (90); cytokines can produce symptoms of 
depression (70), (18). 
IL-6 (interleukin-6) Pro-inflammatory cytokine, upregulated in depressed 
patients (91); cytokines can produce symptoms of 
depression (70), (18). 
IL-8 (interleukin-8) Pro-inflammatory cytokine; upregulated in monocytes of 
depressed patients (92); cytokines can produce symptoms 
of depression (70), (18). 
MAPK14 (mitogen-activated 
protein kinase 14) (p38 MAPK) 
In PBMC, balance between ERK1/2 and MAPK8/MAPK14 
regulates anti- and pro-inflammatory cytokine secretion; 
MAPK14 and MAPK8 expression promotes 
neurodegeneration and pro-inflammation.  
Expected increased levels in MDD (93), (94). 
MAPK8 (mitogen-activated 
protein kinase 8) 
See MAPK14. 
MKP1 (dual specificity 
phosphatase 1) 
Signalling pathways; regulates phosphorylation of ERK1/2 
(and hence activity), induced by glucocorticoids, 
upregulated in rat hippocampus after ECT (95). 
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Lower levels in MDD. 
MR (mineralocorticoid receptor) Higher affinity for CORT than GR, may be downregulated on 
immune cells in depression (85); handling of neonatal rats 
increases GR/MR ratio in hippocampus and prevents 
depression (86); receptor level in dorsal hippocampus 
increased after 10 days of stress (87). 
ODC1 (ornithine decarboxylase) First step and the rate limiting step in humans for the 
production of polyanimes, compounds required for cell 
division; expression linked to cell proliferation and 
immunomodulation.  
P2X7 (purinoreceptor P2X7) 
(P2RX7) 
P2X purinoreceptors are cell membrane ion channels, gated 
by ATP; potentially involved in neuroprotection and 
modulation of the inflammatory response (96) – believed to 
be linked to the onset of bipolar disorders (30); perhaps 
lower levels in MDD.  
PBR (peripheral-type 
benzodiazepine receptor) 
Widely distributed, involved in cell proliferation and 
immunomodulation (97).  
PREP (prolyl endopeptidase) Activity correlates with DPP4 in depressed patients; serum 
activity higher in men than women (81), stress induces 
PREP levels in the blood of responders; higher in subjects 
with PTSD and even higher in subjects with PTSD and 
depression (98). 
RGS2 (regulator of G-protein 
signaling 2) 
Acts as GTPase activation protein to terminate G protein 
signaling; KO mice show increased anxiety, reduced T cell 
proliferation, reduced IL-2 synthesis (99); RGS2 is highly 
expressed in lymphocytes where it can influence cytokine 
production (100). 
Low levels in MDD are expected. 
S100A10 (S100 calcium-binding 
protein A10) (p11) 
Increases localization of 5-HT-1b subtype to cell surface, 
expression increased in rodent brains after antidepressant 
treatment or ECT and decreased in animal model of 
depression or brains of depressed humans (101). 
SERT (serotonin transporter) Target of SSRI / SNRI / TCA antidepressant drugs; 
influences serotonin levels at post synaptic junctions. 
Lower CNS expression/binding in patients with depression. 
VMAT2 (vesicle monoamine 
transporter 2) 
Pumps monoamine neurotransmitters from neuronal 
cytoplasm into synaptic vesicles; VMAT2 binding higher in 
bipolar patients in thalamus and brainstem (102); in 
platelets there is a significant elevation of VMAT2 
expression in MDD patients versus controls (103). 
Table 3: 29 genes selected by Lundbeck 
 
Eleven of the genes in the above list overlap with the ones identified from the 
limited literature search in chapter two. They are SERT, IDO, CREB1, GR, 
MAPK14, MR, IL-1β, IL-6, ERK1, ERK2, P2X7 (all related to depression).  
 
The main reason for the overlap between chapter two genes not being greater 
with the genes listed in table 3, is that a literature search of genes involved in 
each disorder has not been a focus area, but was merely done to get an idea of 
genes involved in the psychiatric disorders described.  
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In the conclusion and discussion chapter, genes separating groups will be 
compared to expected/hypothesized expression regulations in table 3 above 
when possible. It must be stressed that, in general, replication of previous 
findings for complex polygenic diseases is always difficult. The same principal 
replication problems exist for gene expressions studies, especially for 
microarray studies, as for genetic association (SNP) studies, perhaps to an 
even greater extent in the latter due to the millions of SNPs present in the 
human genome. “Initial positive findings are hard to replicate due to small 
number of samples, population stratification, phenotype definition (see chapter 
2), genetic heterogeneity, low relative risk, multiple testing, normalization 
issues, selection bias especially for the control group, and other factors” (61). 
 
3.1 Biological networks, functions and pathways 
More biological knowledge can be obtained from the list of selected genes by 
looking at how different combinations of genes are involved in various 
biological functions and pathways. This requires updated online database tools 
capable of handling such bioinformatics / systems biology queries into data, 
here a list of genes. Several such online tools exist. The best I have worked 
with so far is called Ingenuity Pathways Analysis (104) and makes use of only 
manually curated scientific literature. It is a commercial web application that 
Lundbeck has access to and it will be used to gain more biological insight from 
the list of individual genes.   
 
Below various outputs from Ingenuity are presented that highlight various 
biological network aspects of the selected genes: To begin with, the 29 gene 
products are grouped after their location in the cell, that is, in the nucleus, 
cytoplasm, plasma membrane or extracellular space (figure 4). In addition, the 
29 genes are arranged into networks, the most significant9 and relevant 
biological functions of combinations of genes are presented as well as the most 
significant9 and relevant pathways. All this information may broaden the 
insight of the biological basis of the 29 selected genes and provide insight into 
perturbed systems, once statistical and machine learning techniques have 
identified sets of genes separating different control and patient groups.  
 
Figure 4 shows the location of the 29 genes in the cell and thus relates the 
genes in a cellular context.  
                                                 
9 The significance value associated with a functional or pathway analysis is a measure of the likelihood that the 
association between a set of selected genes and a given process or pathway is due to random chance. This is assessed 
via the right-tailed Fisher's Exact Test. The smaller the p-value the less likely that the association is random and the 
more significant the association.  
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Figure 4: Location of the 29 genes in the cell. ATF2=CREB2, NR3C1=GR, NR3C2=MR, 
DUSP1=MKP1, TSPO=PBR, MAPK1=ERK2, MAPK3=ERK1, INDO=IDO, SLC6A4=SERT, 
SLC18A2=VMAT2, GNAI2=Gi2 and GNAS=Gs. Ingenuity output. 
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From the figure it can be seen that the gene products that function in the 
nucleus consists of the transcription factors CREB1/2, the HPA-axis activity 
regulating gluco- and mineralocorticoid receptors GR and MR as well as MKP1 
and RGS2. The cytoplasm contains the kinases ERK1/2 and MAPK8/14, the 
arrestins ARRB1/2 as well as ADA, ODC1, PBR, PREP and S100A10. The 
transporters SERT and VMAT2 are located in the plasma membrane, as are the 
G proteins Gi2 and Gs, the transmembrane glucoproteins CD8 alpha and CD8 
beta, the ion channel P2X7 as well as DPP4. The extracellular space contains 
all the three interleukins IL-1β, IL-6 and IL-8 related to the immune response.  
 
Next, all the 29 genes are grouped into networks in table 4 and it can be seen 
all the genes group nicely into three networks: 
 
ID Molecules in Network 
Focus 
Molecules Main Functions 
1 
Angiotensin II receptor type 1, ARRB1, ARRB2, 
ATF2, CD3, DUSP1, ERK1/2, G alpha, G alphai, 
G protein beta gamma, Ige, IL1B, JINK1/2, 
Mapk, MAPK1, MAPK3, MAPK8, Mek, Mek1/2, 
NfkB-RelA, P2RX7, p70 S6k, Pdgf, Pdgf Ab, 
PI3K, Pkg, PLA2, Pld, PP2A, Rac, Ras, Ras 
homolog, S100A10, SLC6A4, TCR 11 
Cellular Growth and 
Proliferation, Connective 
Tissue Development and 
Function, Organismal 
Functions 
2 
Akt, Alkaline Phosphatase, AMPK, Ap1, C1q, 
Calcineurin protein(s), Ck2, Creb, CREB1, Fgf, 
GNAS, Hsp70, Hsp90, IL1, IL6, IL8, INDO, 
Insulin, Jnk, LDL, MAPK14, NFkB, NR3C1, 
NR3C2, ODC1, P38 MAPK, PDGF BB, Pka, 
Pkc(s), PLC, RGS2, SLC18A2, STAT5a/b, Tgf 
beta, Vegf 11 
Cell Death, Hematological 
Disease, Immunological 
Disease 
3 
ADA, Adenylate Cyclase, Alcohol group acceptor 
phosphotransferase, ATAD4, beta-estradiol, 
Caspase, CD8A, CD8B, CDCA7, CSTB, Cyclin A, 
dihydrotestosterone, DPP4, GNAI2, H2-T18, 
HCG 1787519, Histone h3, KIAA1967, KLK15, 
MAPK8, MAPK11 PREDICTED, MHC Class I, 
MMD, MYC, NBPF15, NFRKB, PARP10, PREP, 
PRL2C3, RNA polymerase II, RPL21 (includes 
EG:79449), SSBP2, TNF, TSPO, ZNF267 8 
Cancer, Cell Cycle, 
Immunological Disease 
Table 4: The 29 genes arrange nicely into three networks. For different gene names, see 
legend to figure 4. Ingenuity output. 
 
Table 4 shows that e.g. network 1 contains 11 of the 29 genes (shown in 
bold), the top three functions/networks the 11 genes participate in and the 
other genes  in the Ingenuity database in these networks. Looking at the top 
three functions/networks for the three networks some of the most relevant 
functions (for this thesis) have to do with hematological and immunological 
diseases which supports that the genes, Lundbeck has chosen to look at, are 
expressed in blood. Furthermore, cellular growth and proliferation as well as 
cell death/apoptosis is mentioned. This is interesting because one hypothesis 
that was not described in chapter two had to do with neurogenesis. This 
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hypothesis posits that depression is caused by neuronal death and that 
antidepressant cause neuronal growth and proliferation. It is also worth 
noticing cancer is being mentioned. This is interesting in the sense that cancer 
might cause gene expression changes in some of the selected genes, meaning 
it could be important to check subjects for cancer prior to their inclusion in a 
clinical trial.  
 
To demonstrate the complexity of the interactions in a gene expression 
network, a schematic involving the genes for network 1 (from table 4) is 
shown in figure 5. 
 
 
Figure 5: Network 1 from table 4 comprising 11 (shown in grey) of the 29 genes interacting 
with the other genes in the network. See the text for the various kinds of interactions. For 
different gene names, see legend to figure 4. Ingenuity output. 
 
In figure 5, examples of interactions are: Activation/inhibition, binding, 
expression, phosphorylation/dephosphorylation, protein-DNA binding, protein-
protein binding and transcription. Networks 1 (repeated for consensus), 2 and 
3 are shown in appendix 1. Going into details about all the genes and 
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interactions is beyond the scope of this thesis. However, in the results chapter, 
bioinformatics tools will be used to predict new possible biomarkers (with a 
focus on protein-protein interactions) based on either a merged version of the 
three networks (from table 4) or with the addition of putative genes associated 
with bipolar disorder. Note that table 4 and e.g. figure 5 alone can give ideas 
regarding new biomarkers. 
 
 
The top functions/networks shown in table 4 included other genes (in addition 
to the 29 genes) involved in the same functions. It is also possible to look into 
functions of combinations of the 29 genes alone. 61 combinations are 
significant (according to the right-tailed Fisher's Exact Test and a significance 
level of 1%) and listed in appendix 2. Some of the most relevant and 
significant combinations are listed in table 5 below (the most significant first). 
 
Function Molecules 
Inflammatory Disease IL8, DPP4, MAPK3, MAPK8, IL6, P2RX7, CD8A, NR3C1, ODC1, 
GNAI2, ARRB2, MAPK14, DUSP1, ADA, IL1B, SLC6A4, S100A10 
Cell Death DPP4, IL8, MAPK1, MAPK3, MAPK8, P2RX7, IL6, SLC18A2, CD8A, 
NR3C1, ODC1, ATF2, GNAS, ARRB2, MAPK14, DUSP1, CREB1, ADA, 
TSPO, IL1B, S100A10 
Cellular Growth and 
Proliferation 
DPP4, IL8, RGS2, MAPK1, MAPK3, MAPK8, P2RX7, IL6, CD8A, 
NR3C1, ODC1, ATF2, GNAI2, ARRB2, MAPK14, DUSP1, CREB1, ADA, 
IL1B, INDO, SLC6A4, NR3C2, S100A10 
Cancer IL8, DPP4, MAPK1, MAPK3, MAPK8, P2RX7, IL6, CD8B, NR3C1, 
ODC1, ATF2, GNAI2, GNAS, ARRB2, MAPK14, ARRB1, DUSP1, 
CREB1, ADA, IL1B, NR3C2, S100A10 
Cardiovascular Disease IL8, RGS2, MAPK1, MAPK3, MAPK8, IL6, SLC18A2, NR3C1, GNAI2, 
MAPK14, DUSP1, CREB1, IL1B, SLC6A4, NR3C2, S100A10 
Hematological System 
Development and 
Function 
IL8, DPP4, RGS2, MAPK1, MAPK3, MAPK8, P2RX7, IL6, CD8A, 
NR3C1, CD8B, GNAI2, GNAS, ARRB2, MAPK14, DUSP1, CREB1, ADA, 
IL1B, INDO 
Immunological Disease IL8, DPP4, MAPK3, MAPK8, P2RX7, IL6, CD8A, NR3C1, GNAS, 
MAPK14, DUSP1, ADA, IL1B, SLC6A4, S100A10 
Hematological Disease DPP4, GNAS, IL8, MAPK14, MAPK8, ADA, IL1B, P2RX7, IL6, NR3C1 
Neurological Disease IL8, DPP4, MAPK8, IL6, P2RX7, SLC18A2, NR3C1, ATF2, PREP, 
GNAS, MAPK14, CREB1, ADA, TSPO, IL1B, SLC6A4 
Metabolic Disease DPP4, GNAS, DUSP1, CREB1, ADA, SLC6A4, IL1B, NR3C2, IL6, 
NR3C1, S100A10 
Immune Response IL8, DPP4, RGS2, MAPK3, MAPK8, IL6, CD8A, NR3C1, GNAI2, GNAS, 
ARRB2, MAPK14, DUSP1, ADA, IL1B, INDO 
Psychological Disorders RGS2, CREB1, IL1B, TSPO, SLC6A4 
Table 5: Functions of significant combinations of the 29 genes. For different gene names, see 
legend to figure 4. Ingenuity output. 
 
Table 5 lists genes associated with the functions of inflammatory and 
immunological diseases as well as immune response and hematological system 
development and function. These functions fit very well with the HPA-axis and 
cytokine hypotheses of depression. SERT (SLC6A4) is involved in several of the 
functions among them psychological disorders and inflammatory diseases 
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fitting well with the monoamine hypothesis and the interaction between SERT 
and the interleukins/cytokines. As with the top functions/networks, cellular 
growth and proliferation and cell death may be good indications of a 
psychiatric disorder according to the neurogenesis hypothesis of depression 
(described above). It seems like it could be important to check subjects in 
clinical trials for cancer, cardiovascular, neurological and metabolic diseases as 
these might influence quite a lot of 29 genes. This also applies for e.g. 
inflammatory diseases that are not of interest like lupus or acne or 
immunological diseases of no interest in a trial like damage of spleen or 
leucopenia.  
 
Finally, various combinations of genes are involved in different pathways. All 
42 significant pathways (significance level is set to 1%) are listed in appendix 
3. Below in table 6 are some of the most relevant and significant pathways 
ordered after significance (most significant in the top).  
 
Pathway Molecules 
Glucocorticoid Receptor 
Signaling 
IL8, MAPK14, MAPK1, DUSP1, MAPK3, CREB1, MAPK8, IL1B, 
NR3C2, IL6, NR3C1 
IL-6 Signaling IL8, MAPK14, MAPK1, MAPK3, MAPK8, IL1B, IL6 
cAMP-mediated Signaling GNAI2, GNAS, RGS2, MAPK1, DUSP1, MAPK3, CREB1, ATF2 
G-Protein Coupled Receptor 
Signaling 
GNAI2, GNAS, RGS2, MAPK1, DUSP1, MAPK3, CREB1, ATF2 
p38 MAPK Signaling MAPK14, DUSP1, CREB1, IL1B, ATF2 
T Cell Receptor Signaling MAPK1, MAPK3, MAPK8, CD8A, CD8B 
Serotonin Receptor Signaling SLC6A4, SLC18A2 
Apoptosis Signaling MAPK1, MAPK3, MAPK8 
Table 6: Pathways of significant combinations of the 29 genes. For different gene names, see 
legend to figure 4. Ingenuity output. 
 
Table 6 shows the involvement of the HPA-axis by including glucocorticoid 
receptor, p38 MAPK and cAMP-mediated receptor signaling. G-protein coupled 
receptor signaling (this list overlaps completely with the gene list of cAMP-
mediated receptor signaling) is a key focus area of Lundbeck. The immune 
system also comes into play with IL-6 signaling and T cell receptor signaling. 
Monoamine activity is noted via the serotonin receptor signaling. Finally, cell 
death (apoptosis) signaling also seems to play a role involving three genes.   
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We are now ready to present the study design in terms of the various control 
and patient groups analyzed. There is a US control group of 299 individuals, a 
30 person UK control group with three time point measurements on two 
consecutive days, a Danish control group with 89 members and a 78 person 
Serbian control group. Also, there are data from borderline personality disorder 
(BPD) patients, acute post-traumatic stress disorder (PTSD) patients, patients 
with trauma but without PTSD and finally expression measurements from 
remitted PTSD patients.  
For the US control group, the Danish control group and one part of the BPD 
patient group, questionnaire data with clinical information is also available. 
Focus has been on clinical information relating to both psychological factors 
and covariates as both might be indicative of clinical symptoms of the studied 
affective disorders. Examples of psychological factors are a family history of 
depression, anxiety or suicide, lifetime experience of various affective disorder 
episodes, and sleep problems or lack of energy during the two week period 
prior to blood sampling. Examples of covariates are age, gender, body mass 
index, tobacco use, and alcohol use. The clinical variables of interest were then 
coded into numbers, and as an overall guideline, coding was done as intuitively 
as possible with, in general, a score equal to zero if the respondent had not 
experienced a predisposition factor. The score was then increased as the 
symptom level increased. Composite scores were also created like an early life 
stress score covering stressful life events before the age of 15 (this is an 
important factor predisposing to various affective disorders, see chapter 2) and 
vegetative symptom score, which were considered to be a better indicator of 
melancholic depression.  
The chapter also includes a short outline of the applied ‘quantitative 
polymerase chain reaction’ (qPCR) technique for quantifying the gene 
expressions in blood. A short illustration shows how blood is first drawn into a 
tube ‘freezing’ the blood, how RNA is then extracted and cDNA created which is 
finally measured. A crucial part of quantifying gene expressions relates to 
normalization to account for possible variation in the amount and quality of 
RNA or cDNA between the biological samples obtained from the different 
control and patient groups across the world and measured at different time 
points. Here, it is described how Lundbeck chose to work with seven 
housekeeping genes to solve the normalization issue.  
Various sources of measurement errors are described relating to the self 
assessment in the questionnaire responses, the interpretation of the 
questionnaire responses, possible error sources moving from questionnaire to 
excel file and also, relating to the qPCR technique and the actual clinical 
diagnose. 
Finally, qPCR is compared to another widely applied gene expression technique 
– microarrays. In brief, microarrays are suitable for the measurements of 
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thousands of genes simultaneously, but the analytical process involves risk of 
over-interpreting the results due to data overfitting. On the other hand, qPCR 
is more sensitive and advances reproducibility of the data.  
 
As mentioned in the introduction, blood samples have been collected for a 
number of control and patient groups suffering from borderline personality 
disorder and post-traumatic stress disorder (PTSD). Gene expressions in whole 
blood have then been measured for the same 25-30 genes in all samples. 
Depending on control and patient groups compared, the overlapping gene 
expressions were utilized in the analyses. Furthermore, in some cases clinical 
information was accessible. Table 7 sums up the data available from Lundbeck 
for analyses in this thesis. The results of the various analyses are presented in 
the results chapter. 
 
Control/patient group Short description #Subjects #Genes Clinical information? 
1) ABS controls 
 
- SH ABS controls 
All US controls  
(both genders) 
- ‘Super healthy’ US 
controls (both 
genders) 
299 
 
- 59 
29 
 
- 25 
Yes, based on an US 
questionnaire. 
 
2) UK controls UK controls (males);  
3 time points  
30 29 No. 
3) DC controls Danish controls 
(both genders) 
89 29 Yes, based on a 
Danish questionnaire. 
4) Borderline patients Two cohorts of 
patients (mostly 
females) 
21 29 For one cohort only. 
5) PTSD groups: 
- PTSD controls 
 
- Remitted PTSD 
patients 
 
- Acute PTSD patients 
 
 
- Trauma patients 
(Men only) 
- Serbian controls 
 
- Remitted Serbian 
PTSD patients  
 
- Serbian acute PTSD 
patients 
 
- Serbian trauma 
patients without PTSD 
 
78 
 
41 
 
 
66 
 
 
87 
35 
 
No. 
Table 7: Data available for analysis in this thesis. Control/patient group names contain the 
abbreviations used later in the thesis. Content is explained after the table. 
 
Group 1) The first data available was obtained from a large US group of 299 
healthy male and female subjects. 29 gene expressions (listed in table 3, 
chapter three) were measured in this ABS control group that consisted of four 
cohorts. The first of these cohorts was called the ‘super healthy’ controls, in 
short SH ABS. The SH ABS controls were selected by Lundbeck based on 
having a BMI (body mass index) less than 30 and having taken no drugs the 
last three months. By checking their questionnaire answers (more about this in 
the questionnaires section), it turned out that the SH ABS had in general lower 
stress scores, fewer symptoms and less history of family depression, anxiety or 
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suicide than the rest of the ABS subjects. In the SH ABS, only 25 gene 
expressions were measured. The reason was that Lundbeck in the beginning of 
the study was experimenting to identify the final set of genes to be 
investigated. They started with 29 genes, found that four of them showed poor 
expression or large variability, cutting the list down to 25 genes used for 
cohort 1/SH ABS. Later four additional genes were added bringing the list of 
genes up to the 29 genes described in the previous chapter. 
All 299 controls filled out a questionnaire that is described later in this chapter. 
Not being a homogenous control group, the ABS group was used to make 
predictions about potential gene expression changes in depressed patients. 
There were two aspects to the predictions; the first was to detect possible 
gene expression trends in depressed patients and the other was to identify 
intermediate phenotypes among the controls.   
The SH ABS group was used for various comparisons to the patients. 
 
Group 2) The UK controls comprise 30 healthy male subjects that had their 
blood taken at three different time points: Day 0 at 8 am, Day 0 at 2 pm and 
Day 1 at 8 am. The purpose was to investigate whether any of the 29 gene 
expressions differed significantly between the three time points. The UK 
controls have been part of various comparisons to patients.  
 
Group 3) The DC controls consists of 89 Danish healthy male and female 
subjects that had filled out an extensive questionnaire. This questionnaire is 
not the same as the one used for the US ABS controls – questionnaires will be 
dealt with later in this chapter. 29 gene expressions were measured in each 
subject. The expression values of the Danish controls have been compared to 
the US SH ABS controls and also been part of various other comparisons to 
patients. 
 
Group 4) The expression profiles of 21 borderline patients arrived in two 
cohorts with the second cohort ready for analysis eight months after the first. 
The first cohort consisted of female patients only and clinical information was 
also available. The second cohort consisted of mostly females with addition of 
two males and, apart from gender, age and BMI, no clinical information were 
available.  
29 gene expressions were measured in whole blood in all these patients. The 
borderline patients have been used to compare to control subjects and other 
patient groups.  
 
Group 5) All PTSD subjects come from Serbia and are male. They are divided 
into 78 controls, 66 acute PTSD patients, 87 patients with trauma without 
PTSD and 41 remitted PTSD ‘controls’. The last three groups have experienced 
war events. 35 gene expressions were measured in the PTSD groups, that is, 
six genes were added to the analysis compared to the 29 gene list. With the 
PTSD groups, it has been possible to do interesting comparisons, such as 
comparing the expression profiles of controls with remitted patients and 
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compare acute patients with patients with trauma but without PTSD. The PTSD 
groups have also been part of other comparisons.  
 
 
Publicly available data has also been analyzed with bioinformatics tools. The 
Wellcome Trust Case Control Consortium has compared the genetic profiles 
(SNP data) in blood of 2000 UK bipolar patients with 3000 UK controls. The 
interactions between the genes thus associated with bipolar disorder and the 
29 genes are investigated, see the results chapter. 
 
4.1 Questionnaires 
The US ABS control group of 299 healthy subjects filled out a questionnaire 
with approximately 50 questions, the majority of them with multiple answer 
possibilities in the form of check boxes (see appendix 4). Below the questions 
are listed that were chosen by Lundbeck for coding in order to compare 
responses to gene expressions. Coding issues and possible sources of error are 
described as well.   
 
The questions chosen for further processing related to:  
 
1. Age 
2. Gender 
3. Weight and height (BMI) 
4. Frequency of 
a. Tobacco use 
b. Alcohol use 
5. Lifetime and three months drug use 
6. Lifetime and current medical history  
7. Experienced and frequency of experience during the last two weeks of  
a. Feeling low 
b. Lack of energy 
c. Less interesting in daily activities 
d. Difficulties concentrating 
e. Sleep problems 
f. Anxiety  
g. Not being able to cope with daily problems, having considered 
suicide 
8. Experienced changes in and level of change during the last two weeks in 
a. Appetite  
b. Weight 
c. Sexual interest 
9. Lifetime experience of various affective disorder episodes including 
alcohol and substance abuse 
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10. Lifetime treatment of various affective disorder episodes including 
 alcohol and substance abuse 
11. Family history of  
a. Depression 
b. Anxiety 
c. Alcohol abuse 
d. Other substance abuse, 
e. Schizophrenia/psychosis 
f. Suicide 
12. Early life stressful events (before age 15) 
13. Recent stressful events (in the last 12 months) 
 
These questions can be divided into clinical variables, that is psychological 
predisposition factors, and covariates.  The following items on the list are 
considered to be covariates (item 1-5) – age, gender, BMI, tobacco use, 
alcohol use, caffeine intake and lifetime and three months drug use. It is 
hypothesized that some gene expressions might be correlated with a covariate 
or show differences between e.g. smoking and non-smoking respondents. Item 
6 - lifetime and current medical use – is also a covariate included to analyze 
how various diseases and inflammations influence the expression levels of the 
selected genes.  
 
Some of the clinical variables in the list above (item 7 and 8) are directly 
related to the DSM-IV-TR depression symptoms described in Chapter 2. 
Furthermore, as noted in that chapter, depression in some cases runs in 
families. This possibility is covered in the controls by item 11 in the list. Item 
12 and 13 deal with stressful life events as it is known that stressful situations 
might trigger a depressive episode.  Also, since subsequent depressive 
episodes may occur with or without an obvious trigger, checking for previous 
episodes is covered in item 9 and 10. By having questions in the ABS 
questionnaire matching clinical symptoms and possible causes, observation of 
intermediate phenotypes becomes feasible as the clinical variables reflect an 
enhanced risk of developing an affective disorder. Checking for the influence of 
covariates could, in addition, eliminate some false positive findings.   
 
Coding 
After selecting the clinical variables and covariates of interest, they were coded 
into numbers that is, scored. In some cases, Lundbeck calculated composite 
scores as well. Examples of these two kinds of coding are given below. A 
complete list of applied variable coding for the ABS controls can be found in 
appendix 5. As an overall guideline, coding was done as intuitively as possible 
with, in general, a score equal to zero if the respondent had not experienced a 
predisposition factor, that is, a particular symptom was not present at all. The 
score was then increased as the symptom level increased – examples are 
given below.  
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Coding a discrete covariate like tobacco use was done by setting the tobacco 
score equal to zero if the respondent smoked less than a cigarette per week, 
otherwise the score was set equal to one: 
 
Tobacco use 
None ever 
None, past 12 months 0 
Less than 1 per week__________ 
1 to 10 per day 
10 to 20 per day  1 
Greater than 20 per day 
 
Tobacco use was also binned/divided into three levels, low (less than 1 per 
week), medium (1-10 per day) and heavy users (more than 10 per day). 
 
Coding a discrete clinical variable like experienced anxiety was done by giving 
each answer possibility a score:  
 
Anxiety level (past two weeks) 
Never  0 
Sometimes 1 
Most days  2 
Every day  3 
 
 
In the case of scoring the various family histories, a separation was done 
between first and second rank relative affected by an affective disorder. This 
should account for the fact that a respondent with a first rank relative (mother, 
father, child, and sibling) is more prone to develop depression (could have a 
genetic predisposition) than a respondent with a second rank relative (uncle, 
aunt, grandparent, and grandchild). There was no consideration for the 
number of relatives affected. Scoring a family history of e.g. alcohol abuse was 
then done by assigning the score zero if no relatives had a history of alcohol 
abuse, a score of 1 if any secondary relative had that family history, and a 
score of 2 if any primary relative had a family history of alcohol abuse.  
 
The family history of depression was combined with the family histories of 
anxiety and suicide, since these disorders range closely and predispose to 
depression. The scoring of a family history of depression, anxiety and suicide 
was then done exactly as the example with a family history of alcohol abuse 
above. In the beginning, each family history was coded separately but it was 
found to be more advantageous to combine them.  
 
The composite scores, defined by Lundbeck, were early life stress score (105), 
recent stress score (105), seven symptom score, symptom score sum and 
vegetative symptom score (see appendix 5). For instance, early life stress 
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score was defined as the sum of boxes checked for stressful events before the 
age of 15 (item 12 in the questionnaire list above). The top item (death of both 
parents) had a value of twenty and the bottom item in the list (major change 
in living conditions) had a value of eleven. The symptom score sum was the 
sum of scores for ten symptoms (feeling low, lack of energy, less interest in 
daily activities, difficulties concentrating, sleep problems, difficulty coping, 
experienced anxiety, appetite change, weight change and sexual interest 
change). These scores were considered as semi-continuous scores and 
sometimes binned into two or three bins to investigate whether binning would 
yield different results than correlations. This turned out to be the case (more 
about this in the results chapter). In the two-bin symptom score sum case, a 
respondent was assigned the score zero if he/she had no symptoms, otherwise 
the score one. In the three-bin early or recent stress score, the scores were 
divided into bin one if the score equaled zero, in bin two if the score was 
between one and thirty, otherwise in bin three. For the symptom score sum, 
bin one was for the respondents with a symptom score of zero, bin two if the 
score was between one and ten, and from eleven and above bin three applied. 
The composite vegetative symptom score, which were considered to be a 
better indicator of melancholic depression, was coding into four levels ranging 
from zero (no problems) to three (most problems). 
 
 
The Danish DC questionnaire 
The questionnaire used for the Danish control group was also a self-rated 
questionnaire, but it was somewhat more extensive than the above 
questionnaire. It consisted of around 80 main questions with, in general, more 
sub questions/answer possibilities per question than the US questionnaire. 
Since it was 30 pages long (compared to the US 11 page questionnaire), it is 
not included in the appendix.  
 
Focus started and remained on questions relating directly to the US 
questionnaire for comparability reasons. Some of the overlapping questions 
related to age, gender, BMI, lifetime and three months drug use, tobacco and 
alcohol use, family history of affective disorders, lifetime and current medical 
history, recent changes in appetite, weight, sexual interest and sleep, and 
recent stressful life events. As far as possible, these questions were then coded 
the same way as the US questions, but this coding is not described further 
here. 
 
Also, I never obtained the borderline disorder questionnaire, but Lundbeck 
coded the relevant questions just like with the US ABS questionnaire, see 
appendix 5. 
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Sources of measurement error related to the questionnaires 
There are several different sources of measurement errors relating to the 
questionnaires, see table 8 for examples. 
 
 
Source of measurement error Description  
Questionnaire responses 
- self assesment 
Two types of errors pertain to self assessment of 
questionnaires.  
- First, the two questionnaires contain many 
questions, with the DC questionnaire being the most 
extensive. It could be assumed that in some cases 
respondents could get tired from answering the 
questions and would mark some answers without 
paying careful attention to the actual topic.  
- Second, respondents are asked to make self 
assessments. One could question the validity of such 
an approach. For instance, do respondents recall 
events/issues correctly (selective memory)? Do they 
know which disorder a family member actually 
suffered from, if any? These two issues could be 
addressed if the responses could be double checked 
with e.g. other family members or a family medical 
history, if possible. 
Some of self rating questions might be influenced by 
the respondent having a good or bad day at the time 
of filling out the questionnaire or influenced by a 
respondent’s normal (and perhaps unrealistic) way of 
perceiving his/her abilities.  
Interpreting questionnaire responses  
- different rating 
- selection of clinical variables and 
covariates 
- composite scores  
- If a different rating was applied to the categorical 
answer possibilities of a question, it would probably 
not yield different results as long as the rating was 
sensible, but this has not been tested directly10.  
Somewhat similar to the above topic, is the issue of 
whether a continuous clinical variable should stay 
continuous or be binned into a categorical clinical 
variable. Both options have been tried and the results 
are not the same (more about this in the results 
chapter). 
- Selecting the clinical variables and covariates of 
interest involves subjectivity. Selecting other variables 
than the chosen might yield different results and 
interpretations.  
- Related to the above topic, alternative composite 
scores, which would also make sense, could have been 
calculated and would most probably yield different 
results and interpretations compared to the applied 
composite scores. 
From questionnaire to excel-file 
- typing errors 
- coding errors 
- calculation errors 
- The questionnaires are all filled out handwritten. 
Typing the answers into an Excel file might result in a 
probably small fraction of typing errors.  
- When the answers in Excel had to be coded, a small 
                                                 
10 Two and three bin scores applied a different binning to some variables, but in general the results did not differ 
between the two kinds of binning. 
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percentage of the coding might be mistyped. This also 
applies to the composite scores.  
- Also, the composite scores might be miscalculated 
due to human errors. 
Table 8: Sources of measurement error and descriptions related to the questionnaires. 
 
In general, care was taken to avoid as many of the sources of measurement 
error as possible, but still some errors relating e.g. to self assessment or 
typing/coding errors might be present in the data. 
 
4.2 qPCR and normalization 
As mentioned in the introduction, (whole) blood measurements have been 
used in a number of recent studies of various psychiatric disorders (6), (7), 
(8), (9), (10), (11) based on the assumption that peripheral changes are part 
of the biology of mental disorders (5). 
 
An important preprocessing step in the study design relates to the biochemical 
reaction technique (qPCR method) of quantifying gene expressions from whole 
blood samples. All work related to qPCR and normalization was solely done by 
Lundbeck, so below only a brief introduction is given to qPCR, and the applied 
normalization method. qPCR is compared to microarrays to highlight 
advantages and disadvantages of these widely applied gene expression 
measurement techniques. Finally, some sources of qPCR measurement error 
are mentioned. For more information on qPCR, references are given to the 
literature and websites.  
 
qPCR is short for ‘quantitative polymerase chain reaction’ or more accurately in 
this thesis ‘quantitative real-time polymerase chain reaction’. It is a standard 
laboratory technique based on the polymerase chain reaction, which is used to 
amplify and simultaneously quantify a targeted DNA molecule depending on 
the experimental design. It enables both detection and quantification of the 
target. Expression levels can be reported as absolute number of copies or 
relative to specific reference genes. Lundbeck chose the relative method of 
reporting gene expression levels (see below). 
 
“The procedure follows the general principle of polymerase chain reaction; its 
key feature is that the amplified DNA is quantified as it accumulates in the 
reaction in real time after each amplification cycle.” (107) The amount of DNA 
is measured after each cycle by use of fluorescent dyes. As is the case in the 
Lundbeck study, real-time PCR is combined with reverse transcription to 
quantify messenger RNA (mRNA), enabling Lundbeck to quantify relative gene 
expressions in whole blood, see illustration in figure 6. Here it should be 
remembered that unlike the genome (DNA) which is context-independent, the 
transcriptome (RNA) is context-dependent, that is, the mRNA level varies with 
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physiology and pathology (106). Further information on qPCR can be found in 
e.g. (107), (106), (108) and (109).  
             
Figure 6: Real-time PCR process. First blood is drawn into a PAXgene tube having the purpose 
of ‘freezing’ the transcription profile and enabling long-term storage. Then RNA is extracted 
from whole blood sample, then cDNA is generated which is finally measured by quantitative 
real-time PCR. 
cDNA 
RNA 
Blood sample 
Result 
Measure cDNA by 
real-time PCR 
Extract RNA 
Generate cDNA 
 
A crucial part of quantifying gene expressions relates to normalization to 
account for possible variation in the amount and quality of RNA or cDNA 
between different samples and thus control for variables that could mask any 
underlying biological changes. This is certainly relevant in the Lundbeck study 
with blood samples from various control and patient groups from different 
countries and processed at different dates. One way to effectively compare 
gene expression patterns between different samples is to use normalization 
genes, also known as housekeeping genes (HKG). “The term housekeeping 
gene refers to genes that encode for proteins whose activities are essential for 
the general maintenance of cell function” (110). “In the context of qPCR 
relative quantification, it is largely assumed that expression of a HKG is 
invariant across control and disease groups; however, the expression of some 
HKGs is regulated in a number of cell types and tissues” (110) making the 
choice of HKGs challenging.  
It is generally advised not to rely on just a single HKG (106), (109), and 
Lundbeck has spent quite some time and effort to identify a proper set of 
HKGs; Lundbeck started out by trying a method that involved comparing the 
expression of a gene with the expression of two HKGs in each sample. It 
turned out that these two HKGs could not be used to normalize every data set 
since different groups of subjects required different HKGs which might be due 
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to drug effects, disease effects and perhaps also ethnicity differences. If the 
same HKGs are not used in each group, expression values can not be 
compared. Next, Lundbeck tried using seven HKGs based on the rationale that 
even though all seven may not be ideal for any particular experiment, by using 
a large number of HKGs to normalize they would reduce the variation 
introduced by the noisy genes and end up with a good method. The seven HKG 
approach is the one chosen by Lundbeck, and was applied to most of the data 
available (however, not for cohort 2, 3 and 4 of the ABS control data that were 
normalized with two HKGs) for analysis thus allowing the comparison of every 
experiment to all others.  
 
 
qPCR vs. microarrays  
To better understand the advantages and limitations of qPCR, it can be 
compared to the microarray technique that is used to measure thousands of 
gene expressions simultaneously. Table 9 compares some of the pros and cons 
of the two techniques. 
 
 
qPCR (real-time) Microarrays 
Advantages Disadvantages Advantages Disadvantages 
• Extremely sensitive 
• Large dynamic range 
• Relatively inexpensive 
per sample 
• Focus on small number 
of gene expressions 
advances reproducibility 
of data (small chance of 
over-interpretations) 
• Fast 
• Suitable only 
for relatively 
few selected 
genes at the 
time  
• Careful controls 
necessary to 
interpret data 
and avoid 
contamination.  
• Suitable for the 
measurements 
of thousands of 
genes 
simultaneously.  
• Good at 
identifying new 
possible 
biomarkers. 
• Less sensitive 
than qPCR. 
• Relatively 
expensive per 
sample. 
• May be more 
expensive in 
start-up cost 
than qPCR 
equipment 
• Not appropriate 
for a few genes 
• Large numbers of 
genes add to the 
complexity of the 
analytical process 
and involve risk 
of over-
interpretation of 
the results. 
Table 9: Comparing some pros and cons of two techniques to measure gene expressions, qPCR 
and microarrays (111), (112), (113). 
 
In many studies over the last years, microarrays are used first to identify novel 
putative biomarkers and then qPCR is used to validate the microarray findings.  
 
Sources of measurement error related to qPCR and normalization 
Some of sources of qPCR measurement error are mentioned in table 9 and 
relate to RNA quality (possible degradation of RNA) and normalization (choice 
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and number of HKGs). Other qPCR problems relate to the PCR reaction itself 
(like template concentrations and inhibitors present in sample, especially in 
mammalian blood (106)) and reverse transcription (like RNA extraction, choice 
of reverse transcriptase and amount of RNA transcribed) (112). 
 
As mentioned previously, Lundbeck has put a lot of effort in optimizing the 
qPCR process, making sure samples from different groups can be compared, 
and in that process minimized the various sources of measurement error. 
 
 
Other sources of measurement error in the study design 
Another potential and important source of measurement error relates to the 
clinical diagnose. As described in chapter two, many disease phenotypes exist 
within a disorder and often comorbidity with related disorders is present. 
Hence, we can not be absolutely sure that a patient diagnosed with a certain 
disorder actually has this disorder. This source of measurement error may be 
reduced if a patient can be assessed and obtains the same diagnose by at least 
two independent psychiatrists. 
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As explained in the introductory chapters our study involves whole blood gene 
expression measurements and includes selected housekeeping genes for 
normalization. Because of the explorative character of the study, the US 
Lundbeck group and I were not sure which statistical methods would be most 
useful to analyze the data. Analysis of the measured qPCR expression data 
ranges between traditional statistics and microarray analysis with respect to 
the ratio of samples per variable. Chapter 5 describes various statistical 
methods found suitable for our exploratory analysis of the data together with 
the assumptions one must make before applying each of the methods 
(classification issues will be considered separately in the next chapter). Also 
described, is the reason for choosing a particular method as each method 
offers new interpretations of the data. This is followed in each case with an 
example from the available data demonstrating the usability of that method. 
The reasons and the applied methods are;  
 
• A basic and fundamental assumption for parametric statistical tests is 
that data is normality distributed. Normality of a gene expression may be 
assessed by a graphical analysis called a normal QQ plot or by various 
normality tests. Five different normality tests are applied.  
• In order to identify genes separating control and patient groups based on 
various clinical variables, univariate tests are applied. Both parametric 
(t-test and ANOVA test) and nonparametric (Wilcoxon rank-sum test and 
Kruskal-Wallis test) tests are applied, the latter to account for non-
normal expression data.  
• In order to investigate whether any of the gene expressions differ 
significantly between the three time point measurements in the UK 
control group, repeated measures ANOVA is applied. 
• Correlations between gene expressions, and between continuous clinical 
variables and gene expressions, were looked into by Spearman’s 
nonparametric rank correlations. This approach is particularly useful to 
handle non-normal data and outliers. 
• An explorative approach to identify possible clinical variable - gene 
expression relationships is canonical correlation analysis. The method 
facilitates the study of linear interrelationships among sets of multiple 
dependent variables (the gene expressions) and multiple independent 
variables (the clinical variables). 
• Recursive partitioning is used to identify possible disease subtypes with 
distinct gene expression profiles via a classification tree. 
• Cluster analysis can group objects (genes or subjects) into clusters so 
that objects in the same cluster are more similar to one another than 
they are to objects in other clusters. By clustering gene expression 
5. Statistical methods 
profiles, disease subtypes may emerge. Heat maps implement two-way 
clustering combining clustering of genes with clustering of subjects.  
• Finally, in order to investigate the clinical variables that explain most of 
the variance in a gene, stepwise regression is applied.  
 
Quantitative polymerase chain reaction (qPCR) gene expression data analysis 
ranges between traditional statistics and microarray analysis with respect to 
the ratio of samples per variable. Traditional statistics often operates with 
many more observations/samples than the number of variables while the 
opposite applies to microarray gene expression analyses with more variables 
than the number of observations. For some groups of the available qPCR data, 
there are more observations than variables and for other groups, like for the 
borderline patients, there are more variables (gene expressions) than the 
number of subjects. For most groups, the ratio of the number of subjects to 
the number of genes is around only 1-3, making it necessary to consider both 
microarray analysis as well as traditional statistical methods.  
 
Statistical and microarray oriented methods applied to gene expression data 
are discussed in several books (114), (115), (116), (117), (118), (119), 
articles (120), (121), (122), (110), (123), statistical packages (see references 
below) and the online encyclopedia Wikipedia.org. Quite a number of methods 
have been considered and tested primarily in the open-source statistical 
environment R / Bioconductor, secondary in SPSS, Matlab and SAS. The 
Statistical Consulting Center at the Department of Informatics and 
Mathematical Modeling at DTU has assisted a great deal with the initial R 
coding and the initial analyses. A list of selected methods, based on their 
relevance for the study (as decided in collaboration with Lundbeck and me) 
and applicable to the available qPCR data in this thesis, is shown in table 10. 
The table also briefly explains why a particular method was chosen. After the 
table each method is described and an example demonstrating the method is 
included. 
 
This thesis has a special focus on machine learning / classification methods for 
predicting disease status (e.g. control vs. patient) based on gene expression 
profiles of subjects. Simulation studies were performed to determine the best 
classification and variable selection algorithms applicable to the qPCR data. The 
topic is described separately in the next chapter. However, some classification 
issues are also included in table 10. 
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Purpose Method & section Reference 
Is data normally 
distributed? 
5.1 normal QQ plots, normality tests (116), (117) 
Identify genes separating 
control and patient groups 
5.2 univariate tests (t-test/Wilcoxon, 
  ANOVA/Kruskal-Wallis) with multiple test 
correction 
- Variable selecting from machine learning / 
classification methods (next chapter) 
(116), (118), 
(117), (121), 
(110), (122) 
Are gene expression levels 
the same across different 
time points? 
5.3 repeated measures ANOVA  (119) 
Similarity between control 
groups 
5.2 univariate tests, 5.4 correlations and correlation 
tests 
- classification (next chapter) 
(116), (118), 
(117), (121), 
(110), (120), 
(122) 
Identify (intermediate) 
phenotypes 
- clinical variable –  
expression relationships 
(covariate analysis) 
 
 
 
- expression patterns only 
 
 
5.2 univariate tests, 5.4 correlations (for continuous 
clinical variables), 5.5 canonical correlation analysis, 
5.6 recursive partitioning 
 
 
 
5.7 clustering and heat maps 
 
 
(124), (116), 
(118), (117), 
(121), (110), 
(120), (122) 
 
 
(116), (115), 
(117), (122), 
(123) 
Which clinical variables 
explain most of variance in 
a gene? 
5.8 Stepwise regression (114) 
Table 10: Overview of main statistical methods applied in this thesis. The starting point is 
obviously the purpose of a particular analysis and methods are then selected that can perform 
the analysis of interest. Each method is described after the table. 
 
As the table illustrates, whether the gene expressions are considered as 
dependent or independent variables, depend on the type of analysis. This will 
be considered for every method, if relevant. 
 
5.1 Normal probability plots and normality tests  
A basic and fundamental assumption for parametric statistical tests is that data 
is normally distributed. In the univariate case, e.g. the gene expressions are 
considered individually, the data for each gene expression should follow a 
normal distribution in order to apply, for instance, a t-test or an ANOVA test. If 
the variation from the normal distribution is sufficiently large, the resulting 
parametric statistical tests are inappropriate (125). Two options exist for 
dealing with non-normal data; either one can try to apply a data 
transformation like a logarithmic transformation (recommended by the 
statistical department of Lundbeck and having the effect of stabilizing the 
variance) or one can apply a non-parametric test, described in the univariate 
test section.  
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There are different ways of assessing departure from normality. One of these 
is a graphical analysis, called a normal QQ (Quantile-Quantile) plot. This is a 
graphical method for diagnosing differences between the probability 
distribution of a statistical population from which a random sample has been 
taken, i.e. the expression data of a gene, and the normal distribution.  
 
For a gene expression “sample of size n, one plots n points, with the (n+1)-
quantiles of the normal distribution on the horizontal axis (for k = 1, ..., n), 
and the order statistics of the sample on the vertical axis. If the gene 
expression population distribution is the same as the normal distribution this 
plot approximates a straight line, especially near the center. In the case of 
substantial deviations from linearity, the null hypothesis of sameness is 
rejected” (126). Figure 7 shows two normal QQ plots, one using the SERT gene 
expression data for the ABS control group and the other using the natural 
logarithm of the same expression data. As the figure shows, applying the 
logarithm to the expression data makes the data resemble a normally 
distribution more closely than before taking the logarithm. 
 
 
Figure 7 shows that in the case of SERT, a logarithmic transformation makes the SERT 
expression data follow a normal distribution. The plots were made in R. 
 
 
Various statistical tests exist to assess normality (116), (127), (128). The ones 
applied at the beginning of the PhD are the Shapiro-Wilk test (129), the 
Anderson-Darling test (130), the Cramér-von-Mises criterion (131), the 
Lilliefors test for normality (132), and the Shapiro-Francia test for normality 
(133). Each test has its own way of assessing departure from normality and its 
own strengths and weaknesses, see the references for details about the tests. 
By evaluating the results from five different tests, it should be possible to 
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decide if the (logarithm of) expression values of a gene follow the normal 
distribution. In table 11, the tests are applied to the ABS SERT expression data 
(shown in figure 7) both the raw expression data (normalized with 2 HKGs) 
and applied to the natural logarithm of the SERT data as well. The higher the 
p-value, the more likely the data are normally distributed. 
 
Test for normality SERT p-value Log(SERT) p-value 
Shapiro-Wilk  1.0448e-17 0.2088 
Anderson-Darling 7.2025e-30 0.1980 
Cramér-von-Mises 2.5659e-06 0.2101 
Lilliefors 4.3850e-17 0.0439 
Shapiro-Francia 1.8886e-15 0.2901 
Table 11: P-values from the five different normality tests applied to the SERT gene expression 
values from the ABS control group. The analyses were done in R. 
 
With a 1% significance level to account for multiple testing (see the univariate 
section below), table 11 indicates that applying the logarithm to SERT 
improves normality of the distribution of SERT gene expression data.   
 
In the results chapter, the five normality tests are applied to all ‘raw’ gene 
expressions values as well as to all logarithmic expression values. Some 
normal QQ plots are also included. 
 
5.2 Univariate tests 
The univariate tests applied in this thesis comprise the two-sample parametric 
t-test and the two-sample nonparametric analog, the Wilcoxon rank-sum test. 
Also, in the multiple sample case (more than two samples), the univariate 
parametric ANOVA test is used together with the non-parametric analog, the 
Kruskal-Wallis test. I have used the two-sample univariate tests to identify 
genes separating control and patient groups, and to compare control groups 
(see the results chapter). Both the two-sample and multiple sample univariate 
tests are used to establish intermediate phenotype relationships, that is, 
relationships between clinical variables and gene expressions.  
 
The parametric tests are based on the assumption of normality which can be 
tested by the normality tests or a normal QQ plot as mentioned above. 
Furthermore, they are sufficiently robust to allow disregarding “all but severe 
deviations from the theoretical assumptions” (134). However, it is not always 
clear when the deviations are severe. To account for these situations, 
nonparametric tests are included. They do not assume a normal population, 
and are sometimes referred to as distribution-free methods. Also, since they 
are based on the ranks of data, they are generally more robust towards 
outliers than parametric tests. It should be mentioned that “if either the 
parametric or nonparametric test is applicable, that is, if the data is normally 
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distributed, then the former will always be more powerful than the latter” 
(134). 
 
The two-sample t-test is used to test the null hypothesis that the means of two 
independent normally distributed populations, for instance smokers vs. non-
smokers, are equal. Given two such “data sets, each characterized by its 
mean, standard deviation and number of data points”, the two-sided t-test is 
used “to determine whether the means are distinct, provided that the 
underlying distributions can be assumed to be normal” (135), which as 
mentioned above, can be tested by the approaches described in method 1. If 
the calculated p-value is below the threshold chosen for statistical significance 
(see below), then the null hypothesis, stating that the two groups do not differ, 
is rejected in favor of an alternative hypothesis, which states that the groups 
do differ.  
Different t-tests exist, but the applied t-test in this PhD is the Welch's t test, 
because it operates with unequal sample sizes and possibly unequal variances 
(136). Details about the t-test can be found in the references in this subsection 
and e.g. (137). 
 
The nonparametric analog of the two-sample t-test, is the Wilcoxon rank-sum 
test also known as the Mann-Whitney U test (138), here in short, the Wilcoxon 
test. As with other nonparametric tests, the actual measurements are not 
employed, but the ranks of the measurements are used instead. As the t-test, 
the Wilcoxon test assesses whether two independent samples of observations 
come from the same distribution without, however, involving the assumption 
of normally distributed data. The test “does assume that the two sample 
distributions have the same shape and differ only by a possible shift in 
location” (139). “The null hypothesis is that the two samples are drawn from a 
single population, and therefore that their probability distributions are equal” 
(138). Details about the Wilcoxon test can be found in the references given 
above and e.g. (140). 
 
In table 12, an example of the t-test and the Wilcoxon test applied to the 
dependent gene variable SERT and the independent clinical variables ‘tobacco’ 
and ‘gender’, is shown.  
 
Clinical variable Wilcoxon test on SERT 
p-value 
T-test on log(SERT) 
p-value 
Tobacco (non-smokers vs. smokers) 0.000352 7.62E-05 
Gender (male vs. female) 0.27319 0.255765 
Table 12: p-values from the Wilcoxon rank-sum test and t-test on the logarithm of SERT gene 
expression data from the ABS control group. For tobacco there is a significant difference 
(below 1%) in the SERT gene expression levels between non-smokers vs. smokers. There are 
no differences in the SERT levels between men and women. The analyses were done in R. 
 
The parametric one-way ANOVA (ANalysis Of VAriance) test is used in the 
thesis to simultaneously compare more than two group means of a factorial 
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clinical variable based on independent samples from each group, for instance 
simultaneously comparing the gene expression levels of SERT between non-
smokers, and medium and heavy smokers. Thus, the one-way ANOVA is 
basically an extension of the two-sample t-test applied to multiple groups 
(>2). “The bigger the variation among sample group means relative to the 
variation of individual measurements within the groups, the greater the 
evidence that the hypothesis of equal means is to be rejected” (141). The 
assumptions are 
 
• normally distributed data - here meaning the logarithm of the gene 
expressions are used 
• independent samples from each group 
• variance homogeneity among groups - which is assumed. ANOVAs are 
“robust, operating well even with considerable heterogeneity of 
variances, as long as the group sizes are equal or nearly equal” (142).  
 
In case of a significant result, the one-way ANOVA does not identify which 
group means differ. Further analysis must then be undertaken and various 
options exist, like applying Dunnett’s test (141), or sometimes simply looking 
at a plot of the gene expressions in the different groups. Further details may 
be found in the references above and (143). 
  
The nonparametric analogue to the one-way ANOVA test is the Kruskal-Wallis 
test, which is preferred when the gene expression data deviate severely from 
the underlying assumptions of the ANOVA. Furthermore, the Kruskal-Wallis 
test is only slightly influenced by differences in group variances (142). 
The Kruskal-Wallis test is an extension of the Wilcoxon rank-sum test, 
described above, for more than two groups. Like the Wilcoxon test, it is based 
on ranks of the data and may be used in any situation where the parametric 
one-way ANOVA is applicable, however, then it will only “be 95% as powerful 
as the latter” (144). Details can be found in the references above and (145), 
(146). 
 
In table 13, an example of the ANOVA and the Kruskal-Wallis test applied to 
the dependent gene variable ARRB1 and the independent clinical variables 
‘Coping’ with four levels (never, sometimes, most days, or every day) and a  
‘Family history of depression, anxiety or suicide’ with three levels (no relatives 
with any disease, secondary relative with any of the diseases, or primary 
relative with any of the diseases), is shown.  
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Clinical variable Kruskal-Wallis test on 
ARRB1, p-value 
ANOVA test on 
log(ARRB1), p-value 
Coping (4 levels) 0.087172 0.001637 
Family Dep/Anx/Sui (3 levels) 0.18548 0.121896 
Table 13: p-values from the Kruskal-Wallis and the ANOVA test on the logarithm of ARRB1 
gene expression data from the ABS control group. For coping there is a significant difference 
(ANOVA, below 1%) in the ARRB1 gene expression levels between the four levels of coping. 
There are no differences in the ARRB1 levels for the different levels of a family history of 
depression, anxiety or suicide. The analyses were done in R. 
 
As seen in the table above for coping, the ANOVA p-value is significant while 
the Kruskal-Wallis p-value is not. Being an exploratory study, a result is 
considered of interest if either the parametric or the nonparametric analogue 
test result is significant.   
 
Finally, it should be mentioned that I applied the conservative Bonferroni 
multiple comparison correction (147) after recommendation of Lundbeck’s 
statistical department. The Bonferroni correction is one way of reducing the 
number of spurious positives, taking the number of comparisons being 
performed into account. In general, throughout the thesis the significance level 
is set to 1%, unless explicitly stated otherwise.  
 
5.3 Repeated measures ANOVA 
In the UK control group, three time measurements are made; Day 0 at 8 am, 
Day 0 at 2 pm and Day 1 at 8 am. In order to investigate whether any of the 
gene expressions differed significantly between the three time points, I applied 
the repeated measures ANOVA test. “Special attention was given to these 
types of measurements because they cannot be considered independent. In 
particular, the analysis must take provisions for the correlation structure” 
(148).  
 
There are two main analytical approaches for handling repeated measures, a 
univariate approach and a multivariate approach (148). Here, focus is on the 
univariate approach as I have employed both approaches and found they yield 
similar results for the analyses done. The multivariate approach uses the 
repeated measurements as multivariate response vectors in MANOVA tests 
(Multivariate ANalysis Of VAriance); however, in my experience, the approach 
is more cumbersome to perform. Both approaches involve Mauchly’s sphericity 
test (149): This test basically states that the variances of the differences 
between the repeated measurements should be about the same. If the 
sphericity assumption is violated, then either the Greenhouse-Geisser or the 
Huynh-Feldt (less conservative) corrected p-values (149) are calculated.  
 
The univariate approach is based on the ANOVA test described in the previous 
section on univariate tests. Here the temporal aspect is explicitly included as a 
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factor in the ANOVA. This can be regarded as a two-way/two-factor ANOVA 
(time and subjects) (148). Just as with the ANOVA test, normality of the gene 
expressions is assumed (hence, I first take the logarithm of gene expressions 
before performing the repeated measures ANOVA) and variance homogeneity 
among groups are assumed. “In addition, the univariate ANOVA approach 
requires that the each pair of repeated measures has the same correlation, a 
feature known as ‘compound symmetry’”11 (148). The latter assumption is not 
valid in the UK control group as the time points are unequally spaced. 
However, as mentioned above this has virtually no impact on the conclusions. 
Further details on the repeated measures ANOVA are found in the references 
above. 
 
Table 14 shows an example of the repeated measurements ANOVA in the UK 
control group for the CD8 beta and CREB1 three time point gene expression 
values. P-values for Mauchly’s sphericity test are included.  
 
p-values CD8 beta; 3 time points CREB1; 3 time points 
Repeated measures ANOVA p-value 4.47E-05 0.2669 
Mauchly's test p-value 0.8037 0.7627 
Table 14: Repeated measures ANOVA results for the three time point CD8 beta and CREB1 
expression measurements in the UK control group. Mauchly’s sphericity test p-values are 
included and show that the variances of the differences between the repeated measurements 
are similar to each other. CD8 beta shows a significant difference between the three time 
points, while CREB1 does not. The analyses were done in R and SAS. 
 
5.4 Correlations 
The statistical department of Lundbeck has recommended the use of 
Spearman’s nonparametric rank correlations due to their ability to handle non-
normal data (see below) and outliers. I have applied the Spearman 
correlations to examine how correlated continuous clinical variables, like age 
and BMI, are to the gene expressions. The correlations are also used to 
compare control groups. 
 
The Spearman rank correlations are particularly useful when the data is not 
normally distributed and, similar to Pearson correlation coefficients, they range 
from -1 to +1 and have no units. However, unlike the Pearson correlation 
coefficient, Spearman's rank correlation coefficient does not require the 
assumption that the relationship between the variables is linear (151). 
 
In table 15, an example of the Spearman correlation is shown for the 
continuous clinical variables age and BMI vs. the gene expression values of 
CREB1. 
 
 
                                                 
11 “If compound symmetry is met then sphericity is also met” (150). 
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Continuous clinical variable  Spearman rank correlation 
Age  0.109376 
BMI -0.04609 
Table 15: Spearman rank correlation coefficients for the continuous clinical variables age and 
BMI vs. the gene expression values of CREB1 in the ABS control group. Both correlations are 
weak; thus, CREB1 are practically uncorrelated with both clinical variables. The analyses were 
done in R. 
 
Comparing two Spearman correlation coefficients can be done by first applying 
the Fisher z transformation (152), (153). Thereby, correlation coefficients 
between 0 and 1 are transformed to the corresponding values of Fisher’s z 
between 0 and ∞, while correlation coefficients between 0 and -1 are 
transformed to z values between 0 and -∞. This “both normalizes the 
underlying distributions of each of the correlation coefficients, and stabilizes 
the variances of these distributions” (154). Then a test statistic is compared to 
the Student's t-distribution to determine if the null hypothesis of no difference 
between the correlation coefficients is true. Details on how to compare 
correlation coefficients and the Spearman correlations may be found in several 
of the references given in this section, e.g. (152). 
 
In table 16, an example of comparing two Spearman correlation coefficients is 
shown. Here, gene expression correlations are compared between two control 
groups – the Danish (DC) and ‘super-healthy’ Americans (SH ABS). 
 
Gene expression pair DC Spearman 
correlation,  
N=89 
SH ABS Spearman 
correlation, 
N=59 
Comparing 
correlations,  
p-value 
ERK2-ARRB2 0.4955 0.7700 0.0055 
ERK2-DPP4 0.0829 0.1858 0.5413 
Table 16: Comparing Spearman correlation coefficients between the DC and SH ABS control 
groups. One comparison (ERK2-ARRB2) is significant (below 1%) while the other is not. The 
analyses are done in R. 
 
5.5 Canonical correlation analysis 
Canonical correlation analysis (CCA) is an exploratory multivariate statistical 
method “that facilitates the study of linear interrelationships among sets of 
multiple dependent variables (the gene expressions) and multiple independent 
variables” (the clinical variables). CCA “simultaneously predicts multiple 
dependent variables from multiple independent variables” (155). It can use 
both metric and nonmetric data for either the dependent or independent 
variables. I have used CCA for subtyping /phenotype identification purposes in 
order to identify possible phenotypes among the borderline patients, by looking 
at the CCA relationships between the patients’ clinical variables on one side 
and their gene expressions profiles on the other side.  
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CCA “deals with the association between composites of sets of multiple 
dependent and independent variables. The approach develops a number of 
independent canonical functions that maximizes the correlation between the 
linear composites, also known as canonical variates, which are sets of 
dependent and independent variables. Each canonical function is thus based on 
the correlation between two canonical variates, one variate for the dependent 
variables and one variate for the independent variables” (155). Each pair of 
canonical variates (each canonical function) seeks to maximize “the same 
correlation subject to the constraint that they are to be uncorrelated with the 
previous pair of canonical variates” (156). Thus, “the first pair of canonical 
variates is derived so as to have the highest intercorrelation possible between 
the two sets of variables. The second pair of canonical variates is then derived 
so that is exhibits the maximum relationship between the two set of variables 
(variates) not accounted for by the first pair of variates. Successive pairs of 
canonical variates are based on residual variance, and their respective 
canonical correlations become smaller as each additional function is extracted” 
(155).  
 
Classical CCA is recommended to be performed with at least 10 observations 
per variable (155) making it practically useless for the Lundbeck data. 
However, in R the CCA package (124) implements a regularized version of CCA 
to handle such situations and intended for microarray studies or other studies 
where the number of variables exceeds the number of observations.   
 
CCA has the following assumptions; 
 
• linearity among the variables meaning that nonlinear relationships will 
not be captured 
• normality is not required but desirable (155); the logarithm of the gene 
expressions are used 
• homoscedasticity (homogeneity of variance) is assumed 
• “multicollinearity (two or more variables being highly correlated) among 
either variable set will confound the ability of CCA to isolate the impact 
of any single variable, making interpretation less reliable” (155); this is 
an inherent problem with gene expression data and affects all 
multivariate techniques. Correlation among variables can be computed, 
e.g. with the Spearman correlation described previously.   
 
Details on CCA can be found in the references above.  
 
I will now give an example of regularized CCA performed in R. Here, I will 
consider the clinical variables and gene expressions of the first cohort of 
borderline patients, and describe a few examples of how CCA may be 
interpreted. The R package offers a novel graphical output to facilitate 
interpretation of a CCA. In this example, I did CCA with a subset of clinical 
variables and gene expressions. 4 gene expressions were chosen by a 
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univariate comparison with the SH ABS controls applying the Bonferroni 
correction. 6 clinical variables were chosen by first performing CCA with all 
clinical variables (and the 4 gene expressions) and then leaving out the ones 
that did not seem important (see explanation below). This procedure is 
recommended in (155) and (124).  
 
The results are summarized in the figure 8 and consist of two graphs; on the 
left the graph of variables and on the right the graph of individuals (the 11 
borderline patients). The two graphs are connected, so that the graph of 
variables informs about the subject groupings in the graph of individuals.  
 
 
 
Figure 8 shows a CCA output for the borderline patients and a subset of 6 clinical variables (in 
red) and 4 gene expressions. There are two graphs; the graphs of variables to the left and the 
graph of individuals (with the 11 BPD patients) to the right with marked subgroups. The two 
graphs are connected; see the text after the figure. Dimension 1 and 2 represent the most and 
second most important canonical correlation dimension, respectively. The plots were done in R. 
 
First, the graph of variables: Here two circles are seen - an inner circle with a 
radius of 0.5 and the outer circle of radius 1. Genes and variables between 
these two circles are the important ones according to CCA. As it can be seen 
there are no variables in the inner circle and this is because I have left out the 
unimportant variables. On this graph, “variables (both genes and clinical) with 
a strong relation are projected in the same direction from the origin. The 
greater the distance from the origin, the stronger the relation” (124). From 
this it can be seen that e.g. Feeling Low and Gi2 (shown in the middle left  
box) are strongly related and this also goes for MAPK8 and Weight Change in 
the third quadrant of the graph, while Family Schiz/Psyc (a family history of 
schizophrenia or psychosis) stands alone on the opposite side.  
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On the graph of individuals, different subgroups of borderline patients are 
shown. The two graphs are connected so that every direction, e.g. north and 
south or east and west in one graph corresponds to the other graph. An 
example: In the graph of variables, Gi2 and Feeling Low are closely related as 
are GR, 3 months drugs use and Anxiety in the middle left of the graph with 
Family Schiz/Psyc on the opposite side (as described above). In the graph of 
individuals, BP1 (borderline patient number 1) and BP2 are close together 
around the middle left (shown with a box) while e.g. BP4, BP10 and BP11 are 
close together at the opposite side. This can be interpreted as BP1 and BP2 
have high Feeling Low, 3 months drug use, Anxiety, GR and Gi2 scores and a 
low Family Schiz/Psyc score at the same time. BP4, BP10 and BP11 have a 
high Family Schiz/Psyc score and low scores of the other variables and gene 
expressions. At the same time, all the borderline patients below the zero line 
(dimension 2), especially BP3 and BP5, have high MAPK8 expression and 
Weight Change scores while all the borderline patients above the zero line, 
especially BP8 and BP9, have low MAPK8 expression and low Weight Change 
scores. I have checked the gene expressions and clinical variables in the BPD 
data, and in general, CCA seems to reflect the patterns in data well, e.g. BP1 
and BP2 always have the highest expression values for the four genes. 
 
This example shows that CCA offers an exploratory and descriptive approach to 
identify possible phenotypes among the borderline patients. It can be 
hypothesized which borderline patients that resemble each other, measured by 
certain clinical variables (here Family Substance Abuse, Feeling Low, 3 months 
drug use, Anxiety, Weight Change and Family Schiz/Psyc) and gene 
expressions.  
 
5.6 Recursive partitioning 
Recursive partitioning (RP) is a non-parametric multivariate statistical method 
that creates a decision tree, also called a classification tree, “that strives to 
correctly classify members of a population based on a dichotomous dependent 
variable” (157). RP and decision trees for classification purposes are dealt with 
in the next chapter. Here focus is on the use of RP for identification of possible 
(intermediate) phenotypes with distinct gene expression profiles. I have used 
RP for such a purpose by identifying distinct gene expression profiles in the 
two control groups DC and SH ABS. These profiles could be hypothesized to 
belong to distinct intermediate phenotypes, see the Results chapter.  
 
RP analyzes a set of genes jointly. “RP first picks the gene (gene 1) most likely 
to separate sample labels based on the level of expression” (233) and based 
on a so-called Gini splitting index (158). “Both the gene and the threshold 
value are determined by the data. Then, RP may pick another gene if further 
improvement on classification performance can be achieved. This process can 
be visualized as a classification tree, in which the first branching at the top 
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corresponds to gene 1, second-level branchings corresponds to gene 2, and so 
on. A node on the tree can be either a branching point or a terminal leaf” (233)  
 
Some of the advantages of RP include the creating of intuitive tree models, and 
also “allows varying prioritizing of misclassification costs in order to create a 
decision rule that has more sensitivity or specificity” (157). A major 
disadvantage is that RP tends to overfit data, making it difficult to use the 
same decision rules on a new data set. It is possible to circumvent this 
problem to a certain degree, e.g., by applying a cross-validation scheme (see 
next chapter). Further details on RP are found in the references given above. 
 
An example of recursive partitioning is shown in figure 9. Here RP is used to 
split 11 BPD patients (cohort 1 BPDs) and 296 ABS controls. All subjects are 
correctly placed (no misclassifications) in a decision tree created from just 
eight gene expressions (out of a maximum of 25). Using a maximum of six 
splits (genes), every control is correctly classified and the corresponding genes 
are easily identified.  
 
 
Figure 9 shows a decision tree of 11 BPD patients and 296 ABS controls. In the above tree, 
there are no misclassified controls. See the text after the figure for explanation of this decision 
tree. The ‘rpart’ package in R was used to carry out the recursive partitioning (158). 
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The right branch of the tree in Figure 9 shows that just by looking at the 
logarithm of the expression values of GR and ERK2, 5 of the 11 BPD patients 
can be correctly identified. 2 BPDs are classified by the values of GR, ERK2 and 
CREB2. Looking at the ABS controls, the expression levels of GR, SERT, 
CREB2, MR and IL-6 (left tree branch) identifies 274 controls. 14 ABS controls 
are identified by just GR, ERK2 and CREB2 (right branch). In this way, RP may 
be used to identify distinct phenotype gene expression profiles among the BPD 
group, and be used to identify distinct intermediate expression profiles among 
the ABS control group. 
 
5.7 Clustering and heat maps 
The term cluster analysis refers to a set of exploratory multivariate techniques 
whose primary purpose is to group objects, here genes or subjects, based on 
the characteristics they possess, that is pattern recognition and grouping is 
performed. Cluster analysis can group objects “into clusters so that objects in 
the same cluster are more similar to one another than they are to objects in 
other clusters. The attempt is to maximize the homogeneity of objects within 
the clusters while also maximizing the heterogeneity between the clusters” 
(159). The ultimate goal is to identify naturally occurring clusters in the data, if 
possible. Cluster analysis is an unsupervised statistical method in the sense 
that it does not make use of class labels. This make clustering potentially very 
interesting since by clustering gene expressions, (intermediate) phenotypes 
can emerge without imposing any a priori hypotheses on the technique. 
There are many different approaches to cluster analysis with the two main 
types referred to as hierarchical methods (the results of which is represented 
as a hierarchical tree structure) and partitioning methods (which separate the 
objects into a given number of clusters). Other types of clustering methods 
exist as well (160), (161), but here focus is on agglomerative hierarchical 
clustering. “Hierarchical algorithms can be agglomerative or divisive. 
Agglomerative algorithms begin with each object as a separate cluster and 
merge them into successively larger clusters until all objects have been joined 
into one large cluster. Divisive algorithms begin with the whole set and 
proceed to divide it into successively smaller clusters” (160).  
A heat map is a two-way hierarchical agglomerative clustering that combines 
clustering of genes with clustering of subjects in one map, called a heat map 
because colours in the map show the relative gene expression levels, see the 
example at the end of the section. Hierarchical algorithms have been used 
extensively in the analysis of DNA microarray data (115), (162), (161). I have 
used agglomerative hierarchical clustering and heatmaps to identify possible 
phenotypes among both controls and patients. 
 
“An important step in any clustering is to select a distance measure, which will 
determine how the similarity of two objects is calculated. This will influence the 
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shape of the clusters, as some objects may be close to one another according 
to one distance and further away according to another” (160). Two of the most 
commonly used for gene expression data are the Euclidean distance and 
Pearson correlation coefficient (162). I have used both. The Euclidian distance 
– unlike correlation - is sensitive to scaling and differences in average 
expression level, which I why I have standardized (z-scores) the data before 
clustering.  
 
Another important step in clustering is the choice of the actual clustering 
algorithm. Several choices exist, like complete linkage clustering (maximum 
distance between elements of each cluster), single linkage clustering 
(minimum distance between elements of each cluster), average linkage 
clustering (mean distance between elements of each cluster) and Ward’s 
method (seeks to join clusters whose merger leads to the smallest within-
cluster variance) (160), (163). I have used average linkage and Ward’s 
criterion to merge clusters.  
 
Clustering is recommended to be performed in a supervised manner (159) in 
the sense that clustering variables, here genes, should be selected prior to 
clustering and, thus, not include undifferentiated variables. In the heat map 
example below, I use the genes, separating control and patient groups, for 
clustering.  
 
Cluster analysis is not a statistical inference technique, and thus has no 
requirements of normality, linearity or homoscedasticity. However, substantial 
multicollinearity should be avoided, if possible (159).  
 
Some of the advantages of hierarchical clustering include the simplicity by 
which interpretation of the results can be made from a dendrogram 
(hierarchical tree), the deterministic calculations, and the speed of performing 
the clustering. “A disadvantage is that hierarchical clustering can be misleading 
because undesirable early combinations may persist throughout the analysis 
and lead to artificial results” (159). Furthermore, hierarchical clustering is 
sensitive to the choice of similarity measure and specific clustering algorithm, 
meaning different choices yield different results. Further details on hierarchical 
clustering are found in the references given in this section.  
 
In figure 10, I show an example of hierarchical clustering in the form of a heat 
map consisting of two dendrograms, one for the genes and one for subjects. 
The heat map is generated using 21 subjects randomly chosen from a pooled 
control group (DC, SH ABS and PTSD controls) and the 21 borderline disorder 
(BPD) patients. Only genes that separate the three groups from one another 
are used. In the heat map the expression profiles of two distinct BPD clusters 
are identified.  
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Figure 10 shows a heat map with 21 subjects from a pooled control group (DC, SH ABS and 
PSTD controls) and the 21 borderline disorder patients clustered at the top of the heat map. At 
the bottom, I have included the class labels showing two different clusters of BPD patients. 
These clusters may represent different phenotypes. Genes separating the control and patient 
groups are shown to the right. The heat map was done in R. 
 
Finally, it should be mentioned that (unsupervised) clustering can be combined 
with (supervised) classification (described in the next chapter); genes may be 
hierarchically clustered, and then, for instance, discriminant analysis (multi-
class separation) or stepwise logistic regression (two-class separation) may be 
applied to the clinical variables. Thus, the gene clusters may be linked to the 
clinical variables.  
 
5.8 Stepwise regression 
Stepwise regression is an automatic procedure in a multivariate setting 
suitable for establishing a linear relationship between a response (here, a gene 
expression) and the most important explanatory variables. Stepwise regression 
deals with the situation of not being able to precisely formulate a model based 
upon the clinical predictors, and the stepwise part narrows down the list of 
possible explanatory predictors. If it was possible to explain around 15% (164) 
of the variance in a gene expression by a linear combination of clinical 
variables that was to be considered a good result. By performing stepwise 
regression, I wanted to find out whether this also applied to the Lundbeck data 
and, if so, which clinical variables were the most important predictors. In this 
way, I have used stepwise regression as a hypothesis generating technique to 
identify a minimal set of clinical variables per gene expression that explain as 
much of the variance in a gene expression as possible.  
 
0’s = controls 
1’s = BPDs 2 BPD subtypes?
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First, a full linear model is specified with the logarithm of a gene expression 
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stical 
ted 
 
are 
ar model reduced to a 
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eraction model is made that contains 
n, 
 
linical variable Log(ERK2) Log(ADA) 
equal to the sum of all depression-relevant explanatory variables. Then, 
stepwise regression as a combination of backwards elimination and forwa
selection is performed (165), (166). Backward elimination “involves starting 
with all candidate variables and testing them one by one for statistical 
significance, and then deleting any that are not significant” (166). Stati
significance is evaluated by the Akaike information criterion (167) which 
basically is “an operational way of trading off the complexity of an estima
model against how well the model fits the data” (234). Forward selection then
involves starting with the model left from a previous backwards elimination 
step, trying out the left-out variables one by one and including them if they 
statistically significant at the 1% significance level.  
The result is a minimal linear model with the full line
minimum of variables significantly explaining the same amount of variation 
each gene expression as the full model.  
A second step is added in that a linear int
the minimum set of clinical variables together with the sum of all pair-wise 
interactions between these variables. Stepwise regression is performed agai
and the result is a minimal linear interaction model containing the minimum 
set of clinical variables and significant interactions explaining essentially the 
same amount of variation in each gene expression as the original linear 
interaction model. Further details on stepwise regression are found in the
references given above and (168), (169). An example of the results of a 
stepwise regression involving the ABS control group is given in table 17. 
 
C
Appetite change X  
Feeling low : Sleep problems i  
Sleep problems i  
BMI  X 
R2 without interactions 14% 3% 
R2 with interactions 18% 3% 
Table 17: Results of a stepwise regression on epression-relevant clinical variables for the 
ling 
 
tepwise regression has the advantage of producing a minimal set of 
tepwise 
 the d
two gene expressions ERK2 and ADA in the ABS control group. R2 is reported. 18% of the 
variance in ERK2 is explained by appetite change and a significant interaction between ‘fee
low’ and ‘sleep problems’. 3% of the variance in ADA is explained by the single variable BMI. 
An ‘X’ denotes the clinical variable(s) remaining after a stepwise regression, and an ‘i’ denotes
one part of an interaction term remained after a second stepwise regression. The analyses 
were done in R. 
 
S
explanatory predictors for a continuous response. A drawback of the s
regression approach is a tendency to overfit the data (165). 
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5.9 Other exploratory statistical methods 
As mentioned in the beginning of this chapter, I have applied a number of 
statistical methods to the available data and described the reasons for using 
specific procedures. In table 18, I briefly describe a few other exploratory 
methods (including references) that even though their output did not seem 
relevant to Lundbeck, I found them of potential interest.  
 
 
 
Other statistical methods Description Reference 
Two-way ANOVA Two-way ANOVA may be used to study the effects of 
two independent clinical variables with each variable 
having several levels. 
(143) 
MANOVA  Multivariate analysis of variance (MANOVA) is an 
extension of ANOVA methods to cover cases where 
there is more than one dependent variable (gene 
expression). As well as identifying whether changes in 
the independent clinical variables have a significant 
effect on the gene expressions, the technique also 
seeks to identify the interactions among the 
independent clinical variables and the association 
between the gene expressions, if any.  
 
In R, MANOVA is implemented in the package 
‘ffmanova’ designed to handle collinear responses. 
 
MANOVA may be used to study certain combinations 
of gene expressions, e.g. biologically or pathologically 
relevant gene expression combinations, together with 
chosen clinical variables.  
(170) 
 
 
 
 
 
 
 
 
 
 
(171) 
PCA Principal component analysis (PCA) is an unsupervised 
technique used to reduce multidimensional data sets 
to lower dimensions for analysis. PCA results in a 
number of principal components with the first 
component explaining the largest variance in the data 
set, the second component the second greatest 
variance, and so on. Each component is orthogonal to 
the previous one, and consists of a linear combination 
of all gene expressions.  
 
PCA may be used to investigate whether it is possible 
to separate different control and patient groups based 
on the principal components. 
(172), 
(173) 
SPCA Sparse principal component analysis (SPCA) is a 
microarray intended variable selection method based 
on PCA with sparse loadings. It has the advantage of 
identifying sparse principal components that, unlike 
PCA, do not overlap, making interpretations easier.   
 
SPCA may be used in the same way as PCA described 
above, however, with clearer interpretations of the 
principal components.  
(174) 
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PLS Partial least squares (PLS) is a class of supervised 
“methods for modelling relations between sets of 
observed variables by means of latent (i.e. not 
observed or measured) variables. It comprises of 
regression and classification tasks as well as 
dimension reduction techniques and modelling tools. 
The underlying assumption of PLS methods is that the 
observed data is generated by a system of process 
which is driven by a small number of latent variables” 
(176). PLS is similar to CCA, where latent vectors with 
maximum correlation are extracted. PLS generates 
orthogonal vectors by maximizing the covariance 
between different sets of variables.  
 
PLS may thus be used as an alternative to CCA to 
identify possible (intermediate) phenotypes taking 
both gene expressions and clinical variables into 
consideration.  
(175), 
(176) 
AP clustering Affinity propagation (AP) clustering is a novel 
clustering technique that works by passing messages 
between data points. “At any point in time, the 
magnitude of each message reflects the current 
affinity that one data point has for choosing another 
data point as its ‘exemplar’” (177), i.e. a cluster 
center selected among actual data points.  
 
AP clustering has the advantage of only requiring a 
similarity measure in order to derive the ‘naturally’ 
occurring number of clusters in a data set. Thus, 
unlike K-means clustering, the number of clusters is 
not specified beforehand.   
(177) 
Table 18: Other potential relevant exploratory statistical methods including a short description 
and references. 
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Classification with automatic variable selection offers a supervised approach to 
prediction of diagnosis and future events, e.g. response to treatment, as well 
as an algorithm-oriented approach to extracting the variables responsible for 
group/class separation and prediction. This chapter investigates several 
classification methods with related variable selection techniques. As in the last 
chapter, both traditional statistical approaches and microarray approaches to 
classification are considered.  
This chapter also presents a simulation project intended to clarify which 
classifiers and variable selection methods are the most promising at prediction, 
classification and variable selection with the available Lundbeck data. The 
simulation study consists of two phases. In phase 1, twelve different classifiers 
(some with automatic built-in variable selection, some without) and two 
different variable selection methods are tested on a simulated data set with all 
variables drawn from a normal distribution. Phase 1 consists of 42 linear and 
nonlinear tasks (listed in appendix 6). It should be stressed that we do not 
know which kind of gene interactions that exist in reality, so we decided to try 
several simple and classical combinations as shown in appendix 6. The 
performance of the classifiers and variables selection methods is evaluated by 
the accuracy measure in a 10-fold cross-validation scheme and by the Jaccard 
score which indicates how well a classifier identifies the correct explanatory 
variables. The result of phase 1 is a list of classifiers and a variable selection 
method that, in general, performs badly. In phase 2, the remaining classifiers 
and the other variable selection method are tested on a realistic data set 
consisting of three control groups (the Danish, the ‘super-healthy’ American 
and the post-traumatic stress disorder (PTSD) control group) as well as the 
borderline personality disorder patients and acute post-traumatic stress 
disorder patients. 33 linear and nonlinear tasks are given to the classifiers and 
variable selection method (listed in appendix 7). The result of phase 2 is, in the 
two-group case, the recommendation of the classifiers; stepwise logistic 
regression, classification tree (RPART), and support vector machine combined 
with variable selection based on random forests. The last two classifiers are 
also recommended in multiple-group case.  
I set up a classification and variable selection procedure suitable for real data 
sets with different group sizes and used to decide whether a group separation 
is possible or not based on permuted accuracies and univariate tests. An 
example is given demonstrating the two-group advised classifiers on a real 
data set.  
Stepwise logistic regression, variable selection based on random forests and 
support vector machines are described in some detail in section 6.4. 
 
In the preceding chapter on Statistical Methods, I mentioned that qPCR gene 
expression data analysis ranges between traditional statistics and microarray 
6. Classification with variable selection 
analysis as classified by the number of samples and variables, and that for 
most groups in the present study, the ratio of the number of subjects to the 
number of gene expressions is around only 1-3, making it necessary to 
consider both microarray approaches and traditional statistical methods. This 
also applies to classification, and that is why I will consider both classical 
statistical approaches and microarray approaches to classification in the 
present chapter.  
 
Classification with automatic variable/feature selection offers a supervised 
multivariate approach to prediction of future events, e.g. response to 
treatment or disease course, and molecular diagnosis (178) as well as an 
multivariate algorithm-oriented approach to extracting the variables 
responsible for class separation and prediction. In the Statistical methods 
chapter, section 5.2, several univariate approaches, like t-tests and Wilcoxon 
tests, are described capable of identifying variables separating groups. These 
“univariate methods are fast and conceptually simple. However, they do not 
take correlations and interactions between variables into consideration, 
resulting in a subset of variables that may not be optimal for classification” 
(178). Multivariate variable selection approaches, on the other hand, recognize 
that the subset of variables with best univariate discrimination power are not 
the best subset of classification variables, and try to determine which 
combinations of variables yield high prediction accuracies. After agreement 
with both Danish and US Lundbeck co-operators, I looked into classifiers and 
automatic multivariate variable selection methods. This was done to explore 
the best possible classifiers and feature selection methods for the available 
gene expression data.  
 
In the beginning of the classification work, I tested a few classifiers in R and 
identified two that seemed to perform well on the available data – ‘Pelora’ and  
‘SLR’ (see below) – and have used these two classifiers for a range of 
classification tasks presented in the results chapter.  
Pelora (179) is a microarray analysis intended algorithm based on Penalized 
Logistic Regression that “combines gene selection, gene grouping and sample 
classification in a supervised approach” (179). Being based on logistic 
regression, Pelora is intended for two class/group classification tasks, and has 
relaxed the assumptions of normality. Through a mean-based approach of a 
linear combination of predictor variables, Pelora seeks to explain the binary 
outcome. Penalization methods allow distinguishing irrelevant from relevant 
classification variables through modifying their coefficients, and thus perform 
intrinsic feature selection. Details on Pelora are found in the reference above 
as well as in (180). An example of the output of Pelora is given in figure 11 
where a clear separation is seen between the two control groups, the ‘super-
healthy’ Americans (SH ABS) and the Danes (DC). 
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Figure 11 shows in a Pelora plot a clear separation of the two control groups; the DCs (0’s) and 
the SH ABS (1’s). On the x-axis is the mean of a scaled set of Pelora cluster 1 genes; ADA, 
CREB1, CREB2, MAPK14 and ODC1. The plot shows that this set of genes are sufficient for 
separation of the control groups. The Pelora plot was done in R. 
 
SLR is short for Stepwise Logistic Regression, and like Pelora, SLR is also 
intended for response variables with a binary outcome. Apart from the binary 
outcome and the relaxed assumptions of normality, SLR resembles the 
stepwise regression method described in the previous chapter in that forward 
selection and backward elimination is carried out, and variable importance is 
evaluated with the Akaike information criterion. The reader may consult 
section 5.8 in the previous chapter for a description of the stepwise approach. 
Using SLR on the previous example yields the output gene list; ADA, CREB1, 
Gs and MAPK8 with an (LOOCV – Leave-One-Out Cross-Validation (181)) error 
rate of only 2%. A certain gene overlap between Pelora and SLR is noticed 
(ADA and CREB1). This example clearly demonstrates that different 
classification algorithms may yield good predictive results with different sets of 
predictor variables for the same data set.  
Finally, I should mention that SLR – unlike Pelora - performs well with clinical 
variables as predictors. This is demonstrated in the results chapter, section 
7.5.3 and 7.6. 
 
It soon turned out, that despite the initial promising Pelora and SLR results, 
these classification algorithms contained some inherent limitations; 
 
1. Per default, Pelora and SLR only consider a linear combination of the 
predictor variables, meaning predictor nonlinearities are not taken into 
account. 
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2. The two classifiers can only predict a threshold-based outcome (y), that 
is, an outcome that is above or below a threshold, meaning that an 
interval-based outcome can not be discovered. In the simple case, an 
example of an interval-based outcome is a scaled gene expression with 
a value of less than -1 leading to a disease state, a value between -1 
and +1 being the healthy state, and a value above +1 again leading to 
a disease state (see more details in the Simulation study section 
below).  
 
These limitations and the availability of a broad range of classifiers in R, led to 
a comprehensive simulation study. 
 
6.1 Simulation study 
In a close co-operation with Jan Bastholm Vistisen from Lundbeck Denmark, 
we decided to explore Pelora, SLR and a wide variety of linear and nonlinear 
classifiers and related automatic feature selection methods in more detail. I 
wanted to identify some classifiers and feature selection methods that would 
perform well with the available data, and that could take different kinds of 
gene interactions into account (see below). We decided to set up a simulation 
study to investigate which classifiers and feature selection methods that we 
would trust to analyze the qPCR data. Key questions were;  
 
• Which classifiers can identify the correct explanatory genes? 
• How good are the different classifiers at classifying and predicting new 
subjects? 
 
Simulated data sets allow us to create data sets where we define the outcome, 
that is 
 
• We know which combination of variables is used to define the outcome. 
• The outcome can be defined in any desired form like be threshold- or 
interval-based. 
• We wanted to explore various roads to a disease state, so we decided to 
create different variable combinations of interest; linear, ratio and 
product combinations of genes. According to Lundbeck Research, ratio 
and product gene combinations may be of biological interest (see below).  
 
Here, it should be stressed that we did not know which kind of gene 
interactions that exist in reality, so we decided to try several simple and 
classical combinations as described above.  
 
We decided to divide the simulation study into two phases. In phase 1, the 
simulated data sets had approximately the same amount of variables as in the 
real data; 30 variables were used. The number of samples per data set was set 
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to both N=100 and N=1000, which should mimic more or less the number of 
samples in the real data set at that time as well as the size of data set to be 
analyzed in the future. The correlation between variables was set in some data 
sets to 0 and in other data sets to 0.5. The major distinction between phase 1 
and phase 2 were that in phase 1 all variables were drawn from a normal 
distribution, while in phase 2 a realistic data set was considered, see the phase 
2 section later in this chapter.  
 
In phase 1, we wanted to rule out classifiers that could not solve tasks, we 
deemed important, and came up with 42 linear and nonlinear tasks, see 
appendix 6. Here it should be noted, that had we focused on other tasks (than 
the ones in appendix 6 and 7), different results would probably have been 
obtained. 
 
The major aspects of the phase 1 tasks were; 
 
● As a start, the outcome was just a function of one variable above a 
threshold or in an interval. This was done to understand, how the 
classifier would perform with simple tasks. 
● The outcome was then a function of different combinations of two 
or five variables in a linear, ratio or product manner and always 
either above a threshold or in an interval. 
 
Three separate scenarios were performed: 
1. Different magnitudes of two involved variables were tested (X1≈X2, 
X1≈10*X2 and X1≈100*X2). This was done to see whether the 
magnitude of involved variables played an important role. 
2. Different fractions of data points classified as Y=1 (0.05, 0.20 and 
0.50). This was very relevant to us, as in some cases, the number 
of patients was much smaller than the number of controls 
compared with. 
3. Two populations with different mean values in gene no. 1 ranging 
from (total of five scenarios):  
Y=1 if Gene 1 ~N(-3,1), Y=0 if Gene 1 ~N(+3,1)) to 
Y=1 if Gene 1 ~N(-0.25,1), Y=0 if Gene 1 ~N(+0.25,1))  
This was done to see how small a difference, the classifiers could 
detect. 
 
 
Tested classifiers and automatic feature selection methods 
We decided to look at broad range of classifiers. Based on classifier course 
material from the CBS course ‘DNA Microarray Analysis’ and various available 
classifiers in R, I came up with a list of classifiers that operated based on 
(more or less) different algorithms. Focus was on classifiers with either built-in 
variable selection or with variable selection as a pre-step to classification.  
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The following linear and nonlinear classifiers and variable selection methods 
were tested in phase 1 - in general, not in all cases, the default options in R for 
each classifier were used: 
 
1. Pelora with only the first Pelora cluster used to avoid overfitting (180), 
(179). 
2. SLR (168) and (182). 
3. PLR - Penalized Logistic Regression with a stepwise variable selection 
(183).  
4. RPART - Recursive PARTtioning (classification tree), see section 5.6 in 
the previous chapter and (158). 
5. NB12 – Naive Bayes is a standard classifier known to perform well (186) 
and (187). 
6. LDA12 – Linear Discriminant Analysis is a classical classification method 
(188) and (187).  
7. SKNN12 – Simple K Nearest Neighbor. K-NN is described in (115), (189) 
and (187). 
8. Random Forest12 (190), (191) and (192).  
9. QDA13 – Quadric Discriminat Analysis is also described in (115), and 
(194), (193). 
10. SVM13 – Support Vector Machines (193) and (195). 
11. NNET13 – Neural NETwork with a single-hidden-layer (193). For  
     neural network theory, see (196). 
12. LogitBoost13 – a new boosting machine learning technique (193) and     
    (197). 
 
The interested reader may consult the references for details on these 
classifiers. 
 
Accuracy, cross-validation and the Jaccard similarity coefficient 
In order to determine the performance of a classifier for both two and multiple 
(phase 2) class tasks, I decided to measure the accuracy (198): 
 
 
 
 
 
 
The accuracy was measured in each cross-validation sample and finally 
averaged. As recommended in (199), 10-fold stratified14 cross-validation was 
                                                 
12 Initial testing demonstrated that the variable selection method (varselrf (184),(185)) performed very well, so the 
classifiers NB, LDA, SKNN and random forest were started of with the varselrf-selected variables.  
13 QDA, SVM, NNET and LogitBoost were tested with two different variable selection methods: msc (based on mass 
spectra classification (193)) and varselrf (variable selection based on random forests). 
14 Stratified cross-validation means that each fold contains approximately the same ratio of patients to controls as is 
present in the entire data set.  
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6. Classification with variable selection 
used. This also explicitly meant that the accuracy measured would not be 
inflated due to overfitting. 
 
To measure how well a classifier identified the correct variables, the Jaccard 
similarity coefficient (200), recommended in the ‘DNA Microarray Analysis’ 
course, was used (binary form): 
 
 
111001
11
MMM
MJ ++= 
 
 
“M11 represents the total number of attributes where the binary vectors A and 
B both have a value of 1.  
M01 represents the total number of attributes where the attribute of A is 0 and 
the attribute of B is 1.  
M10 represents the total number of attributes where the attribute of A is 1 and 
the attribute of B is 0” (200).  
 
The Jaccard score yielded a number (0-100%) indicating how well a classifier 
identified variables compared to the correct explanatory variables as we had 
defined them. The higher the Jaccard score, the better an agreement between 
the two.  
 
 
Phase 1 results 
Now I present a few of the results from phase 1 in the form of plots with the x-
axis representing the accuracy and the y-axis the Jaccard score. The 
abbreviations in the plots refer to the classifier names given in the classifier list 
above. A suffix of ‘.RF’ means that the variable selection method ‘varselrf’ 
(variable selection based on random forests) was used as a pre-step to the 
corresponding classifier. Otherwise, the feature selection method ‘msc’ 
(variable selection based on mass spectra classification) was used as a pre-
step to the quadratic discriminant analysis (QDA), Random Forest (RF), 
support vector machines (SVM), neural network (NNET) and boosting 
LogitBoost classifiers.  
 
In figure 12, the 16 classifier possibilities are shown for a task involving a 
linear combination of two variables with the outcome above a threshold. 
Furthermore, there is no correlation between the variables. This plot indicates 
that the LDA, NB, SKNN, LogitBoost, LogitBoost.RF, QDA, NNET and SVM 
classifiers do not perform well for this kind of task. 
 
In figure 13, a linear combination of predictor variables is explored as well. 
However, the correlation between the variables is now 0.5, and the outcome is 
in an interval. Only four classifiers solve this tasks well; RF.RF, SVM.RF, 
QDA.RF and NNET.RF. 
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Figure 12 shows the 16 classifier possibilities solving the task shown at the top of the figure. 
The best performing classifiers are: PLR, Pelora, SLR, SVM.RF, QDA.RF, NNET.RF, RF.RF and 
RPART. The figure was made in Excel based on output from R. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 shows the 16 classifier possibilities solving the task shown at the top of the figure. 
The best performing classifiers are: RF.RF, SVM.RF, QDA.RF and NNET.RF. The figure was 
made in Excel based on output from R. 
 
In figure 14, the ratio between two variables is explored for a large data set 
(N=1000) with 0.5 correlation between the variables, given a threshold. The 
best performing classifiers were; SVM.RF, RF.RF, RPART and QDA.RF. The msc 
variable selection method could not solve this task as all. 
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Pelora
SLR
PLR
NB
LDA
QDA.RF
RPART
SKNN RF.RF
SVM.RFNNET.RFLogitBoost.RF
0%
20%
40%
60%
80%
100%
120%
0 20 40 60 80 100 120
Accuracy
Ja
cc
ar
d
Figure 14 shows 12 classifier possibilities solving the task shown at the top of the figure. The 
best performing classifiers are: SVM.RF, RF.RF and QDA.RF. The msc variable selection method 
could not solve this task. The figure was made in Excel based on output from R. 
 
In figure 15, the product between two variables is explored for N=100 in an 
interval with no correlation between the variables. The best performing 
classifiers were; SVM.RF, RF.RF and QDA.RF.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene 1 * Gene 2 in interval, N=100, 0 corr.
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Figure 15 shows 16 classifier possibilities solving the task shown at the top of the figure. The 
best performing classifiers are: SVM.RF, RF.RF and QDA.RF. The figure was made in Excel 
based on output from R. 
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Finally, in figure 16, a linear combination of five variables is explored for 
N=100 with 0.5 correlation between the variables, given a threshold. The best 
performing classifiers were; Pelora and SLR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene 1 + Gene 2 - Gene 3 - Gene 4 + Gene 5 > threshold, N=100, 0.5 corr.
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Figure 16 shows 16 classifier possibilities solving the task shown at the top of the figure. The 
best performing classifiers are: Pelora and SLR. The figure was made in Excel based on output 
from R. 
 
By looking at the 42 plots (available on request) corresponding to the different 
linear and nonlinear phase 1 tasks, we concluded; 
 
• The variable selection method varselrf seemed very promising especially 
in connection with the classifiers SVM, random forest or QDA dealing 
with a broad range of linear and nonlinear classification problems. 
 
• When the outcome was a linear combination of variables, SLR and Pelora 
did the best classification job. 
 
• The following cases were not well handled by the above mentioned 
classifiers in general: 
● “Large” ratios – 5 variable ratios 
● “Large products” – 5 variable products 
● Data sets of size N=100 with only 5% Y=1 
● The difference between Y=0 and Y=1 variable mean values was 
~0.5 
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Most importantly, we concluded that the following classifiers and variable 
selection methods in general performed the worst 
 
● NB 
● LDA 
● SKNN 
● QDA (msc selection method) 
● SVM (msc selection method) 
● NNET (msc selection method) 
● LogitBoost (msc and varselrf selection methods) 
 
and would not be part of phase 2 tested classifiers. The reasons for poor 
performance were typically these classifiers and selection methods low Jaccard 
score (i.e. they were not able to identify the responsible genes satisfactory) 
and/or bad accuracy score considered overall for the various tasks.   
 
Phase 2 
The worst performing classifiers from phase 1 were omitted, and thus, the 
following classifiers and feature selection methods were tested in phase 2: 
 
1. Pelora with only the first Pelora cluster used 
2. SLR 
3. PLR  
4. RPART 
5. QDA15 
6. Random Forest15  
7. SVM15 
8. NNET15 
 
The phase 2 data set consisted of the DC, SH ABS and PTSD control groups as 
well as the borderline personality disorder and acute PTSD patients. 25 
variables/genes were included. The number of samples was 263. All data was 
normalized the same way; the variables used were in one case z-score 
standardized, as in phase 1, and in another case, real unstandardized 
expression values. As in phase 1, the outcome was defined as different 
combinations of the variables. 
 
33 different tasks were given to the classifiers (see appendix 7) with most of 
them similar to the tasks in phase 1: 
● To begin with, the outcome was just a function of one variable 
above a threshold or in an interval. 
● Then, the outcome was a function of different combinations of two 
or five variables in a linear, ratio or product manner and always 
either above a threshold or in an interval. 
                                                 
15 QDA, Random Forest, SVM and NNET were tested with the variable selection method varselrf. 
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Four separate studies were performed: 
1. Completely random outcome – how would the classifiers / variable 
selection method perform in this situation?  
2. Different fractions of data points classified as Y=1 (0.05, 0.20 and 
0.50) 
3. Actual data (no z-score): Different magnitudes of two involved 
variables were tested (X1≈X2, and X1≈100-300*X2) 
4. 3 groups/classes: Which classifiers were able to handle multiclass 
classification? This issue was important to Lundbeck Research. It is 
generally known, that most classifiers work only on two-class data 
sets (201). 
 
Phase 2 results 
Below, I present five of the results from phase 2 (full documentation available 
on request) in the same kind of plots as in phase 1. The abbreviations in the 
plots are also the same as in phase 1. Here it should be emphasized that one-
gene simulations were only performed to see how the classifiers dealt with this 
task, and they are not included in the examples below. Since the diseases we 
are considering are believed to be polygenenic, a classifier is not of interest if it 
only performs well in a single variable/single gene case.  
 
Figure 17 shows how the 8 classifiers perform with a simple linear task 
involving two variables and an outcome threshold. All classifiers solve this task 
well.  
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Figure 17 shows the 8 classifiers solving the task shown at the top of the figure. All classifiers 
perform well. NB! Notice the x-axis. The figure was made in Excel based on output from R. 
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However, in figure 18 the outcome is now interval dependent, otherwise with 
the same settings as in the previous example. The worst performing classifiers 
are; SLR, Pelora and PLR. 
 
 
Figure 18 shows the 8 classifiers solving the task shown at the top of the figure. Three 
classifiers do not perform well; SLR, Pelora and PLR, while the encircled classifiers solve this 
task well. The figure was made in Excel based on output from R. 
 
In figure 19, the product between two variables was explored with a simple 
threshold outcome. The best performing classifiers were; SVM.RF, RF.RF and 
PLR.  
 
Figure 19 shows the 8 classifiers solving the task shown at the top of the figure. The encircled 
three classifiers perform well; SVM.RF, RF.RF and PLR. The figure was made in Excel based on 
output from R. 
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In figure 20, the ratio of two variables was explored with an interval dependent 
outcome. The best performing classifiers were; SVM.RF and RF.RF.  
 
 
Figure 20 shows the 8 classifiers solving the task shown at the top of the figure. The encircled 
two classifiers perform well; SVM.RF and RF.RF. The figure was made in Excel based on output 
from R. 
 
Finally, in figure 21, a linear combination of five variables was explored with a 
simple threshold outcome. The best performing classifiers were; SLR, Pelora 
and PLR. 
 
 
Figure 21 shows the 8 classifiers solving the task shown at the top of the figure. The encircled 
three classifiers perform well; SLR, PLR and Pelora. The figure was made in Excel based on 
output from R. 
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In order to compare the classifiers on a quantitatively basis, we decided to 
focus on classifiers that yielded an accuracy above 80% and that had a Jaccard 
similarity score above 70%. This we believed would reflect good-performing 
classifiers on the available qPCR data, even though these percentages were 
chosen more or less arbitrary. In table 19, the eight classifiers are listed 
together with information on the percentage of tasks solved, the average 
accuracy (above 80%), the average Jaccard score (above 70%) and the 
specific tasks solved. 
 
 
 
Table 19: Phase 2 tasks solved with an accuracy above 80% and a Jaccard score above 70%. 
The column ‘Tasks solved’ refer to the specific tasks solved, see appendix 7. The conclusions in 
the text sum up the table.  
 
 
Based on the table 19 results and the 33 plots, we concluded; 
 
● Above an accuracy threshold of 80% and a Jaccard score of 70%, RPART, 
SVM (varselrf) and Random Forest (varselrf) solved the largest fraction of 
given tasks. 
● SVM and Random Forest solved the same tasks, however, SVM yielded a 
slightly higher accuracy. 
● RPART was very good at dealing with one variable (threshold and interval) 
incl. small fraction of 1’s. Furthermore, RPART identified some of the same 
variables as varselrf did. It was reassuring to have some kind of gene list 
consistency, that is, to have the same variables selected by two methods 
(although the methods share some similarity they are not alike).    
● SLR solved less tasks than RPART and SVM, but more than Pelora and 
yielded both 100% average accuracy and average Jaccard score.  
Furthermore, as mentioned previously, unlike Pelora SLR is able to handle 
categorical clinical variables well. 
2 groups %tasks solved avg. accuracy avg. Jaccard Tasks solved
Pelora 28% 95% 97% r1,r3,r9,r16,r17,r18,r22
SLR 36% 100% 100% r1,r3,r9,r16,r17,r18,r20,r21,r22
PLR 28% 100% 100% r1,r3,r5,r9,r16,r17,r18
RPART 56% 94% 97% r1,r2,r3,r4,r6,r16,r17,r18,r20,r21,r22,r23,r24,r26
Random Forest (varselrf) 52% 95% 98% r3,r4,r5,r6,r7,r8,r9,r20,r21,r22,r23,r24,r26
QDA (varselrf) 48% 89% 98% r3,r4,r6,r7,r8,r9,r20,r21,r22,r23,r24,r26
SVM (varselrf) 52% 97% 98% r3,r4,r5,r6,r7,r8,r9,r20,r21,r22,r23,r24,r26
NNET (varselrf) 16% 91% 94% r3,r4,r9,r22
3 groups (7 tasks in total): 
3 groups %tasks solved avg. accuracy avg. Jaccard Tasks solved
RPART 43% 88% 98% r27,r28,r30
Random Forest (varselrf)* 43% 91% 98% r28,r29,r30
QDA (varselrf)* 43% 89% 98% r28,r29,r30
SVM (varselrf)* 43% 95% 98% r28,r29,r30
NNET (varselrf)* 14% 97% 93% r28
2 groups (25 tasks in total): 
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● Accuracies thresholds above 80% seem to yield very high Jaccard scores > 
95% and high classifier accuracies ~90-95% 
● As expected standardization of data yielded the same results as 
unstandardized data. 
● NB! In general, all classifiers were used with default settings or default 
recommendations. Optimizations of various settings would probably lead to 
different results. 
 
 
Based on phase 1 and phase 2 simulation studies, we recommended the use 
of; 
 
Two groups: 
● SVM in combination with varselrf 
● RPART  
● SLR (can handle linear cases with multiple variables above a 
threshold which neither SVM nor RPART is good at.) 
 
Furthermore, we concluded that if groups of equal sizes could be separated 
with an accuracy above 80%, this would mean that we had identified the key 
variables/gene expressions. In the next section, I have made a classification 
procedure that I have used for real case classifications and variable selections. 
 
Multiple groups (>2): 
● SVM in combination with varselrf 
● RPART 
 
Also, if groups could not be separated with SVM or RPART (or additional SLR in 
the two-group case), we would say there were no expression differences 
between the groups. 
 
These two- and multiple-group classifiers and variable selection methods are 
used in the Results chapter, section 7.5, to perform classification on various 
control and patient groups. An example of the application of the two-group 
classifiers is shown in the ‘real case’ section (section 6.3) later in this chapter. 
 
6.2 Classification and variable selection procedure 
Since the accuracy values are dependent on the group sizes, the following 
classification procedure is used to decide whether a group separation is 
possible or not, and if it is possible, how to report the responsible genes: 
 
1. Calculate 10-fold stratified CV (cross-validation) accuracies in the real 
case scenario, i.e. with the actual control and patient data. 
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2. Calculate permuted accuracies by doing 10 permutations (due to pc 
temporal limitations) of the class labels leading to 10 x 10 (CV) = 100 
permuted accuracies.  
I apply the permutation step in order to calculate the accuracy values 
expected at random in the real data set (excluding the class label) for a 
classifier (202). 
3. Compare the 10 real case accuracies with the 100 permuted accuracies 
using a t-test if the accuracy values follow a normal distribution (tested 
with a Shapiro-Wilk test), otherwise use a Wilcoxon test.   
4. Significant result is obtained (that is, the groups are separable) if the p-
value is below the significance level 1% (adjusted for multiple tests). 
5. Genes corresponding to the significant result are listed.  
Genes are extracted from the complete data set from each classifier 
(selected genes may depend on classifier). 
Overlapping genes are reported as a request from the US Lundbeck 
group.  
 
The above five steps apply both to the two-group and multiple-group case. 
Furthermore, in the two-group case, to get additional useful information from 
the classifications, the positive and the negative predictive values are reported. 
“The positive predictive value (PPV) is the proportion of patients with positive 
test results who are correctly diagnosed” (203); 
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The PPV “is the most important measure of a diagnostic method as it reflects 
the probability that a positive test reflects the underlying condition being 
tested for” (203). 
 
Correspondingly, “the negative predictive value (NPV) is the proportion of 
patients (here controls) with negative test results who are correctly diagnosed” 
(204). 
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6.3 Real case example 
To demonstrate the three classifiers SVM with varselrf, RPART and SLR on a 
two-group classification task, they are now used on a data set consisting of a 
pooled control group (DC, SH ABS, UK, PTSD controls) and the acute PTSD 
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patient group (25 genes). The classification and variable selection procedure is 
applied. 
 
Table 20 contains the accuracy values of each classifier, both from the 
classification task and from permuted data sets. PPV and NPV values are 
reported as well. 
 
 Accuracy (average) PPV (average) NPV (average) 
SVM.RF 85,6% 70,0% 87,1% 
Permuted.RF 78,4%    
RPART 82,2% 65,4% 88,1% 
Permuted.RPART 70,3%     
SLR 88,1% 81,2% 90,1% 
Permuted.SLR 78,3%     
Table 20: Accuracy, PPV and NPV values for the classification task involving a pooled control 
group and the acute PTSD patient group (25 genes). The table is commented in the text. 
 
Below are the Wilcoxon two-group p-values of the 10 real case accuracies vs. 
the 100 permuted accuracies; 
 
SVM.RF vs. Permuted.RF: 
Wilcoxon p-value: 0.0005644 
 
RPART vs. Permuted.RPART: 
Wilcoxon p-value: 5.757e-05 
 
SLR vs. Permuted.SLR: 
Wilcoxon p-value: 1.589e-05 
 
All these p-values are below 1%, meaning the pooled control group and the 
acute PTSD group is separable. In this case, just by looking at the accuracy 
values, it appears that the groups are separable. However, in other cases the 
difference between the real case and permuted accuracy values may seem 
small, yet be significant.  
 
The permuted accuracies are quite high. The reason is that there are 256 
controls and only 66 acute PTSD patients, meaning the group sizes are far 
from equal (which would have implied a permuted accuracy of approximately 
50%). In this case, about 80% of the subjects (controls and patients) are 
controls. 
 
Genes separating the groups: 
SVM.RF16: ARRB2, ERK2, RGS2 
                                                 
16 Due to the random aspect, different runs of RF produce (slightly) different gene lists. Focus is on the most consistent 
list. 
6. Classification with variable selection 
RPART: ADA, ARRB1/2, CREB2, ERK1, GR, MKP1, P2X7, RGS2 
SLR: ARRB1/2, CD8 beta, ERK2, IDO, IL-6, MR, PREP, RGS2 
 
Overlapping genes: ARRB2, RGS2 
 
 
The conclusion of this example is then, that the groups are separable, and that 
ARRB2 and RGS2 are involved in the separation. However, for use in a 
commercial diagnostic test, the separation of the two groups may be optimized 
to yield higher PPV values. 
 
6.4 Variable selection based on random forests and SVM 
While stepwise logistic regression (SLR) and recursive partitioning (RPART) 
have been described previously, I will now describe the particularly promising 
variable selection method based on random forests (varselrf) and the support 
vector machines (SVM) classifier in more detail.  
 
Variable selection based on random forests 
To explain variable selection based on random forests, I will start by explaining 
a random forest. A random forest is a classifier that consists of many 
classification trees (described in the Statistical methods chapter, section 5.6 
and known from RPART) and outputs the class that is the most frequent of the 
classes output by individual trees. “In a classification tree, each node is split 
using the best split among all variables. In addition to constructing each tree 
using a different bootstrap sample of the data, random forests change the way 
the classification trees are constructed. In a random forest, each node is split 
using the best among a subset of predictors randomly chosen at that node. 
This somewhat counterintuitive strategy turns out to perform very well 
compared to many other classifiers, including discriminant analysis, support 
vector machines and neural networks, and is robust against overfitting” (205).  
 
The random forests algorithm (205):  
1. “Draw ntree (default 5000) bootstrap samples (with replacement) from 
the original data. 
2. For each of the bootstrap samples, grow an unpruned classification tree, 
with the following modification: at each node, rather than choosing the 
best split among all predictors, randomly sample mtry (default 1) of the 
predictors and choose the best split from among those variables.  
3. Predict new data by aggregating the predictions of the ntree trees (i.e., 
majority votes for classification). 
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An estimate of the error rate can be obtained, based on the training data, by 
the following: 
1. At each bootstrap iteration, predict the data not in the bootstrap sample 
(also called “out-of-bag”, or OOB, data) using the tree grown with the 
bootstrap sample. 
2. Aggregate the OOB predictions. (On the average, each data point would 
be out-of-bag around 36% of the times, so aggregate these predictions.) 
Calculate the error rate, and call it the OOB estimate of error rate.” 
 
 
“Variable selection based on random forests is then performed using the OOB 
error as a minimization criterion, by carrying out variable elimination from the 
random forests, by successively eliminating the least important variables (with 
importance as returned from random forest)” (184). More specific (184): 
 
1. “With the default parameters, all forests that result from eliminating, 
iteratively, a fraction, of the least important variables used in the 
previous iteration are examined.  
2. After fitting all forests, the OOB error rates from all the fitted random 
forests are examined. The solution with the smallest number of genes 
whose error rate is within c.sd17 (default 1) standard errors of the 
minimum error rate of all forests are chosen”.  
 
 
Support vector machine (SVM) 
After varselrf has determined the variables/genes separating groups, the 
support vector machine classifier performs the actual classification based on 
these variables.  
 
As explained in (195), considering the two-class case, the input data may be 
viewed as “two sets of vectors in an n-dimensional space. An SVM will 
construct a separating hyperplane in that space, one which maximizes the 
‘margin’ between the two data sets. To calculate the margin, two parallel 
hyperplanes are constructed, one on each side of the separating one, which 
are ‘pushed up against’ the two data sets”, see figure 22. “Intuitively, a good 
separation is achieved by the hyperplane that has the largest distance to the 
neighboring data points of both classes. The hope is that, the larger the margin 
or distance between these parallel hyperplanes, the better the generalization 
error of the classifier will be” (195). 
 
 
                                                 
17“ Setting c.sd = 1 is similar to the common ‘1 standard error rule’, used in the classification tree literature; this 
strategy can lead to solutions with fewer genes than selecting the solution with the smallest error rate, while achieving 
an error rate that is not different, within sampling error, from the ‘best solution’“(184). 
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Figure 22 shows SVM classification in the linear case. A separating hyperplane (thick bold line), 
the two parallel hyperplanes, the margin and the support vectors are shown. The figure 
appears in (206). 
 
In the actual implementation of SVM in R for classification purposes, the so-
called kernel trick is applied, meaning we are performing nonlinear 
classification with an otherwise linear classifier. “The kernel trick is a method 
for using a linear classifier algorithm to solve a nonlinear problem by mapping 
the original nonlinear observations into a higher-dimensional space, where the 
linear classifier is subsequently used; this makes a linear classification in the 
new space equivalent to nonlinear classification in the original space” (207). 
The specific kernel applied is the radial basis function (208), which is 
recommended for classification (206). Also, SVMs are known to be very 
sensible to the proper choice of parameters, and the before mentioned 
reference recommends checking a range of parameter combinations. This I do 
by tuning the two available SVM parameters, gamma (parameter needed for all 
kernels except linear) and cost (cost of constraints violation) in the parameter 
space; gamma = 2^(-2:2)18, cost = 2^(1:8) based on (208). This parameter 
space was always searched for every classification task. 
 
 
                                                 
18 ‘2^(-2:2)’ means gamma is tested in the grid interval from 2-2 to 22. 
7. Results 
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The US Lundbeck group and I defined a number of questions to be considered, 
see table 21 in the present chapter (this table is based on the questions listed 
in table 10, chapter 5, and revised to include bioinformatics and classification 
tasks). This chapter describes answers to these questions by providing results 
obtained by means of bioinformatics and of various statistical and classification 
methods. The questions/purposes and results comprise  
• Bioinformatic predictions of new possible biomarkers; using the web 
application Ingenuity, new possible biomarkers like Hsp90, PP2A and 
NFkB (and others) are predicted.  
• Bioinformatic predictions of altered gene expressions in an as yet 
unanalyzed patient group – bipolar disorder patients; Gs, IL-1 beta, 
CREB1 and ERK1 are predicted to show altered expression.  
• Various gene expression and clinical data relationships are reported, e.g. 
o 20 hypotheses are constructed as gene expression predictions for 
depressed patients. These hypotheses are based on expression 
patterns from controls and identified possible intermediate 
phenotypes. 
o Possible borderline personality disorder (BPD) subtypes are 
identified by recursive partitioning (RP) looking at the BPD patients 
and the Danish and ‘super-healthy’ American controls. At the same 
time, RP shows that the two control groups are more similar than 
the patient group.  
o Other possible BPD subtypes are identified with canonical 
correlation analysis incorporating both clinical variables and gene 
expressions. 
• The effect of pooling both two control groups and all control groups are 
investigated and recommended.  
• Repeated measures ANOVA test results indicate that five gene 
expressions differ significantly between three time point measurements; 
CD8 beta, IL-8, MKP1, MR and ODC1. 
• Classification results indicating genes separating 
o controls from borderline personality disorder (BPD) patients 
o controls from acute post-traumatic stress disorder (PTSD) patients 
o controls from trauma patients (without PTSD). This separation is 
not convincing due to low performance measures.  
o controls can not be separated from remitted post-traumatic stress 
disorder patients – a result that is in good agreement with the 
clinical diagnosis.  
• Possible disease subtypes both in BPD and PTSD are identified by the use 
of clustering and heat maps. 
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In close cooperation with the US Lundbeck group, we defined a number of 
questions to be considered. I have looked into these questions by the use of 
various bioinformatic approaches and by the statistical and classification 
techniques described in earlier chapters. In order to structure all the different 
results I obtained by analyzing the qPCR data, I have summed up the main 
purposes, the applied methods, and the data used for the analyses in table 21. 
This table also lists the section in which the results are presented. The table is 
inspired by the statistical summary table 10 from the Statistical methods 
chapter, and revised to include bioinformatics and classification tasks. It should 
be noted, that sometimes a purpose in the table answers more than one 
question. With the many different aims of our analyses, some of them are 
overlapping. In the table and in the relevant sections, I make the reader aware 
of any such overlapping purposes.  
 
Analysis purpose Method Data / group Section 
Bioinformatic predictions: 
 
- Prediction of new possible 
biomarkers 
 
- Which gene expressions are 
expected to be regulated in 
bipolar disorder patients? 
 
 
- bioinformatics; STRING and 
Ingenuity 
 
- bioinformatics; NCBI’s SNP 
database, STRING and Ingenuity 
 
 
- List with 29 
genes 
 
- Two articles 
and list with 29 
genes 
7.1 
 
7.1.1 
 
 
7.1.2 
Is the qPCR data normally 
distributed? 
normal QQ plots, normality tests ABS19 controls 7.2 
Identify clinical variable – gene 
expression relationships20: 
 
- Biomarkers for depression – 20 
hypotheses 
- Gene expression subgroups 
identified via RP 
 
 
- Possible BPD phenotypes 
through CCA 
 
Special focus: 
- which clinical variables explain 
the most variance in a gene? 
 
- any gender differences in the 
expression profiles? 
 
- pooling of two control groups 
into one group? 
 
- should all control groups be 
pooled into a single large group? 
 
 
 
- univariate tests, correlations 
 
- recursive partitioning 
 
 
 
- canonical correlation analysis 
 
 
 
- stepwise regression 
 
 
- Pelora / SLR (initial classifiers), 
correlations, univariate tests 
 
- univariate tests, correlations and 
correlation tests, classification 
 
- univariate tests, plots, Pelora / 
SLR 
 
 
 
- ABS19 controls 
 
- ABS19 and DC 
controls, BPD 
patients 
 
- BPD patients 
 
 
 
- ABS19 controls 
 
 
- ABS19 and DC 
controls 
 
- ABS19 and DC 
controls 
 
- all control 
groups 
7.3 
 
 
7.3.1 
 
7.3.2 
 
 
 
7.3.3 
 
 
 
7.3.4 
 
 
7.3.5 
 
 
7.3.6 
 
 
7.3.7 
                                                 
19 In table 21, I do not differentiate between the ABS group and the SH ABS group, and just call it ‘ABS controls’. 
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Are gene expression levels the 
same across different time 
points? 
repeated measures ANOVA  UK controls 7.4 
Variable selection (identifying 
genes separating various control 
and patient groups) and 
classification. 
 
 
 
 
- 2-group comparisons 
 
- multiple group comparisons 
 
Special focus: 
- Genes and clinical variables 
separating control and patient 
group 
varselrf and variable selection from 
the classification methods RPART 
and SLR 
 
Classifiers: SVM (with varselrf), 
RPART and SLR 
 
 
- SVM (with varselrf), RPART, SLR 
 
- SVM (with varselrf) and RPART 
 
 
- SLR 
ABS19, UK and 
DC controls, 
PTSD controls, 
remitted PTSDs, 
BPD patients,  
acute PTSDs and 
trauma patients 
 
 
 
 
 
 
- ABS19 controls 
and BPD patients 
7.5 
 
 
 
 
 
 
 
7.5.1 
 
7.5.2 
 
 
7.5.3 
Identify gene – gene 
relationships 
(expression patterns only) 
clustering and heat maps ABS19 controls, 
BPD and PTSD 
acute patients 
7.6 
Table 21 presenting the various purposes of our analysis, the applied methods (bioinformatics, 
statistical, classification), the data used for analysis, and the sections containing the 
corresponding results. 
 
The table contains a column for the data used to analyze a purpose. It should 
be noted that I have analyzed the different purposes with the control and 
patient data available at time of the analysis, and always in agreement with 
Lundbeck US. This also explicitly means that all purposes or methods have not 
been analyzed using all group combinations, as we have not found it necessary 
to investigate all permutations, even though this might be possible. In general, 
the results illustrate the usability of the various methods, which is a major 
purpose of the study.  
 
7.1 Bioinformatic predictions 
Prior to any statistical or classification analysis in R, bioinformatics can be used 
to answer important prediction questions. One such question concerns the 
identification of new possible biomarkers based on the gene list with the 29 
genes, and the results from this analysis are presented in section 7.1.1. 
Bioinformatics may also give the answers to a question concerning which gene 
expressions that may be expected to be regulated in a not-yet data analyzed 
patient group. I present such results from a bioinformatic analysis looking into 
SNP (single nucleotide polymorphisms - a variation in a gene caused by the 
                                                                                                                                                                  
20 Here is an example of a (broadly defined) purpose that answers more than one important question; besides identifying 
clinical variable – gene expression relationships (determining intermediate phenotypes), this task also gives insight into 
which gene expressions that are expected to be regulated in depressed patients, see section 7.3. 
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change of a single base in DNA) analyses from bipolar disorder patients in 
section 7.1.2. 
 
7.1.1 Prediction of new possible biomarkers 
The US Lundbeck group had chosen to measure the gene expressions of 
approximately 30 genes, see ‘The genes selected by Lundbeck’ chapter. The 
genes were chosen based on a literature search. Bioinformatics can now be 
used to predict novel biomarker genes, that it could make sense to measure in 
the same control and patient groups. Based on the list of 29 genes, the 
bioinformatics web application Ingenuity lets us know that the 29 genes are 
gathered in three networks, see network 1, 2 and 3 in appendix 1 that also 
explains the gene abbreviations. These networks include various kinds of 
interactions between the genes. The reader may recall that in Chapter 3, I 
wrote, that examples of interactions were: Activation/inhibition, binding, 
expression, phosphorylation/dephosphorylation, protein-DNA binding, protein-
protein binding and transcription.  
 
In the CBS course ‘Bioinformatics and Gene Discovery’, we were taught that a 
protein in a protein complex may be a good biomarker if the protein complex 
contain other putative disease specific proteins. The more disease specific 
proteins in a complex, the more likely it is that another protein in the complex 
could be a possible biomarker. Thus, in order to predict novel biomarkers, I 
merged the three networks into one big network and focused on protein-
protein interactions (PPI), see figure 23. 
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Figure 23 shows PPI interactions between 29 genes selected by Lundbeck (marked grey). The 
full red circled proteins are directly interacting with at least three Lundbeck selected genes, 
while the dotted red circled proteins directly interact with maximum two of the Lundbeck 
selected genes. The network was created with Ingenuity.  
 
In figure 23, the proteins interacting with at least three of the Lundbeck 
selected genes/proteins are (full red circled);  
 
• Hsp90 (heat shock protein 90kDa alpha (cytosolic), class A member 1) 
• PP2A (protein phosphatase 2A activator, regulatory subunit 4)  
• NFkB (nuclear factor-kappa B) 
 
Proteins interacting with maximum two of the Lundbeck selected 
genes/proteins are; Ras, MHC Class I (major histocompatibility complex, class 
I), Mek (mitogen-activated protein kinase kinase kinase 1), Akt (protein kinase 
B) and Ap1 (activator protein 1). 
 
The above 3+5 genes could be potentially new biomarkers, if they are 
expressed at detectable levels in whole blood.  
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7.1.2 Prediction of regulated gene expressions in bipolar disorder patients 
Bioinformatics may also offer a qualified guess as to which gene expressions, 
among the 29 selected genes, that may be expected to be regulated in a 
patient group whose gene expressions have not been measured yet.  
 
Last year, the Wellcome Trust Case Control Consortium (WTCC) (209) 
compared blood SNPs in ~2000 UK BD (bipolar disorder) patients with blood 
SNPs in ~3000 UK controls (210). In the article (210), WTCC identified a little 
more than 100 SNPs with strong or modest association to BD. Using NCBI’s 
SNP database (211), I found that these SNPs affect 57 genes (multiple SNPs 
may be present in the same gene, and some SNPs are located in non-coding 
regions of the genome). Furthermore, Baum and colleagues looked in blood 
SNP in BD in both an American and a German case-control group (59). In 
total, their article mentioned 11 genes that might be implicated in BD. 
Appendix 8 lists all the 68 genes. There are no overlapping genes between the 
11 and 57 genes. Also, none of 68 genes are identical with any of the 29 genes 
selected by Lundbeck. Furthermore, there is only a very little overlap between 
the 68 genes and the BD associated genes listed in chapter 2. This aspect is 
discussed in the next chapter.  
 
After agreement with the US Lundbeck group, I decided to look into PPI 
interactions to investigate any possible protein-protein interactions with the 29 
selected genes/proteins. I did this using the PPI database STRING (212) and 
Ingenuity (104), see figure 24 for the work flow for the whole task. 
 
WTCC; Blood SNPs 
from 2000 BD and  
3000 controls  
100+ SNPs show strong  
or moderate association 
NCBIs SNP db 
WTCC Nature 2007 paper: 
57 genes affected by the 
WTCC SNPs 
(new potential biomarkers) 
STRING 
transciptional influence (Ingenuity + 
Lundbeck US) 
PPI-network w/chosen genes +  
+ 11 genes mentioned in Baum article  
Figure 24 shows the work flow in identifying which gene expressions, among the 29 selected 
genes, that may be expected to be regulated in BD patients. The diagram is explained in the 
text. 
 
In figure 25, I show the STRING PPI network containing the 29 selected 
genes/proteins and 68 BD associated proteins.   
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Figure 25 shows a STRING PPI network consisting of the 29 Lundbeck selected genes/proteins 
(red circled) and 68 BD associated proteins. Blue encircled ‘BD’ proteins interact with red 
encircled proteins. See the text for explanations of this figure. 
 
In figure 25, the red encircled proteins are the 29 selected by Lundbeck, while 
the blue encircled genes are the BD associated proteins that interact with any 
of the 29 proteins. The 12 blue encircled interacting proteins are possible BD 
biomarkers21 related to the 29 proteins:  
 
SYK (spleen tyrosine kinase), BDNF (brain-derived neurotrophic factor), PTPRE 
(protein tyrosine phosphatase, receptor type, E), CDC25B (cell division cycle 
25B), IRE2 (endoplasmic reticulum-to-nucleus signaling 2), DPP10 (dipeptidyl 
peptidase 10), THRB (thyroid hormone receptor, beta), NRG1 (neuregulin 1), 
DISC1 (disrupted in schizophrenia 1), PAX5 (paired box 5), GRIN2B (glutamate 
receptor, ionotropic, N-methyl D-aspartate 2B) and GLUR6 (Glutamate 
receptor 6). 
 
                                                 
21 Before the 12 genes are considered as possible biomarkers, it is important to see if these genes are expressed at 
detectable levels in white blood cells. If they are not expressed in blood, they are not relevant as blood biomarkers.  
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In order to refine this list further, Joseph Tamm from Lundbeck US suggested 
focusing on interactions where gene X directly influences transcription of gene 
Y. This I did in Ingenuity, and shortened the list down to SYK, BDNF and THRB.  
 
At the level of transcription, the three BD associated genes seem to affect:  
 
• Gs 
• IL-1 beta 
• CREB1  
• ERK1 
 
Thus, expression differences between BDs and controls may be expected to be 
seen in the above four genes. At this point, it is not possible to say whether 
the genes are expected to be up or down regulated in BDs.  
 
7.2 Normally distributed qPCR data? 
The parametric tests applied later in this chapter assume that the qPCR gene 
expression data is normally distributed. In the Statistical methods chapter, 
section 5.1, I mention the five different normality tests; the Shapiro-Wilk test, 
the Anderson-Darling test, the Cramér-von-Mises criterion, the Lilliefors test 
for normality, and the Shapiro-Francia test for normality. I applied these five 
tests to the ABS control group containing 29 genes. In table 22, the number of 
gene expressions following a normal distribution according to the five tests is 
shown. I included a column called ‘Ratios’ dealing with various gene expression 
ratios that are explained in the next section (7.3).  
 
1% significance level Gene expressions Ratios Total 
Anderson-Darling (normal) 0 7 7 
Anderson-Darling (log10) 7 24 31 
Cramer-von Mises (normal) 1 9 10 
Cramer-von Mises (log10) 9 26 35 
Lilliefors (normal) 3 11 14 
Lilliefors (log10) 12 29 41 
Shapiro-Francia (normal) 0 2 2 
Shapiro-Francia (log10) 7 18 25 
Shapiro-Wilk (normal) 0 2 2 
Shapiro-Wilk (log10) 7 19 26 
Table 22 presents the number of gene expressions and gene ratios following a normal 
distribution according to the five normality tests on a 1% significance level. Each test is applied 
to both the raw expression data and to the logarithm of the expression data. The ABS control 
data was investigated with 29 genes and 40 ratios. The tests were done in R. 
 
Table 22 shows that, in general, applying a logarithmic transformation to the 
gene expression data and the gene ratios improves the number of gene 
expressions and ratios following a normal distribution. The results above also 
support the use of non-parametric tests as the majority of gene expressions do 
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not follow a normal distribution. Here is should be stressed that the standard 
parametric tests, I applied, are robust, that is, known to be useful when the 
deviations from normality are relatively small. Exactly when this is the case, is 
not clear from the literature, so in the next section I make use of both non-
parametric tests and parametric tests on the logarithm of the expression data. 
We thus decided to apply the logarithm to all gene expressions. 
 
In section 5.1, I mentioned normal QQ plots and in figure 26 and figure 27 I 
show a few examples of these plots for different gene expressions both applied 
to the raw data and to the logarithm of the expression data. 
 
In figure 26, normal QQ plots are shown for ARRB2, both applied to the raw 
expression data and to the logarithm of ARRB2. ARRB2, as was the case with 
SERT in figure 7 in section 5.1, follows a normal distribution when the 
logarithm of the expression data is considered.  
 
On the other hand, in figure 27, GR does not follow a normal distribution 
neither using the raw expression data nor using the logarithm of the 
expression data. However, as seen in figure 27, applying the logarithm 
diminishes the departure from normality. This is the case for most of the gene 
expressions, not all. Since most of the gene expressions look more or less like 
figure 27, no further QQ plots are shown.  
 
 
Figure 26 shows that in the case of ARRB2, a logarithmic transformation makes the ARRB2 
expression data follow a normal distribution. The plots were made in R. 
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Figure 27 shows that in the case of GR, a logarithmic transformation diminishes the departure 
from normality. In particular, the extreme outliers in the left plot are not as evident in the 
right plot. The plots were made in R. 
 
 
7.3 Clinical variable – gene expression relationships 
As described in the Study design chapter (chapter 4), the Lundbeck study 
includes both questionnaire data and qPCR data for the ABS and DC control 
groups and for one half of a patient group (BPD). Some of the first work, the 
US Lundbeck group and I did, included the identification of clinical variable – 
gene expression relationships in the ABS control group. This was done in order 
to determine intermediate phenotypes, and also to predict which gene 
expressions that we expected to be regulated in depressed patients. Later, I 
looked into questionnaires and qPCR data for the borderline personality 
disorder (BPD) patients, and made some initial comparisons with the ABS 
controls. Finally, the same gene expression – questionnaire relationships found 
in the ABS controls were investigated in the DC controls. Below, I present the 
results from these three studies. The section also provides answers to four 
questions; 1) which clinical variables explain the most variance in a gene?, 2) 
are there any gender differences in the expression profiles?, 3) are the control 
groups similar?, and 4) should all control groups be pooled into one big control 
group? 
 
7.3.1 Biomarkers for depression – 20 hypotheses 
Some of the first work I did involved looking at the 299 ABS controls. We 
wanted to predict gene expressions that might be expected to be regulated in 
depressed patients solely on the basis of data from controls. This also formed 
the start of our work on intermediate phenotypes as explained below. 
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Besides directly investigating the 29 genes described in chapter 3, we decided 
to include gene ratios, since they could expand the window of detecting 
differences between groups. Ratios were also included to expand the 
hypothesis generating phase in that several combinations/ratios of gene 
expressions had a biological interest. This included 40 ratios of e.g. some anti-
inflammatory cytokines to pro-inflammatory cytokines, various kinase 
combinations, a glucocorticoid and mineralocorticoid combination, etc., see 
appendix 9 for a list of 97 ratios in total. In that appendix, 57 ratios formed on 
the basis of Spearman correlations are included as well. We included both 
ratios between genes with high Spearman correlations (>0.80), which 
generally included correlations between gene pairs seen in the literature, and 
low correlations (<0.30), which in general included gene pairs not expected to 
be correlated in the literature. In this way, the gene ratios were partly formed 
on a biological basis, partly on a data driven basis which was then not 
necessarily biologically biased.  
 
I applied the statistical univariate tests described in the Statistical methods 
chapter, section 5.2; the parametric t-test and ANOVA test on the logarithm of 
the gene expressions and ratios, and the non-parametric Wilcoxon and 
Kruskal-Wallis tests. In order to reduce the number of false positives, the 
significance level for individual genes was set to 1%, and for ratios of gene 
expressions to 0.1%. Spearman correlations were also used. 
 
The ABS questionnaire consisted of approximately 50 questions as described in 
the Study design chapter. The US Lundbeck group picked questions and 
composite scores defining depression related intermediate phenotypes on the 
basis of the DSM-IV-TR clinical descriptions of depression in chapter 2. The 
interested reader is referred to the Study design chapter for the chosen 
questions and composite scores as well as the coding aspect22.  
 
Expression patterns for individual genes or ratios that yielded significant p 
values with multiple questionnaire responses were used to generate 
hypotheses regarding patient populations. The reason for considering multiple 
questionnaire responses, and not individual responses, was a wish to further 
reduce the number of false positives. As the results below indicate, even the 
strict significance levels applied to individual genes and ratios still yielded a 
small number of false positives. However, we did not want to set even more 
strict significance levels due the whole exploratory nature of the study. 
 
 
 
                                                 
22 The coding of each clinical variable is shown in appendix 5. For tobacco use, a 3-bin coding (low, medium and heavy 
users) was attempted, but this led to no new results compared to the two-bin case (non-smokers vs smokers). In general, 
3-bin coding of various clinical variables did not provide additional information compared to 2-bin codings.  
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The first results obtained were; 
 
• 42 combinations of gene expression vs questionnaire response23 satisfied 
the p<0.01 criteria (42/1564 comparisons). 
• 65 combinations of ratio vs questionnaire response satisfied the p<0.001 
criteria (65/4462 comparisons). 
• No Spearman correlation coefficients were greater than 0.3 between the 
continuous clinical variables like age and BMI and any gene expression.  
• Results obtained from MANOVAs, briefly described in the Statistical 
methods chapter, essentially represented a subset of those obtained 
using gene expression ratios. At this point, it was reassuring that two 
different statistical approaches gave similar results for each hypothesis. 
 
Table 23 sums up the results for the 6+1 (see table text) significant individual 
genes whose expression correlates with multiple responses. Arrows in the table 
indicate whether the general trend is an increase or decrease in expression as 
one moves from the most normal to the most affected subjects. This was 
assessed by looking at various scatter plots of gene expressions, and in figure 
28 a few are shown as examples (the other plots are not included). 
 
 
 
 
 
 
 
 
 
 
 
Table 23 presents a summary of individual genes whose expression correlates with multiple 
responses. 6+1 genes show significant trends with respect to multiple questionnaire responses 
(p<0.01). MAPK14 is on the list, because both the parametric and non-parametric test results 
are significant. The results are commented in the working hypotheses at the end of this 
subsection. (1) “Treatments” in the table refers to treatment by a physician for depression, 
anxiety, etc. An arrow pointing upwards means that the general trend is an increase in 
expression as you move from the most normal to the most affected subjects. An arrow 
pointing downwards means that the general trend is a reduction in expression as you move 
from the most normal to the most affected subjects. 
 
 
 
 
 
                                                 
23 The composite clinical semi-continuous variables were binned. Considering them as entirely continuous and 
correlating them with the gene expressions did not yield any interesting results.  
SERT DPP4 ERK2 G alpha s MKP1 PBR MAPK14
More alcohol use
Any lifetime "treatments" (1)
More tobacco use
Increased anxiety
Decreased appetite
Decreased concentration
Decreased energy
Increased feeling low
More sleep problems
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DPP4 vs Lifetime Treatments SERT vs Appetite 
Appetite Lifetime Treatments 
Figure 28 shows that in the case of SERT in controls, a significant decrease in gene expression 
is seen for a decreased appetite compared to the two other levels of appetite. For DPP4 vs 
lifetime treatments in controls, a significant increase is seen in subjects having at least one 
lifetime treatment compared to the ones not having experienced any lifetime treatment. The 
plots were made in GraphPad. 
 
Table 24 sums up the results for significant gene expression ratios. 13 ratios 
showed significant trends with respect to multiple questionnaire responses 
(p<0.001) involving additional 10 genes compared to the significant individual 
genes. Arrows in this table indicate whether the general trend is an increase or 
reduction in ratio as one moves from the most normal to the most affected 
subjects. This was also assessed by looking at various plots, and in figure 29 
an example with Gs/CREB2 vs anxiety is shown (other plots are not included). 
Also included are plots of Gs, and CREB2 vs anxiety, and here it can be seen 
that these plots do not contain any significant differences between the four 
levels of anxiety. 
 
 
 
 
 
 
 
 
 
 
Table 24 presents a summary of individual genes whose expression correlates with multiple 
responses. 13 ratios show significant trends with respect to multiple questionnaire responses 
(p<0.001). The results are commented in the working hypotheses at the end of this 
subsection. (1) “Experiences” refers to episodes of depression, anxiety, etc. (2) “Treatments” 
refers to treatment by a physician for depression, anxiety, etc. * Any drug use includes both 
prescription and illicit drugs. An arrow pointing upwards means the general trend is an 
increase in ratio as one moves from the most normal to the most affected subjects. An arrow 
pointed downwards indicates that the general trend is a reduction in ratio as one moves from 
the most normal to the most affected subjects. 
ERK2/MAPK8+14 Gi2/ARRB1 Gi2/ARRB2 Gs/ARRB2 Gi2/CREB Gs/CREB2 MKP1/ERK1 MKP1/MAPK14 ERK1/GR ERK2/ARRB1 MAPK8/PREP ARRB1/GR IL-8/SERT
Gender    males    males    males    males    males    males
Any illicit drug use           
Lifetime "experiences" (1)                          
Lifetime "treatments" (2)                
More tobacco use      
Increased anxiety
Decreased appetite      
Any drug use last 3 months *                     
Decreased Energy      
Increased feeling low           
More sleep problems           
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Figure 29 shows the ratio Gs/CREB2 vs the clinical variable anxiety with four levels (top plot). 
At the top plot, a significant difference is seen between “Some days” and “Most days”. The two 
individual plots below show Gs vs anxiety and CREB2 vs anxiety respectively. None of these 
plots contain significant differences between the four levels of anxiety. The plots were made in 
GraphPad. 
 
 
The results from table 23 and table 24 are summed up in table 25 that show 
gene expression patterns that may define subgroups and intermediate 
phenotypes. After the table, the 20 hypothesis for depression markers are 
listed. 
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Table 25 summarizes the results from table 23 and 24. The table indicates gene expression 
 patterns that may define intermediate phenotypes and subgroups of patients. The results are
commented in the hypotheses in the text. (1) “Experiences” refers to episodes of depression, 
anxiety, etc. (2) “Treatments” refers to treatment by a physician for depression, anxiety, etc. 
 
Based on table 25, the ABS control data predict the following trends in 
. SERT expression will be lower in patients - as SERT is lower in controls with 
s DDP4 is increased in 
gly 
ltered in patients – as ERK2 is decreased in 
ion will be decreased in patients – as G alpha s is 
. 
Questionnaire topic
depressed patients and, at the same time, define the corresponding 
intermediate phenotypes: 
 
1
decreased appetite and in controls who smoke. 
2. DDP4 expression will be increased in patients - a
controls who have decreased concentration and energy, feeling increasin
low, having more sleep problems and been treated in their life for e.g. 
depression, anxiety, etc. 
3. ERK2 expression will be a
controls with decreased appetite and increased in controls who feel 
increasingly low. 
4. G alpha s express
decreased in controls with increased anxiety and decreased appetite
5. MKP1 expression will be altered in patients – as MKP1 is increased in 
controls who feel increasingly low and who have been treated in their 
lifetime for e.g. depression, anxiety, etc. On the other hand MKP1 is 
decreased in controls with decreased appetite. 
Increased expression Decreased expression
Any illicit drug use Gi2/CREB
Any lifetime "experiences" (1)
Gi2/ARRB1, Gi2/CREB, MKP1/ERK1, 
ERK2/ ARRB1, IL-8/SERT  ARRB1/GR, MAPK8/PREP
Any lifetime "treatments" (2)
DPP4, MKP1, Gi2/CREB, 
MKP1/ERK1, MAPK8/PREP
More tobacco use Gi2/ARRB1 SERT
Increased anxiety Gs, Gs/CREB2, ERK1/GR, ARRB1/GR
Decreased appetite IL-8/SERT SERT, ERK2, Gs, MKP1, PBR, MAPK14
Any drug use last 3 months
Gi2/CREB, MKP1/ERK1, 
MKP1/MAPK14, MAPK8/PREP ERK1/GR
Decreased Energy DPP4, MKP1/MAPK14
Increased feeling low
DPP4, ERK2, MKP1, 
ERK2/MAPK8+14, Gi2/ARRB2 Gs/ARRB2
More sleep problems DPP4, Gi2/ARRB2, Gs/ARRB2
More alcohol use PBR
Decreased concentration DPP4
Males
ERK2/MAPK8+14, Gi2/ARRB1, 
Gs/ARRB2, Gi2/CREB, Gs/CREB2, 
ERK2/ARRB1
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6. PBR expression will be altered in patients – as PBR is increased in controls 
who have more than one drink per day and decreased in controls with 
decreased appetite. 
7. MAPK14 expression will be lower in patients – as MAPK14 is decreased in 
controls with decreased appetite. 
8. ERK2/MAPK8+14 expression will be altered in patients  - as 
ERK2/MAPK8+14 is lower in male controls and increased in controls who 
feel increasingly low. 
9. Gi2/ARRB1 expression will be altered in patients - as Gi2/ARRB1 is 
decreased in male controls, increased in controls who smoke, and increased 
in controls who ever experienced severe depression, severe anxiety, alcohol 
abuse, etc. 
10. Gi2/ARRB2 expression will be increased in patients – as Gi2/ARRB2 
is increased in controls with more sleep problems and increased in controls 
who feel increasingly low. 
11. Gs/ARRB2 expression will be altered in patients – as Gs/ARRB2 is 
decreased in male controls, in controls who feel less low and increased in 
controls with more sleep problems. 
12. Gi2/CREB expression will be altered in patients – as Gi2/CREB is 
decreased in male controls and increased in controls who had any illicit drug 
use, who ever experienced e.g. severe depression, who ever were treated 
for e.g. depression, anxiety, and who had prescription drugs and/or illicit 
drugs the last 3 months. 
13. Gs/CREB2 expression will be decreased in patients - as Gs/CREB2 is 
decreased in male controls and in controls with increased anxiety. 
14. MKP1/ERK1 expression will be increased in patients - as MKP1/ERK1 
is increased in controls who ever experienced e.g. severe depression, 
severe anxiety, in controls who ever were treated for e.g. depression, 
anxiety, and in controls who had prescription drugs and/or illicit drugs the 
last 3 months. 
15. MKP1/MAPK14 expression will be increased in patients - as 
MKP1/MAPK14 is increased in controls who had prescription drugs and/or 
illicit drugs the last 3 months and increased in controls with decreased 
energy. 
16. ERK1/GR expression will be decreased in patients – as ERK1/GR is 
decreased in controls with increased anxiety and in controls who had 
prescription drugs and/or illicit drugs the last 3 months. 
17. ERK2/ARRB1 expression will be altered in patients - as ERK2/ARRB1 
is decreased in male controls and increased in controls who ever 
experienced severe depression, severe anxiety, etc. 
18. MAPK8/PREP expression will be altered in patients - as MAPK8/PREP 
is decreased in controls who ever experienced e.g. severe depression and 
increased in controls who ever were treated for e.g. anxiety, and increased 
in controls who had prescription drugs and/or illicit drugs the last 3 months. 
 
102
7. Results 
19. ARRB1/GR expression will be decreased in patients - as ARRB1/GR 
is decreased in controls who ever experienced e.g. severe depression, and 
in controls with increased anxiety. 
20. IL-8/SERT expression will be increased in patients - as IL-8/SERT is 
increased in controls who ever experienced e.g. severe depression, and in 
controls with decreased appetite. 
 
In the next chapter, I compare the 20 hypotheses to a small group of severely 
depressed patients (Lundbeck confidential data, and thus not available). At the 
present, it does seem like gene expression patterns can be used to segment 
control subjects based on various clinical variables. Expression differences 
were clearly identified between genders.  
 
7.3.2 Gene expression subgroups identified via recursive partitioning  
Recursive partitioning (RP) is described in the Statistical methods chapter, 
section 5.6. RP was mostly used as a classification technique, but in a few 
cases, I also applied RP for the identification of possible (intermediate) 
phenotypes. This was done to look for distinct gene expression profiles in the 
SH ABS and the DC controls. Below, I also present the result of applying RP to 
a matched (explained later in this subsection) data set consisting of 20 DC 
controls, 21 SH ABS controls and the 21 BPD patients.  
 
In figure 30, all the DC and SH ABS controls are correctly placed (no 
misclassifications) in a decision tree created from just seven gene expressions.  
Using a maximum of five splits (genes), every control is correctly classified and 
the responsible genes for each subgroup are easily identified. 
 
From figure 30, it can be seen from e.g. the right branch of the tree that just 
by looking at the logarithm of the expression values of MAPK14 and ODC1, 43 
of the 58 SH ABS are correctly identified (0/43 in the figure means 0 subjects 
are misclassified and 43 subjects correctly classified) . Looking e.g. at MAPK14, 
CREB2 and ARRB2, 8 SH ABS are identified. In this way, RP was used to 
identify two distinct gene expression profiles in the total SH ABS population. 
Looking at the DC controls, the expression levels of MAPK14, CREB2, CREB1 
and ODC1 can identify 80 out of 89 DC controls. 
 
Neglecting the small subgroups (<5 subjects), it thus seems like there might 
be two SH ABS subgroups and one large DC subgroup, each subgroup 
identified by looking at the expression profiles of no more than 4 genes.  
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Figure 30 shows a decision tree of the DC and SH ABS controls. The table shows that there are 
no misclassified controls. See the text after the figure for explanation of this decision tree. The 
‘rpart’ package in R was used to carry out recursive partitioning. 
 
As mentioned in the statistics chapter, overfitting is an issue with RP, but still, 
I believe the results above indicate that RP could be used for the identification 
of control subgroups and thus of possibly intermediate phenotypes.  
 
RP was also applied to three groups of almost the same size consisting of 20 
DC controls, 21 SH ABS controls and the 21 BPD patients. The 21 SH ABS 
controls were picked by a gender and age match with the BPD patients. The 20 
DC controls are a ‘super healthy’ DC control group matched with the SH ABS 
by having a BMI < 30 and not having used any drugs in the past 3 months.  
In figure 31, all subjects are correctly placed in the decision tree created from 
only four gene expressions (out of possible 25). Here, using a maximum of 
four genes, every subject is correctly classified. 
 
Ignoring the small subgroups (<5 subjects) in figure 31, it can be seen that 
almost all BPD patients (20 out of 21) can be identified by only considering the 
expression value of GR (and ARRB2) in this data set (20/0/0 in the figure 
means 20 subjects are classified as BPD, 0 as DC, and 0 as SH ABS (the last 
digit)). On the other hand, 17 out of 20 DCs can be identified by GR, SERT, 
and CD8 beta. Almost all SH ABS (20/21) are identified by GR, SERT, CREB2 
(and ADA).  
0 = DC 
1 = SH ABS 
Pred / y DC SH ABS
DC 89 0
SH ABS 0 58
7. Results 
 
Figure 31 shows a decision tree with 20 DC controls, 21 SH ABS controls and the 21 BPD 
patients. There are no misclassified subjects. See the text for explanation of the decision tree. 
The ‘rpart’ package in R was used to carry out RP. 
 
Especially in this case with only one gene expression - GR – indicating almost 
perfect separation between BPD patients and the controls, overfitting must be 
considered. However, the tree does illustrate that the two control groups are 
more similar than the patient group; they both share the GR threshold and 
diverge mainly on the value of SERT. This is an argument for pooling the 
controls groups (see section 7.3.6). 
 
7.3.3 Possible BPD phenotypes through CCA 
Canonical correlation analysis (CCA) was used in combination with different 
sets of genes to identify various possible phenotypes among the BPD patients. 
This was done for cohort 1, since clinical variables were available for this 
group. In the Statistical methods chapter, section 5.5, CCA was demonstrated 
on the BPD group using 4 genes. 
 
Here I present the results of a regularized CCA analysis using 11 genes, and at 
the end of this subsection compare the result with the 4 gene CCA case. These 
11 genes were – like the 4 genes - selected based on a comparison with the 
SH ABS controls. The 11 genes were differentially expressed between the two 
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groups assessed with univariate tests, however here without applying the 
Bonferroni correction. We wanted to investigate if these differentially 
expressed genes could give rise to hypotheses about BPD subtypes.  
 
Like in the 4-gene CCA case, the set of 11 gene expressions and 6 clinical 
variables was chosen by first performing CCA with all clinical variables (and the 
11 gene expressions) and then leaving out the ones with a correlation less 
than 0.5. The result is summarized in the figure 32 with the graph of variables 
to the left, and the graph of individuals to the right.  
 
 
 
Figure 32 shows a CCA output for 11 BPD patients and a subset of 6 clinical variables and 11 
gene expressions. The left graph is the graph of variables (clinical and gene expressions), and 
to the right, the graph of individuals (with the 11 BPD patients). The two graphs are 
commented in the text. Dimension 1 and 2 represent the most and second most important 
canonical correlation dimension, respectively. The plots were done in R. 
 
On the graph of variables, there are no variables in the inner circle which is 
due to the fact that I left out the unimportant variables. I have marked several 
groups of clinical variables and genes with boxes. The boxes contain variables 
and genes with a strong relation (since they are projected in the same 
direction from the origin). Also, the reader may recall, that the greater the 
distance from the origin, the stronger the relationship. From this graph, it can 
be seen that e.g. ELS score sum and Tobacco (shown in the upper box) are 
strongly related and this also goes for DPP4 and MR in the bottom of the 
graph, while Family Schiz/Psyc (a family history of schizophrenia or psychosis) 
stands alone. Opposite is a large group of 9 genes and 3 clinical variables with 
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Feeling low being close to ARRB1, etc. I checked DPP4 and MR, and their 
correlation was 0.94, which is nicely reflected on the graph. 
 
In the graph of variables, ELS score sum and Tobacco are closely related at the 
top of the graph while DDP4 and MR are closely related almost opposite (at the 
bottom of the graph). On the right graph (individuals), different subgroups of 
borderline patients are marked. In this graph, BPD3 (borderline patient 
number 3) and BPD8 are close together at the top (shown with a box) while 
e.g. BPD5 and BPD9 are close together at the bottom. This can be interpreted 
as BPD3 and BPD8 having high ELS score sums and high Tobacco score while 
BPD5 and BPD9 have low ELS score sums and low tobacco score. At the same 
time all the borderline patients below the zero line (dimension 2) have high 
DPP4 and MR expressions while all the borderline patients above the zero line 
have low DPP4 and MR expressions. Furthermore, BPD4 and BPD10 have a 
high Family Schiz/Psyc score, and low score of the group of 9 genes and 3 
clinical variables. The opposite applies for BPD1 and BPD2.  
 
Compared with the 4-gene CCA example in the statistics chapter, it can be 
seen that there is not a big difference between applying CCA to a 4-gene vs 
11-gene analysis of the same data. Using different gene sets highlights 
different phenotype patterns in the data.  In the 4-gene CCA case, the clinical 
variables are slightly different from the 11-gene CCA case; there are still 6 
clinical variables, however the variables ELS and Tobacco have been replaced 
by Anxiety and 3 month drug use. Also, the clinical variables and genes are 
located similar in the two cases. On the graph of individuals, BPD1 and BPD2, 
and BPD10 and BPD11 are closely related in both cases. The other marked BPD 
subgroups are somewhat different with the biggest difference being a switch of 
BPD3 and BPD9 between the top and bottom marked subgroups. This is 
connected to the different clinical variables and genes used in the two cases.  
 
All in all, CCA seems to generate hypotheses about subtypes of patients by 
linking their gene expression profiles to their clinical variables.  
 
7.3.4 Clinical variables explaining the most variance in a gene 
In the Statistical methods chapter, section 5.8, I described stepwise 
regression, and illustrated this statistical method with two examples in table 
17. I applied stepwise regression to the ABS control groups with focus on the 
depression-relevant clinical variables described in the Study design chapter 
and in section 7.1.1. I wanted to identify a minimal set of clinical variables per 
gene expression that explained as much of the variance in that gene 
expression as possible. The cut-off was set to ~15% as explained in section 
5.8. Table 26 lists gene expressions, clinical variables, and interactions 
between clinical variables, the latter two accounting for at least ~15% of the 
variance in the shown genes. 
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SERT ERK2 MKP1 ODC1 PBR S100A10 P2X7
ender i1, i2 (male)
ifetime experiences i1
ifetime treatments i3
obacco x i i3
ppetite Change x x x x i4, i6 x x
oping x
njoyment x
eeling low i i
leep Problems i x i4, i5, i7 x i
eight Change x x i2, i8
ge x i6, i7, i8 x
MI i
LS score x i1, i2
ecent Stress score i2
ymptom score sum i1, i5
^2 without interactions 16% 14% 14% 18% 17% 15% 17%
^2 with interactions 16% 18% 16% 20% 36% 15% 21%
Table 26: Results of stepwise regression on the depression-relevant clinical variables for the 
ABS controls. R2 is reported. An ‘x’ denotes the clinical variable(s) remaining after the stepwise 
regression, and an ‘i’ denotes one part of an interaction term remained after a second stepwise 
regression. The i-numbers indicate which variables are interacting. The logarithm is applied to 
all the gene expressions. The analyses were done in R. 
 
None of the variation in the other genes (not included in table 26) was 
explained well by the resulting linear model (<15% of the variance). Looking 
at the table, e.g. 16% of the variation in SERT could be explained by the 
combination of tobacco use, appetite change, coping, weight change, age and 
ELS (early life stress) score. There were no significant interactions between 
any of these variables in SERT. On the other hand, looking at e.g. P2X7 17% 
of the variation in this gene could be explained by the combination of appetite 
change, feeling low and sleep problems (no interaction considered here). There 
was one significant interaction between feeling low and sleep problems, and by 
including this interaction 21% of the variation of P2X7 could be explained. The 
remaining results are not outlined, but these findings do indicate that a linear 
combination of various clinical variables with possible interactions considered, 
can explain some part of the variance in a gene expression.  
 
7.3.5 Gender differences? 
One of the first things I investigated was the extent of possible gene 
expression differences among the genders. From a clinical perspective, 
depression, BPD and PTSD are mental disorders known to affect more women 
than men (see chapter 2). In the available data, patient gender differences 
could not be investigated (not enough data from men among the BPD patient, 
and no women among the PTSD patients), so we looked at gender differences 
in various comparisons between and among the ABS and DC controls. Back 
then, I applied the initial classifiers Pelora and SLR, as well as correlation tests 
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and univariate tests. The actual goal was to see if gender made a significant 
impact on the results obtained from these classification and statistical 
approaches.  
 
First, results from Pelora were explored. Since Pelora is intended for 
microarray analysis (see the classification chapter), we wanted to minimize 
any possible overfitting to the data by only considering the first Pelora cluster/ 
gene set. In figure 33, three Pelora plots show almost perfect separation of the 
DC controls vs. the SH ABS, the DC males vs. SH ABS, and the DC females vs. 
SH ABS, only considering the first Pelora cluster (x-axis genes). 
 
Figure 33 shows three Pelora plots, all with an almost perfect separation using only the x-axis 
genes. The top plot shows all DC controls vs all SH ABS controls; x-axis genes are MAPK14, 
ODC1, CREB1, CREB2 and ADA. The bottom left plot shows the DC males vs the SH ABS 
controls; x-axis genes are MAPK14, ODC1, CREB1, CREB2, ADA, MR, MAPK8 and Gs. The 
bottom right plot shows the DC females vs the SH ABS controls; x-axis genes are MAPK14, 
ODC1, CREB1 and CREB2. DC controls are the 0’s and the SH ABS are the 1’s. The Pelora plots 
were done in R. 
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Below is a summary of Pelora cluster/gene set 1 genes (consistent genes are 
marked in bold, while italics marks genes appearing in two out of three 
comparisons): 
 
• DC males only vs SH ABS: MAPK14, ODC1, CREB1, CREB2, ADA, MR, 
MAPK8, Gs 
• DC females only vs SH ABS: MAPK14, ODC1, CREB1, CREB2 
• All DC subjects vs SH ABS: MAPK14, ODC1, CREB1, CREB2, ADA 
 
These results showed that basically the same genes were identified by Pelora 
regardless of gender selected in the DC group.  
SLR showed a similar result (data not shown).  
 
Two negative Pelora results are shown in figure 34.  
 
 
Figure 34 shows two Pelora plots. The left plot shows the DC males vs the DC females (DC 
controls are the 0’s and the SH ABS are the 1’s), and the right plot shows all male controls 
(0’s) vs all female controls (1’s) (UK controls excluded). The Pelora plots were done in R. 
 
From figure 34, using Pelora, it was difficult to separate males from females 
within the DC control group (N=89), or within all controls (DC, SH ABS and 
PTSD controls, N=226). Likewise, SLR showed a poor performance, and picked 
similar genes as Pelora (results not shown).  
 
Based on the Pelora and SLR results, gender thus did not seem to play a large 
role in determining gene expression patterns.  
 
Next, we tested the differences in Spearman correlations split by gender. In 
total, 300 gene expression correlations were made within the DC or SH ABS 
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controls. The gene expression correlation pairs between the two groups were 
compared on the 1% significance level (as described in the statistics chapter):  
 
• DC all subjects: 12 correlations were significantly different from the SH 
ABS (4%) 
• DC only males : 9 were different (3%). 7/9 were seen using “all 
subjects” 
• DC only females: 5 were different (2%). 4/5 were seen using “all 
subjects” 
  
The Spearman correlations thus seemed similar regardless of gender selected 
in the DC group.  
 
Finally, univariate tests were applied. The DC group was split by gender and 
the expression levels were compared to the SH ABS. Of 25 genes tested, 6 
showed statistically different expression in one gender only (ARRB2, DPP4, 
IDO, IL-6, MR and RGS2). However, only one of those genes (MR) was 
selected by SLR or Pelora to discriminate DC controls from the SH ABS 
controls. 
 
Based on the univariate comparisons, there were some expression differences 
detected between the genders with the DC group. However, these genes were 
not utilized by the multivariate techniques Pelora or SLR to distinguish the two 
groups. All in all, the gender differences did not seem critical.  
 
7.3.6 Pooling of control groups into one group? 
After having investigated various aspects of the ABS control group (see section 
7.2, 7.3.1, and 7.3.4), we received the DC control data. Initially, we had a 
hypothesis stating the two control groups would be very similar in terms of 
gene expression profiles, and that it therefore would be natural to combine the 
two control groups for comparisons to patients. The two first points below 
made us realize that the expression profiles were not that identical: 
 
1. Univariate tests revealed that 22 out of 25 genes were significantly 
different expressed between the two control groups. Only MR, P2X7, 
PREP did not differ significantly. 
 
2. Pelora and SLR were able to separate the two groups based on their 
expression values, see figure 33 (top plot) and the previous section 
(7.3.5).  
 
On the other hand, 
 
3. Spearman correlation tests between the ABS controls (299 subjects) and 
the DC controls indicated that the two groups were 90% the same, 
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statistically speaking. This result was obtained by calculating the 
Spearman correlations between the 25 gene expressions within each 
group, and then compare gene expression pairs between the groups as 
described in chapter 5, section 5.4. 
 
4. We thereafter turned to the clinical information to see if the expression 
differences had anything to do with clinical differences. A SH DC group 
was defined the same way the SH ABS was defined, that is, having no 
drug use the last three months and low BMI). It turned out, that the SH 
DC subjects had ultra clean personal and family histories (no personal 
lifetime psychiatric disorders of any kind, no first rank family history of 
schizophrenia or suicide, just one person had both a mother and father 
diagnosed with depression). 
The univariate tests now revealed that 15 out of 25 genes were 
significantly different between the groups. This could indicate that the 
initial differences noted between the groups (the 22 out of 25 genes) 
may have been influenced by the way the SH ABS subjects were 
selected, not because Danes and Americans were that different regarding 
expression.  
 
5. The gene expression patterns in DC vs all 299 ABS subjects, with respect 
to specific clinical variables, was more than 90% in agreement (see 
appendix 10).  
 
6. Performing Pelora and SLR with the DC and SH ABS combined vs the 
BPD patients yielded a very good separation of the two groups (data not 
shown). A similar result (data also not shown) was also obtained using 
Pelora and SVM with varselrf in connection with the acute PTSD patients; 
both these classifiers see all SH ABS as belonging to the DCs and none 
as acute PTSD patients.  
Therefore, the control groups, though not identical, were both 
segregated from the patients. These results further indicated that the 
two control groups were more similar than different compared to the 
patients. 
 
Based on the above arguments (two arguments against and four arguments for 
combining the Danish and American control groups), we decided to pool the 
two control groups into one control group for comparison with patients.  
In a broader perspective the rationale for pooling the two control groups was 
that, since we are dealing with controls groups from Denmark and healthy US 
controls, we should operate with a combined control group that spanned the 
expression differences in and between these groups, because in this way a 
"normal"/control gene expression pattern would contain more variation, and a 
disease expression pattern should be different from the natural gene 
expression variation in controls.  
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7.3.7 Pooling of all control groups into a single large group? 
After realizing that the gender differences in the control expression profiles 
were not large, and we had combined the DC and SH ABS control groups into 
one control group, it was natural to investigate whether all control groups 
could be pooled into one large control group. 
 
First, univariate tests and scatter plots were employed. A few examples are 
shown in figure 35 and figure 36 comprising the DC, SH ABS, SH DC, UK (time 
point 1) and PTSD controls. These plots show that the SH ABS appears to be 
the most different from the other groups, but that there, nonetheless, seems 
to be quite some overlap of points. 
 
Figure 35 shows two scatter plots for the gene expression GR (left) and Gi2 (right). In the left 
plot, the SH ABS expression level is clearly less compared to the other groups. In the right 
plot, the SH ABS and UK expression levels are less compared to the other groups. The plots 
were done with GraphPad. 
 
 
 
Figure 36 shows two scatter plots for the gene expression CREB1 (left) and MR (right). In the 
left plot, the SH ABS expression level is higher compared to the other groups. In the right plot, 
the expression levels of all control groups are the same. The plots were done with GraphPad. 
GR_all controls
DC ABS SH DC SH UK PTSD
0
25000
50000
75000
100000
125000
150000
175000
Kruskal-Wallis test
  P value P<0.0001
co
pi
es
Gi2_all controls
DC ABS SH DC SH UK PTSD
0
100000
200000
300000
400000
500000
Kruskal-Wallis test
  P value P<0.0001
co
pi
es
CREB1_all controls
DC ABS SH DC SH UK PTSD
0
50000
100000
150000
Kruskal-Wallis test
  P value P<0.0001
co
pi
es
MR_all controls
DC ABS SH DC SH UK PTSD
0
1000
2000
3000
4000
5000
6000
Kruskal-Wallis test
  P value 0.0545
co
pi
es
7. Results 
 
The univariate tests and plots (all data/results not shown) showed that the 
expression level was: 
 
• Clearly less in ABS SH compared to all other groups:  10/25 genes 
• Low in ABS SH plus other groups:    6/25 genes 
• Most/all groups were the same level:   7/25 genes 
• Greater in ABS SH than all other groups:  2/25 genes 
 
These results led us to believe the expression data for the four control groups 
(DC, SH ABS, UK and PTSD) overlapped somehow, and that it would be a good 
idea to investigate the control groups versus the patient groups in various 
Pelora and SLR comparisons. The results of the Pelora plots are summed up in 
table 27 (however, the Pelora plots are not shown). In table 27, various 
combinations of controls vs one patient group were used as a training data set, 
and then a control or patient group, that had not been part of the training 
data, was used as a validation data set. This was done to see how Pelora would 
classify an ‘unknown’ group in the sense that the unkown group had not been 
part of the classifier training process. 
 
The results in table 27 were summed up: 
 
• Comparing related training sets; larger data sets seemed to be better for 
validation performance (table 27, compare sets 1 and 2, sets 3 and 4) 
• Large control groups (the bottom part of table 27) seemed to do a good 
job of classifying validation sets (see training set 5) 
• Note 1: 100% of the controls in the training set were properly classified 
as controls. The patients in the training set were classified correctly 66% 
of the time (data not shown). 
• SLR produced similar results to Pelora for each set tested. 
• (It was noted how GR always appeared in the gene list.) 
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Set no. Training sets Validation 
sets 
Score with validation set Genes identified 
(1st Pelora gene set only) 
1 53 SH ABS vs 
16 BPD 
89 DC 82% scored 
as controls 
GR 
2 16 SH ABS 
(matched) vs 
16 BPD 
20 SH DC 43% scored as controls GR 
3 89 DC vs  
21 BPD 
59 SH ABS 100% scored as controls GR, Gi2 
4 20 SH DC vs 
21 BP 
21 SH ABS 52% scored as controls GR, ARRB2 
5 59 SH ABS and 89 
DC vs 21 BPD 
30 UK  100% scored as controls GR, ERK1, ERK2, ARRB2 
Table 27: Summary of Pelora results for various comparisons between control and patient 
groups. * is commented in the text below the table, while the table is summed up in the text 
above the table. The analyses were done in R.  
 
Overall, it seemed like the different control groups were more alike than they 
were different. Using larger control groups for Pelora and SLR seemed to 
produce better classification than when smaller groups were used.  
Based on these results, we decided to combine multiple control groups when 
we had to make classification comparisons to patients, see section 7.5. Thus, 
like in the previous section, the pooled large control group would span the 
biological gene expression variation in all controls combined.  
 
7.4 Expression levels across multiple time points 
As the reader may recall, in the UK control group, three time measurements 
were made; Day 0 at 8 am, Day 0 at 2 pm and Day 1 at 8 am. I applied 
repeated measures ANOVA tests (see the statistics chapter, section 5.3) in 
order to investigate whether any of the gene expressions differed significantly 
between the three time points on the 1% significance level.  
 
Out of 29 gene expressions, 5 gene expressions differed significantly between 
the time points; CD8 beta, IL-8, MKP1, MR and ODC1. In figure 37, scatter 
plots for MR and IL-8 are shown. For IL-8, there is a significant difference 
between baseline (day 0, 8 am) / 6 HR (day 0, 2 pm) and 24 HR (day 1, 8 
am), while for the four other gene expressions the significant difference is 
between morning and afternoon measurements.  
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Figure 37 shows two scatter plots for the gene expressions MR (left) and IL-8 (right) at three 
time points. In the left plot, there is a significant difference between baseline (day 0, 8 am) / 
24 HR (day 1, 8 am) and 6 HR (day 0, 2 pm). In the right plot, there is a significant difference 
between baseline / 6 HR and 24 HR. The plots were done with GraphPad. 
 
 
At the present state of the investigation, the US Lundbeck group was not 
interested in including genes in the study that displayed a circadian effect in 
whole blood. Three time points were far from adequate to establish any 
possible circadian effect of the gene expressions, so I checked Pubmed for 
articles involving the 5 genes and circadian behavior. Disregarding other 
species than man and other tissue like liver, I only found MR to have a 
circadian pattern in man (213), (214), however not in blood.  
 
Based on the repeated measures ANOVA results for the day and afternoon 
differences, and the Pubmed findings, even though circadian effects might be 
involved, no conclusion either way could be made with so few time points.  
 
For IL-8, there seemed to be a difference in the expression measurements on 
consecutive days (both in the morning). However, inspection of the scatter 
plots, see the right figure in figure 37, suggested that this was caused by a few 
individuals (N=5), not the entire group (N=30). If the 5 subjects were 
removed from the analysis, the statistical difference disappeared. Also, it was 
not unreasonable to imagine that in any given individual, these genes could be 
subject to more noise, since they are proinflammatory cytokines, and 
expression can be altered by many factors.  
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7. Results 
Overall, the 5 genes remained in the list of genes measured in the study, and 
the first time point was used when UK controls were included in any analysis.  
 
7.5 Variable selection and classification among various groups 
In the classification chapter, the classifiers and variable selection techniques 
SVM (support vector machine) with varselrf (variable selection based on 
random forests), SLR (stepwise logistic regression – both for gene selection 
and classification) and RPART (recursive partitioning – both for gene selection 
and classification) were identified as the most promising methods for a 
multivariate approach to classification and variable selection. In this section, I 
present the results of applying these methods to various comparisons among 
the control and patient groups. Also, following the results in section 7.3.7, the 
various patient groups are compared to a pooled control group. 
 
It should be noted, that at this point of the thesis work, we (the US Lundbeck 
group and I) did not consider univariate tests anymore for variable selection, 
since we were interested in accuracy, PPV (positive predictive value – relates 
to classification of patients) and NPV (negative predictive value – relates to 
classification of controls) for the applied classification techniques.  
 
7.5.1 2-group comparisons 
For the two group comparisons, it was possible to report PPV and NPV together 
with the accuracies. Four main 2-group comparisons were made; controls vs 
BPD patients, controls vs PTSD acute patients, controls vs PTSD in remission 
and controls vs trauma without PTSD. Below I present the results of these four 
comparisons in summary tables including genes selected to differentiate 
groups, PPV, NPV and both the actual accuracy values as well as the permuted 
accuracy values (in parenthesis in the table), all in percentages. I also indicate 
whether the accuracy values of a comparison is significant on the 1% 
significance level compared to permuted values as described in the 
‘Classification and variable selection procedure’ section of the classification 
chapter. 
 
In the summary tables ‘All controls’ were derived from 4 different subject 
groups (SH ABS, DC, UK and PTSD controls) and 25 gene expression values 
were used for comparison. ‘Controls’ were derived from 3 different subject 
groups (DC, UK and PTSD controls) and 29 gene expression values were used 
for comparison (the same 25 used above plus 4 additional). 
 
First, in table 28, controls were compared with the borderline personality 
disorder patients. Here, ‘all controls’ included 254 subjects, ‘controls’ 196 
subjects and ‘BPD patients’ 21 BPD patients. In general, genes selected were 
very similar regardless of variable selection technique. Furthermore, all 
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accuracies were high and significant compared to the permuted values (data 
not shown). The reasons for the high permuted values are unbalanced data 
sets as described in chapter 6. The predictive values were high except for 
RPART. 
 
 
Comparison Classifier Genes selected to differentiate 
groups 
PPV NPV Accuracy 
(permuted) 
SVM/varselrf ERK1, Gi2, GR, MAPK14, MR 82 98 98 (92) 
SLR Gi2, GR, MAPK14, MR 93 100 99 (92) 
All controls vs 
BPD patients 
(25 genes) 
  
RPART Gi2, GR 68 98 96 (91) 
SVM/varselrf Gi2, GR, MAPK14 97 98 98 (90) 
SLR Gi2, GR, MAPK14, MR 93 99 98 (88) 
Controls vs BPD 
patients 
(29 genes) 
  
RPART Gi2, GR 68 98 95 (88) 
Table 28: Summary of controls vs BPD patients comparisons. PPV, NPV and accuracy values 
are in percentages. Permuted accuracy values are in parenthesis in the last column. All 
accuracy values are significant compared to permuted values (data not shown). The analyses 
were done in R.  
 
In table 29, controls were compared to PTSD acute patients. All controls 
included 254 subjects, controls 196 subjects and 66 PTSD acute patients. In 
general, genes selected depended on the variable selection technique but not 
on the control group. It was noted that ARRB2, ERK2, and RGS2 were 
consistently picked. Also, it was noted that RPART performed worse than the 
other classifiers, just as in the case with controls vs BPD patients. All 
accuracies were significant compared to the corresponding permuted values 
(data not shown) except for RPART in the 29 gene comparison. The positive 
predictive values were considered marginal but still a lot better than the PPVs 
from the controls vs PTSD in remission comparison described next.  
 
In table 30, controls were compared to PTSD in remission. All controls included 
254 subjects, controls 196 subjects and 41 PTSD in remission. The two groups 
could not be separated by any classifier on the 1% significance level (data not 
shown, but the reader may notice how close the actual and permuted accuracy 
values are), so the gene expression profiles seemed to reflect the clinical 
diagnosis well. The PPV values were markedly lower than in the PTSD acute 
patients case (table 29).  
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Comparison Classifier Genes selected to differentiate 
groups 
PPV NPV Accuracy 
(permuted) 
SVM/varselrf ARRB2, ERK2, RGS2 70 87 86 (78) 
SLR 
ARRB1,ARRB2, CD8 beta, ERK2, 
IDO, IL-6, MR, PREP, RGS2 81 90 88 (78) 
All controls vs 
PTSD acute 
patients 
(25 genes) 
  
RPART 
ADA, ARRB1, ARRB2, CREB2, 
ERK1, GR, MKP1, P2X7, RGS2 65 88 82 (70) 
SVM/varselrf ARRB2, ERK2, RGS2 79 83 80 (73) 
SLR 
ARRB1,ARRB2, CD8 beta, ERK2, 
IDO, IL-6, MR, ODC1, PREP, 
RGS2 77 87 84 (71) 
Controls vs PTSD 
acute patients 
(29 genes) 
  
RPART -  48 82 72 (64) 
Table 29: Summary of controls vs PTSD acute patients comparisons. PPV, NPV and accuracy 
values are in percentages. Permuted accuracy values are in parenthesis in the last column. All 
accuracy values are significant compared to permuted values (data not shown) except for 
RPART in the 29 gene comparison (p-value: 0.02349). The analyses were done in R. 
 
 
Comparison Classifier Genes selected to differentiate 
groups 
PPV NPV Accuracy 
(permuted) 
SVM/varselrf - 52 89 88 (86) 
SLR - 46 91 86 (86) 
All controls vs 
PTSD in remission 
(25 genes) 
  
RPART - 39 90 83 (81) 
SVM/varselrf - 49 86 82 (82) 
SLR - 33 86 80 (81) 
Controls vs PTSD 
in remission 
(29 genes) 
  
RPART - 28 86 76 (75) 
Table 30: Summary of controls vs PTSD in remission. PPV, NPV and accuracy values are in 
percentages. Permuted accuracy values are in parenthesis in the last column. No accuracy 
values are significant compared to permuted values (data not shown). The analyses were done 
in R. 
 
Finally, in table 31, controls were compared to patients with trauma but 
without PTSD. All controls included 254 subjects, controls 196 subjects and 87 
trauma patients without PTSD. All accuracy values were significant compared 
7. Results 
 
120
to permuted values. However, the PPV values were not impressive so the two 
groups were anyway considered to be poorly separated regardless of classifier 
or control group employed. It was noted that ARRB2 and ERK2 were 
consistently picked just as they were in the PTSD acute patients. Furthermore, 
Gs and IL-6 were also consistently picked. In the 25 gene comparison, RPART 
again performed worse than the other classifiers. 
 
 
Comparison Classifier Genes selected to differentiate 
groups 
PPV NPV Accuracy 
(permuted) 
SVM/varselrf 
ARRB2, CREB1, DPP4, ERK1, 
ERK2, GR, Gs, IL-6, MAPK8, 
MKP1 63 84 79 (72) 
SLR 
ARRB2, CD8 beta, CREB1, 
ERK2, IL-6, MAPK8, MAPK14, 
MR, RGS2, SERT 63 85 80 (73) 
All controls vs 
trauma without 
PTSD 
(25 genes) 
  
RPART 
ARRB2, CD8 beta, CREB2, 
DPP4, ERK2, Gi2, Gs, MKP1 46 80 72 (63) 
SVM/varselrf 
ARRB2, CREB1, DPP4, ERK1, 
ERK2,  Gs, IL-6, IL-8,  MAPK8, 
MKP1, MR, PBR, PREP, SERT 59 79 74 (65) 
SLR 
ADA, ARRB2, CD8 beta, CREB1, 
ERK2, Gs,  IL-6,  MAPK14, 
MKP1, MR, RGS2, VMAT2,  
IL-1 beta 59 80 73 (64) 
Controls vs 
trauma without 
PTSD (29 genes) 
  
RPART 
ARRB2, ERK2, Gs, IL-6, IL-8, 
MKP1, PREP, SERT 63 82 76 (58) 
Table 31: Summary of controls vs patients with trauma but without PTSD. PPV, NPV and 
accuracy values are in percentages. Permuted accuracy values are in parenthesis in the last 
column. All accuracy values are significant compared to permuted values (data not shown). 
The analyses were done in R. 
 
7.5.2 Multiple group comparisons  
Since our focus was on 2-group comparisons, I did not do many multiple (>2) 
group comparisons (even though there were several possible combinations).  
Thus, below I present two comparisons. It should be remembered that PPV and 
NPV were not reported for these multiple group comparisons, and that only the 
classifiers SVM with varselrf and RPART were applied.  
 
In the first comparison, three groups were compared; all controls (SH ABS, 
DC, UK and PTSD controls) vs. BPD patients vs. PTSD acute patients. 25 genes 
were used in this comparison. The result is summed up in table 33. The 
accuracy values were high and highly significant compared to the permuted 
values (data not shown). It was noted that ERK1, ERK2, GR and MKP1 were 
picked by both variable selection methods. ERK2 was a key gene picked in the 
2-group comparison with the same pooled control group vs. PTSD acute 
patients, while GR was a key gene picked in the similar 2-group comparison 
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with BPD patients. MKP1 appeared in the former 2-group comparison as well 
(see table 29), while ERK1 appeared in both comparisons (see table 28 and 
29). It was also noted that the RPART selected genes DDP4 and MAPK8 were 
not part of any 2-group comparison with the large pooled control group; 
neither compared with the BPD patients nor compared with the PTSD acute 
patients.  
 
 Classifier Genes selected to differentiate groups Accuracy 
(permuted) 
SVM/varselrf ARRB2, ERK1, ERK2, GR, MAPK14, MKP1 80 (22) 
RPART DPP4, ERK1, ERK2, GR, MAPK8, MKP1, MR 78 (22) 
Table 33: Summary of the three group comparison including 25 genes; all controls (SH ABS, 
DC, UK and PTSD controls) vs. BPD patients vs. PTSD acute patients. Permuted accuracy 
values are in parenthesis in the last column. All accuracy values are in percentages. Both 
accuracy values were significant compared to the permuted values (data not shown). The 
analyses were done in R. 
 
In the second multiple group comparison, four groups were compared; PTSD 
controls vs. PTSD acute patients vs. PTSD in remission vs. patients with 
trauma without PTSD. This comparison comprised 35 genes (see table 7, 
chapter 4). The result is summed up in table 32. Here, it can be seen that only 
RPART is able to separate the four groups and that only with a relative poor 
accuracy. The reason for the latter is that 2-group comparisons showed no 
separation between controls and remitted patients. There is some overlap 
between the selected genes now and genes selected by RPART in various 2-
group comparisons described in the previous subsection. Besides two new 
genes in the list (EGR2 and MMP9), the overlap is not perfect as it must be 
remembered that pooled control groups were utilized in the 2-group 
comparisons.   
 
 Classifier Genes selected to differentiate groups Accuracy 
(permuted) 
SVM/varselrf - 36 (25) 
RPART 
CD8 beta, CREB1, EGR2, IL-6, IL-8, MAPK14, MKP1, MMP9, 
MR, ODC1, P2X7, PBR, PREP, RGS2 36 (26) 
Table 32: Summary of the four group comparison including 35 genes; PTSD controls vs. PTSD 
acute patients vs. PTSD in remission vs. patients with trauma without PTSD. Permuted 
accuracy values are in parenthesis in the last column. All accuracy values are in percentages. 
Only the RPART actual accuracy was significant compared to the permuted values (p-value: 
0.001204). The analyses were done in R. 
 
7.5.3 Genes and clinical variables separating ABS controls from BPD patients 
Here follows a short section on the use of SLR (stepwise logistic regression) 
with clinical variables as well as gene expressions for a comparison of the 
same groups. 
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Clinical data for patients was only available for 11 BPD patients (cohort 1). As 
reported in the classification chapter, SLR performed well on clinical variables. 
For the ABS control group, consisting of 299 subjects, clinical information and 
gene expression data were available, and utilized in e.g. section 7.3.1 and 
7.3.4. In this subsection, a way is shown to link clinical variables with gene 
expression profiles using a classifier approach.  
 
The 299 ABS controls and 11 BPD patients were separated using SLR, both on 
the gene and the clinical level, see table 34.  
 
ABS vs. BPD with SLR  LOOCV 
Genes selected to differentiate groups ADA, CD8 beta, DPP4, ERK2, GR, MKP1, MR, 
RGS2, VMAT2 97,7% 
Clinical variables selected to 
differentiate groups 
Recent stress score sum, Coping score, 7 
symptom score sum, Family Alcohol Abuse, 
Tobacco score, Lifetime drug use, Lifetime 
experiences 97,4% 
Table 34: Summary of genes and clinical variables selected by SLR to differentiate between the 
ABS control group and 11 BPD patients. The Leave-One-Out Cross-Validation accuracy is 
reported in the last column. The analyses are done in R. 
 
Table 34 shows that whether the control and patient group is separated by the 
gene expressions alone or only by the selected clinical variables, an almost 
perfect separation of the two groups is possible. Thus, it may be hypothesized 
that the two sets of variables (genes and clinical variables) are closely 
connected, and that either of them may be used to reveal information of the 
other. 
 
 
Finally, the genes and clinical variables may be combined so that they both are 
independent variables, while the class label (controls vs patients) is considered 
the dependent variable. SLR then selects ERK1, GR, SERT, 7 symptom score 
sum and recent stress score sum as the differentiating variables with a LOOCV 
accuracy of 98,1%. In this case, this accuracy is very close to the previous 
reported ones. It is noted that ERK1 and SERT are selected, none of which are 
listed in table 34. 
 
7.6 Heat maps and clustering 
After having identified genes separating groups in the previous section 7.5 or 
via univariate tests, these genes may be used in clustering as described in the 
statistics chapter. This was done in the very last part of the thesis work, so 
only a few preliminary heat maps were constructed. One of them is shown in 
the statistics chapter, section 5.7, in figure 10 using four genes that separated 
the controls from the BPD patients. These four genes were identified in the 
previous chapter, section 7.5.1. 
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In figure 38, I present another heat map generated using 30 randomly chosen 
subjects from a pooled control group (DC, SH ABS and PTSD controls) together 
with 30 randomly chosen PTSD acute patients. I did not choose more subjects 
for visual reasons. Only genes that separated the two groups from one another 
were used. These genes (ARRB2, ERK2, RGS2) were also identified in the 
previous subsection 7.5.1 on 2-group comparisons. In the heat map the 
expression profiles of two distinct PTSD acute patients clusters are identified.  
 
 
 
0’s = controls 
1’s = acute PTSDs 2 PTSD subtypes? 
 
Figure 38 shows a heat map with 30 subjects randomly chosen from a pooled control group 
(DC, SH ABS and PSTD controls) and 30 randomly chosen PTSD acute patients clustered at the 
top of the heat map. At the bottom, I have included the class labels showing two different 
clusters of PTSD acute patients. These clusters may represent different phenotypes. Genes 
separating the three control and patient groups are shown to the right. The heat map was 
done in R. 
 
 
In figure 39, a third heat map is shown, generated on the basis of data for 20 
subjects from the same pooled control group as before, 20 borderline patients 
and 20 acute PTSD patients. Each group of 20 subjects was randomly chosen 
from the respective group. Only genes (ERK1, ERK2, GR, MKP1) that separated 
the three groups from one another were used. These genes were identified in 
the previous subsection 7.5.2 on multiple group comparisons. In the heat map 
the expression profiles of two distinct BPD and PTSD acute patients clusters 
are identified.  
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Figure 39 shows a heat map with 20 subjects from a pooled control group (DC, SH ABS and 
PSTD controls), 20 borderline disorder patients and 20 acute PTSD patients clustered at the 
top of the heat map. At the bottom, I have included the class labels showing two different 
clusters of BPD and PTSD patients. These clusters may represent different phenotypes. Genes 
separating the three control and patient groups are shown to the right. The heat map was 
done in R. 
 
Due to lack of clinical data for patients24, the principle of identifying gene 
expression phenotypes and linking them to clinical information is demonstrated 
with the SH ABS controls. Here, focus is on two distinct control subgroups 
within the SH ABS control group in the heat map in figure 40. 20 subjects were 
randomly chosen among the SH ABS controls, the BPD patients and the PTSD 
acute patients. Genes separating the groups are listed to the right in the 
figure.  
 
Next, using the classifier and variable selection method SLR, I looked into the 
clinical variables selected in chapter 4 for the two subgroups of SH ABS 
controls25. SLR was able to separate the two subgroups using the clinical 
variables Age, BMI, Early life stress score and Anxiety score, however only with 
a LOOCV (Leave-One-Out Cross-Validation) accuracy of 72%. This relatively 
low accuracy is not surprising given that the SH ABS control group is very 
homogenous. Nonetheless, this result indicates that a combination of 
unsupervised gene clustering and supervised clinical variable classification may 
yield a link between distinct gene expression profiles and related distinct 
clinical profiles, and thus be used to identify patient subtypes or control 
intermediate phenotypes.  
 
 
 
                                                 
24 Only clinical data for cohort 1, that is, 11 BPD patients is available which is not sufficient for subtyping purposes 
with the heat map clustering approach. 
25 SLR was used in a related task in section 7.5.3. 
0’s = controls 
1’s = BPDs 
2’s = PTSD acute 
2 BPD subtypes? 2 PTSD subtypes? 
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Figure 40 shows a heat map with 20 subjects from the SH ABS control group, 20 borderline 
disorder patients and 20 acute PTSD patients clustered at the top of the heat map. At the 
bottom, I have included the class labels showing two different clusters of SH ABS control 
subgroups. These clusters may represent different phenotypes as investigated with SLR using 
the SH ABS clinical information in the text. Genes separating the three control and patient 
groups are shown to the right. The heat map was done in R. 
0’s = SH ABS 
1’s = BPDs 
2’s = PTSD acute 
2 control subtypes? 
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This chapter makes conclusions based on some of the most interesting results 
obtained in the previous chapters and discusses interesting aspects of the use 
of gene expressions in peripheral whole blood as a ‘psychiatric’ probe of a 
mental condition, see table 35. Let us first note that our results support the 
use of gene expressions in whole blood as biomarkers for affective disorders. 
Validation of the results is needed, however. In particular, I link the genes that 
look promising in separating various groups with biological knowledge related 
to molecular and cellular function, physiological system development and 
function, and various diseases and disorders. In this way it becomes possible 
to see which processes (e.g. cell death, cell signaling or hematological system 
development and function) are perturbed and which other diseases (like cancer 
and cardiovascular disease) to be aware of. Here, the separating genes are 
also related to the bioinformatic predictions in section 7.1.1. On this 
background, it is concluded that since every gene set separating the various 
groups is also connected to some of the most promising new biomarkers, it 
strengthens the arguments for including the additional biomarkers PP2A, 
Hsp90 and NFkB in future trials.  
Based on the classifier simulation study in chapter 6 and the classification 
results in section 7.5, the most promising classification and variable selection 
methods seem to be support vector machines (SVMs) combined with variable 
selection based on random forests (varselrf) and stepwise logistic regression 
(both for 2-group comparisons). For multiple group comparisons, SVM/varselrf 
is recommended together with recursive partitioning. Classifier aspects are 
discussed in section 8.2. Both classifiers and variable selection method are 
used by the US Lundbeck group on other data sets.  
Statistical methods are discussed in section 8.3 and based on the results. 
Some of the suggested methods are   
• Spearman correlations for pair wise gene expression comparisons. 
• Repeated measures ANOVA for identifying differences between multiple 
time points measurements. 
• For gene expression disease subtyping: hierarchical clustering and heat 
maps. 
• Canonical correlation analysis for gene expression-clinical variable 
relationships supplemented by the univariate tests. 
Validation of the results obtained with the statistical methods is in general 
required.  
 
Further conclusions and discussions are included concerning 
• pooling of controls (section 8.4) with expression profiles of various 
control groups being more similar to each other than to expression 
profiles of patient groups 
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• intermediate phenotype results (section 8.5) with some of the 20 
depression hypotheses from section 7.3.1 being confirmed in a small 
group of severely depressed patients (Lundbeck confidential data) 
• possible disease phenotypes (section 8.6) on the expression level that 
may be identified with heat maps and canonical correlation analysis. 
Clinical data from patients are needed to establish a connection between 
the expression subtypes and possible disease subtypes. 
Finally, bioinformatic predictions (section 8.7), gender differences (section 
8.8), and time point measurements (section 8.9) are concluded on and 
discussed.  
 
All in all, the study has yielded several results and pointed to different aspects 
that deserve to be combined, concluded upon and discussed. I have summed 
up the most interesting topics, arranged in order of perceived importance, in 
table 35 which is based upon many of the results of the previous chapters.  
 
Topic Short description Section 
Whole blood biomarkers for psychiatric 
diseases  
Conclusion on and discussion of genes 
identified in various comparisons in section 
7.5 are reported.  
 
The overlapping genes are  
1) compared to the genes listed in chapter 2 
2) related to the bioinformatics findings in 
chapter 3 dealing with the 29 Lundbeck 
genes 
3) related to the bioinformatics predictions in 
section 7.1.1  
8.1 
Classifiers and variable selection 
methods 
Conclusion and discussion of the applied 
classification algorithms and variable 
selection methods. Promising classifiers / 
variable selection methods are listed.  
 
Furthermore, the simulation study in 
classification chapter is discussed. 
8.2 
Statistical methods Conclusion and discussion of the applied 
statistical methods. Promising methods are 
listed. 
8.3 
Pooling of controls Conclusion and discussion of the results on 
pooling the control groups. 
8.4 
Intermediate phenotypes (clinical 
variable – gene expression relationships) 
 
Conclusion and discussion of results 
concerning the 20 depression hypotheses in 
section 7.3.1.   
8.5 
 
 
Phenotypes / disease subtypes Conclusion and discussion of results related 
to phenotype identification, section 7.3.3, 
7.3.2 and 7.6.  
8.6 
 
127
8. Conclusion and discussion 
 
128
Bioinformatics predictions 
 
 
Conclusion and discussion of the use of 
bioinformatics for prediction of new possible 
biomarkers is discussed.  
 
Also, bioinformatics is discussed as a 
prediction tool in the context of a yet un-
analyzed patient group (bipolar disorder 
patients).  
8.7 
 
 
Gender differences Conclusion and discussion of the gender 
differences results.  
8.8 
Temporal measurements of gene 
expressions 
Conclusion and discussion of the 3-time 
point measurement results. 
8.9 
Table 35 presenting the various topics that are related, concluded upon and discussed in this 
chapter. 
 
8.1 Whole blood biomarkers for psychiatric diseases 
Here conclusions are drawn with respect to the genes separating the various 
groups in section 7.5 of the previous chapter and overlapping between the 
classifiers26 for consistency. These genes are compared partly to the genes 
reported for each affective disorder in chapter 2, partly related to the 
bioinformatics predictions in section 7.1.1, and at the end of this section partly 
related in table 36 to the bioinformatics findings in chapter 3 dealing with the 
29 Lundbeck genes.    
 
In section 7.5, comparisons between different control and patient group were 
made, and several genes were found to be significantly and differentially 
expressed between groups. For controls versus BPD patients, the overlapping 
genes between the classifiers, and that separated the groups were26: Gi2, GR, 
MAPK14 and partly MR (25 gene comparison).  Only GR is mentioned 
(indirectly) in the chapter two section ‘Borderline Personality Disorder and 
genes’ in connection with the glucocorticoid neurotransmission. Besides GR, 
Gi2, MAPK14 and MR may be involved in the pathology of borderline 
personality disorder and may be novel whole blood biomarkers for BPD.  
In relation to the new biomarker predictions of section 7.1.1 (here especially 
considering PP2A, Hsp90, NFkB and MHC Class I), GR and MR are interacting 
with Hsp90 on the protein level, while GR is also interacting with NFkB.  
 
For controls versus PTSD acute patients, the separating and overlapping genes 
were26: ARRB2, ERK2 and RGS2. None of these genes are reported in the 
chapter two section ‘PTSD and genes’ and, hence, they may be involved in the 
pathology of post-traumatic stress disorder, and also be novel whole blood 
biomarkers for PTSD. 
In relation to the new biomarker predictions of section 7.1.1 (again especially 
considering PP2A, Hsp90, NFkB and MHC Class I), ARRB2 is interacting with 
Hsp90 on the protein level, while ERK2 is interacting with PP2A.  
                                                 
26 2-group RPART results are disregarded as explaining in the section 8.2. 
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No significant genes were found to separate the controls from the remitted 
PTSD subjects. Thus, remitted PTSD subjects and controls have a similar gene 
expression profile. This result is in good agreement with the clinical diagnosis, 
and indicates that the gene expressions are ‘normalized’ upon remission.  
 
For the final 2-group comparison, comparing the controls with the trauma 
patients without PTSD, the significant and overlapping genes26 were: ARRB2, 
CREB1, ERK2, IL-6 and partly MAPK8 (25 gene comparison), Gs, MKP1 and MR 
(the latter three genes appeared in the 29 gene comparison). It should be 
remembered here, that the PPV values were not great, making us wonder 
about the validity of the results. Nonetheless, all classifiers yielded significant 
results. Trauma without PTSD has not been investigated in chapter two, since 
this group of subjects was only included for comparison reasons. OMIM has no 
record of trauma (without PTSD), so my informal guess would be that these 
eight genes may be (novel) whole blood biomarkers for trauma without PTSD, 
and be involved in the pathology of the disorder. Since ARRB2 and ERK2 were 
consistently picked as they were in PTSD acute patients, it could be 
hypothesized that the trauma subjects may be at risk for developing PTSD. 
In relation to the new biomarker predictions of section 7.1.1 (again considering 
PP2A, Hsp90, NFkB and MHC Class I), ARRB2 and MR are interacting with 
Hsp90 on the protein level, ERK2 is interacting with PP2A, and IL-6 with NFkB.  
 
For the multiple group comparison of controls versus BPD patients versus PTSD 
acute patients, the separating and overlapping genes were: ERK1, ERK2, GR 
and MKP1. As described above, GR has been implicated in BPD, and GR has 
also been implicated in PTSD (see chapter two ‘PTSD and genes’). The other 
three genes, ERK1, ERK2 and MKP1, have not previously been associated with 
any of these two disorders, and may thus, besides GR, be involved in the 
peripheral pathology of two disorders. Furthermore, they may present new 
whole blood biomarkers appropriate when a comparison is made between the 
two disorders and controls, if relevant.  
In relation to the new biomarker predictions of section 7.1.1 (again considering 
PP2A, Hsp90, NFkB and MHC Class I), ERK2 is interacting with PP2A on the 
protein level, and GR interacts with both Hsp90 and NFkB. 
 
The last multiple group comparison (all PTSD groups versus each other) is not 
described here, since only one classifier yielded a significant result. This makes 
me doubt the value of the result, also because we have seen above that there 
is no difference between controls and remitted subjects.  
 
In the various group comparisons above, every gene set separating the various 
groups is also connected to some of the most promising new biomarkers of 
section 7.1.1. This strengthens the arguments for including the additional 
biomarkers, PP2A, Hsp90 and NFkB, in future trials. 
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In order to obtain hypotheses of perturbed biological functions, I have looked 
closer at the separating genes mentioned above and related them to the 
biological functions from Ingenuity described in chapter 3 and listed fully in 
appendix 2. I have looked for biological functions consisting of all genes from a 
separating comparison. All the biological functions also contained additional 
genes. In table 36, I have summed up the most relevant results and arranged 
the biological functions after molecular and cellular functions, physiological 
system development and functions, and diseases and disorders (see the table).  
 
Biological functions / 
Disease associated genes in BPD BPD+1 
acute 
PTSD Trauma Trauma+1 
BPD and 
acute PTSD 
Molecular and Cellular 
Functions          
Cell Death     X X X 
Cell Signalling   X      
Gene Expression     X X X 
Molecular Transport  X X      
           
Physiological System 
Development and Functions          
Hematological System 
Development and Function X  X X X X 
Immune Response X         
           
Diseases and Disorders          
Cancer  X   X X X 
Cardiovascular Disease X       X 
Inflammatory Disease X           
Table 36 lists biological functions according to appendix 2 where sets of disease associated 
genes participate. BPD=Gi2, GR and MAPK14; BPD+1= Gi2, GR, MAPK14 and MR; acute 
PTSD= ARRB2, ERK2 and RGS2; trauma=ARRB2, CREB1, ERK2 and IL-6; trauma+1=ARRB2, 
CREB1, ERK2, IL-6 and MAPK8; BPD and acute PTSD=ERK1, ERK2, GR and MKP1. The 
trauma+3 (ARRB2, CREB1, ERK2, IL-6, Gs, MKP1 and MR) is not shown for visual reasons and 
only appeared in ‘Gene Expression’. 
 
From table 36, it can be seen that under the category ‘Molecular and Cellular 
Functions’ different gene sets are involved in the biological functions of cell 
death, cellular development, cell signaling, gene expression and molecular 
transport.  
Cell death, comprising functions associated with cellular death and survival, 
seems to be a relevant biological function for the trauma without PTSD 
associated genes (see legend to table 36) in whole blood and for the BPD and 
acute PTSD genes. In chapter three, the neurogenesis hypothesis was 
mentioned in connection with depression, so it is interesting but perhaps not 
that surprising to see cell death mentioned here. Cell signaling, comprising 
functions that are involved in intracellular signaling pathways, seems to play a 
role in whole blood for the genes associated with acute PTSD (again, see table 
36 legend). The genes associated with trauma, and BPD and acute PTSD, are 
also part of the gene expression function, which confirms their basic role. 
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Finally, molecular transport comprising functions associated with the intra- and 
extracellular movement of molecules, is associated with BPD and PTSD 
(acute). It may not be surprising that this function may be impaired in these 
disorders. 
Under the category ‘Physiological System Development and Function’, 
‘hematological system development and function and immune response’ is 
listed. The former biological function includes functions associated with the 
normal development and function of blood, and thus makes good sense for all 
the disorders being measured in whole blood. The immune response biological 
function seems particularly activated in BPD compared to the other disorders in 
whole blood.     
In the final category in table 36, diseases and disorders include cancer, 
cardiovascular and inflammatory diseases. There is an overlap between cancer 
genes and genes associated with all the disorders. This is not surprising 
(anymore) as I mentioned in chapter three that cancer might cause gene 
expression changes in some of the selected genes, meaning it could be 
important to check subjects for cancer prior to their inclusion in a clinical trial. 
Cardiovascular disease genes overlap with BPD associated genes and genes 
associated with BPD and PTSD. It could be interesting to investigate whether 
BPD or PTSD patients have a higher risk of cardiovascular diseases 
(comorbidity?) than other e.g. trauma subjects without PTSD.  
Finally, there is an overlap between genes involved in inflammatory diseases 
and BPD. Subjects in BPD trials should therefore be screened for inflammatory 
diseases like damage of spleen or leucopenia as mentioned in chapter three.  
 
Of all the group comparisons, only the gene set involved in separating controls 
from BPD and PTSD acute patients (ERK1, ERK2, GR and MKP1) is part of a 
significant biological pathway (listed in appendix 3). These four genes are part 
of the glucocorticoid receptor signaling pathway. 
 
 
All in all, even though the amount of patient and control qPCR whole blood 
data analyzed in this thesis was only enough to generate hypotheses, the gene 
expression profiles, as described above, convincingly seem to reflect the 
pathology of the studied affective disorders. This seems to support the use of 
gene expressions in peripheral blood as biomarkers of affective disorders, 
showing a correlation between brain and blood (5). Several articles mentioned 
in chapter 1 indicated this in other blood studies for psychiatric disorders (6), 
(7), (8), (9), (10), (11), (also supported and reviewed in (215)) and the 
argument in favor of using such blood biomarkers is underpinned by the 
current findings, although the genes identified have to be validated in 
independent trials. Only then can the validity of the possible novel biomarkers 
be established and be exploited as a neural probe of the studied psychiatric 
disorders.  
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8.2 Classifiers and variable selection methods 
The simulation study in the classification chapter identified the classifiers and 
variable selection methods SVM combined with varselrf (variable selection 
based on random forests), RPART and SLR as the best choices for analyzing 
the qPCR data in the two group comparison case, and in the multiple group 
comparison case SVM/varselrf and RPART. The simulation study did not include 
PPV and NPV values that were reported for the classification results in section 
7.5 of the previous chapter. In almost all the 2-group comparisons of section 
7.5.1, the PPV and accuracy values for the RPART results were consistently 
lower than the ones for two other classifiers. We (the US Lundbeck group and 
I) were not impressed by the bad RPART PPV results, so we decided to skip 
RPART in the 2-group case.  
In the multiple group comparisons, PPV and NPV values were not reported. 
With the few multiple group comparisons made, we did not have support to 
exclude any of the chosen classifiers. 
 
Thus, the most promising classifiers and variable selection methods for 
analyzing the Lundbeck qPCR data are SVM combined with varselrf and SLR in 
the 2-group comparison case, and SVM combined with varselrf and RPART in 
the multiple group comparison case. 
 
For the classification results in the previous chapter the same parameters were 
used as in the simulation study in chapter 6. A next step can be to tune the 
parameters of the chosen classifiers and variable selection methods (various 
options exist, see (184), (208), (168) and (158)) to see if a better 
performance can be obtained.  
 
Another possible way to improve the performance in the 2-group case of SLR is 
to include categorical clinical variables together with the gene expressions. 
This was demonstrated in the last part of subsection 7.5.3, although not 
convincingly in that case. It is not unreasonable to imagine that in other cases 
the combination of gene expressions and clinical variables may improve the 
classification performance considerably compared to using either set of 
variables as independent variables.  
 
 
The simulation study 
Some issues concerning the simulation study in the classification chapter are 
raised here. The basis for the mathematical approach to the gene-gene 
interactions was that we did not know the exact biological interactions between 
genes on the expression level. We investigated several classical mathematical 
approaches to gene interactions in the form of different linear and nonlinear 
tasks. Had we chosen to pursue other (mathematical) approaches, other 
classifiers and variable selection methods might have been recommended. 
Furthermore, other classifiers and variable selection techniques might have 
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been explored, like regularized discriminant analysis, classification using 
generalized partial least squares, neural networks, or other advanced methods. 
I mainly chose ones that I had been introduced to in the CBS course ‘DNA 
Microarray Analysis’ or read about in various articles. Also, the classifiers had 
to perform relatively fast in R and be able to perform some simple tasks from 
phase 1, all of which I tested. Having said that, had other classifiers and 
variable selection methods been included, I might have made different 
recommendations that the ones, I did.  
In relation to the choice of classifier, a different strategy could have been to 
identify a single classifier that was able to handle a broad range of 
classification tasks. However, the US Lundbeck group and I decided to choose 
more than one classifier partly because we could not identify a single classifier 
that performed well in all classification tasks and partly because we pursued a 
strategy of having different classifiers, so that overlapping genes (between the 
classifiers) could be identified for consistency reasons. This was of interest for 
the US Lundbeck group. It should be stressed, however, that overlapping 
genes alone, can not be used to build a good classifier. All genes identified by 
a chosen classifier / variable selection method should be used. 
 
Another issue deals with the use of the accuracy measure. Having a single 
accuracy measure surely was not very informative as the group sizes alone 
could be responsible for a large part or most of the actual accuracy value. The 
permutation tests, albeit a time consuming step, improved the benefit of the 
accuracy measure. The accuracy measure was chosen because multiple group 
(>2) comparisons were wanted. Had this not been the case, and had we only 
focused on two-group comparisons, the Matthews correlation coefficients would 
have been a better choice. It ”is generally regarded as a balanced measure 
which can be used even if the classes are of very different sizes”, and is 
generally regarded as being one of the best performance measures (216). 
Finally, it should be said that for the two-group comparisons, we supplemented 
the accuracy values with the PPV and NPV values. These latter values made us 
aware of the predictive values, which were considered informative measures 
for the classification performance.  
 
Also, 10-fold stratified cross-validation was applied as recommend in (199). 
Other validation schemes, like LOOCV or holdout validation, might have 
resulted in different performance values, and hence different 
recommendations. 
 
A final issue concerning the simulation study has to do with the stability of the 
classifiers (178). This encompasses removing one or more observations and 
comparing the classification result before and after this exercise. It could also 
include adding an incorrect observation and noticing the impact on the 
classification result (accuracy, PPV and NPV values) as well as on the selected 
variable list. I considered these general and additional tasks to be beyond the 
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scope and timeframe of the simulation study. Nonetheless, they are interesting 
aspects that might be worth looking into. 
 
8.3 Statistical methods 
The various applied statistical methods are discussed, and the promising 
methods for future analyses of Lundbeck qPCR data listed. 
 
It is always a good idea to check the expression data for normality. As it was 
seen in section 7.2 of the previous chapter, applying the recommend (from the 
statistical department of Lundbeck) logarithm to the expression data made, in 
general, more gene expressions follow the normal distribution. Other data 
transformations might have been considered like the square root or the 
reciprocal transformation before testing for normality. Still, more than half of 
the gene expressions could not be considered normally distributed according to 
any of the 5 applied normality tests. Even though the parametric univariate 
tests were robust and thus allowed all but severe deviations from normality, I 
believed it was a good idea to include nonparametric methods. It tuned out 
that in most cases, the univariate results were significant using both 
parametric and nonparametric tests, which made us believe (more in) the 
results.  
 
The basic statistical methods, univariate tests and correlations, gave a good 
first impression of the data and were the basis of the 20 depression 
hypotheses of section 7.3.1. These methods are recommended for a first 
impression of data and establishing basic hypotheses about the data at hand. 
Furthermore, they are simple methods and in my experience, simple methods 
are less likely to overfit the data compared to more advanced methods.  
 
For multiple time point measurements, repeated measures ANOVA is 
recommended to evaluate any statistical expression difference between the 
time points. If Lundbeck wanted to rule out circadian variation of any of the 
genes, many more time measurements would be needed; the circadian aspect 
is discussed in the final (Perspectives) chapter.   
 
 
Even tough stepwise regression in some cases could explain ~15-20% of the 
variance in a gene expression by a linear combination of automatically chosen 
clinical variables, stepwise regression was not useful for most of the gene 
expressions. Also, considering the relative low explanation degree listed above, 
stepwise regression is not recommended for this type of data.  
 
In general, clinical data for patients were missing (except for cohort 1 of the 
BPD patients). This made it difficult to evaluate several of the statistical 
methods for phenotype identification of patients. Recursive partitioning might 
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be an interesting phenotyping tool, but the RP results have to be validated and 
compared to clinical data. Considering that RP is prone to overfitting, and that 
RPART did not perform well as a classifier, RP is not recommend as a first 
choice of applicable exploratory statistical tools.  
The value of canonical correlation analysis was also difficult to evaluate due to 
the lack of patient clinical data. Section 7.3.3 demonstrated that CCA might be 
an interesting phenotyping tool. However, again, there were too few patient 
data to firmly establish CCA as a promising tool. With more patient clinical data 
and linked gene expression data, CCA could reveal an interesting link between 
clinical and gene expression characteristics of subgroups of patients, and is 
then recommended as such. 
The heat map results in section 7.6 also showed some very interesting possible 
disease phenotypes in simple visual plots. The hierarchical clustering used for 
the heat maps were based on the correlation as a distance measure. The 
Euclidian distance could also have been used, and would presumably result in 
other gene expression clusters. Again, the lack of patient clinical data did not 
make it feasible to link the disease phenotypes with clinical characteristics 
using e.g. SLR as demonstrated in that section. Still, heat maps are 
recommended for their promising phenotyping abilities (demonstrated several 
times in section 7.6) and simple visual layout.  
 
Considering the last two methods, with few clinical data, CCA may be better to 
identify gene-clinical relationships compared to heat maps. With more clinical 
data, CCA supplemented with heat map clustering and classification of the 
clinical variables could yield quite interesting results. 
 
8.4 Pooling of controls 
Here, results from section 7.3.6 and 7.3.7 are summed up and discussed.  
 
In section 7.3.6, we decided to pool the DC and SH ABS control groups. This 
was done based on the similarity of the (SH) DC and SH ABS clinical data, the 
large degree of agreement between the Spearman correlations of the two 
control groups, and because various classifiers recognized almost perfectly 
controls of one control group as belonging to the other control group when 
compared to either the BPD or acute PTSD patient groups. There were clearly 
expression differences between the two control groups; first 22 out of 25 
genes was significantly different expressed by univariate tests but as we 
defined a SH DC group matching the clinical criteria of the SH ABS group, the 
list of significantly different expressed genes was down to 15 genes. Pelora and 
SLR were also able to separate the groups based on the gene expression 
profiles. I think this is a good example of biological variability between control 
groups from different countries and different trials. Solely based on the gene 
expression differences, we could have chosen to pursue another strategy; the 
US controls should only be compared to US patients and the Danish controls 
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should only be compared to Danish patients, etc. However, this approach is 
more prone to overfitting. Also, if Lundbeck wants a more universal classifier, 
this classifier should have a more universal ability to recognize controls which 
is another argument for pooling the control groups. 
 
In section 7.3.7, the main question was whether all control groups should be 
pooled into one large control group or not. Again, there were univariate gene 
expression differences between the four control groups; SH ABS, DC, UK and 
PTSD controls. The classifier SVM/varselrf was also able to separate the four 
groups (data not shown), and thus confirmed the expression differences 
between them. However, comparisons between various (pooled) control groups 
and patients (see section 7.3.7) using Pelora and SLR, made us conclude that 
the different control groups were more alike than they were different. We did 
those analyses before the classifier simulation study. Given the limitations of 
Pelora, it could have been interesting to see the results of the control versus 
patient comparisons using e.g. SVM/varselrf.  
At the end, the four control groups were pooled into one large control group 
that thus spanned the biological expression variability of the various control 
groups.   
 
With clinical data for the PTSD controls and UK controls, we could have studied 
intermediate phenotypes (see next section) more carefully after pooling all the 
controls into one large control group. A possibility would be to define a super 
healthy control group based on the clinical data from the pooled control group. 
Then various intermediate phenotypes for BPD and PTSD patients could be 
defined like in section 7.3.1 for depressed patients.  
With different clinically defined intermediate phenotypes, it would be very 
relevant to investigate the gene expression path from absolutely healthy 
controls over various intermediate phenotypes to various disease phenotypes 
(also clinically defined). Would the expression profiles along this path be 
completely random or would some kind of expression continuum be revealed? 
Questions like this could lead to more insight into the biological basis of 
affective disorders.  
 
8.5 Intermediate phenotypes 
In section 7.3.1, clinical variable - gene expression relationships were 
investigated in the ABS control group with respect to intermediate phenotypes.  
 
Based on univariate tests of depression related clinical variables involving both 
individual genes and gene ratios, table 25 was constructed indicating gene 
expression patterns that could define intermediate phenotypes. The table was 
expanded in more detail by the 20 subsequent depression hypotheses. The 
first seven hypotheses involved individual genes, and could thus be compared 
to the expected gene regulation noted in table 3, chapter 3. For SERT 
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(hypothesis 1) and G alpha s (hypothesis 4), the down regulated predictions in 
table 25 are also expected in depressed patients from the literature (table 3). 
The DDP4 (hypothesis 2, up regulation expected) and MAPK14 (hypothesis 7, 
down regulation expected) predictions do not correspond with the table 3 
literature predictions. The predicted expression directions of ERK2 (hypothesis 
3) and MKP1 (hypothesis 5) are ambiguous (may present different 
intermediate phenotypes). In table 3, both genes are expected to be down 
regulated, which is also predicted in table 25 only considering decreased 
appetite. For PBR (hypothesis 6) there was no expected up or down regulation 
in table 3. Thus, there seems to be a certain overlap between the findings of 
section 7.3.1 and the expected regulations from the literature in table 3. It is 
not surprising the overlap is not greater mainly given that we can not be really 
sure that the intermediate phenotypes are actually at risk for developing 
depression and that we are comparing with trials conducted by other research 
groups with probably different inclusion criteria, different normalization and 
measurement methods, etc. 
 
Section 7.3.1 ended with stating that it did seem like gene expression patterns 
could be used to segment control subjects based on various depression 
relevant clinical variables. The conclusions on the 20 depression hypotheses 
were;  
 
• Different gene expression patterns were intermediate phenotype 
dependent. 
• Expression differences in controls were related to symptoms of 
depression (but no current diagnosis of depression). 
• Simple statistical modeling could identify factors that explained a 
clinically relevant degree of the variation in gene expression. 
• The expression pattern observed in a small group of severely depressed 
patients partially confirmed the results from control subjects.  
(This was based on Lundbeck confidential data that could not be part of 
the thesis) 
 
Overall, it thus seemed like our approach for identifying intermediate 
phenotypes did produce results that, at least partially, could be confirmed in 
severely depressed patients. The gene expression intermediate phenotypes 
would have to be validated in further large clinical trials.  
 
 
It could have been interesting to do the same exercise with relation to the BPD 
and PTSD disorders, where I did have access to the patient data. Furthermore, 
in relation to PTSD it could have been interesting as well to compare the gene 
expression profiles of intermediate phenotypes to the expression profiles of 
remitted PTSD patients, and, hence, look more into how gene expressions are 
‘normalized’ by treatment as the reported in section 8.1.   
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8.6 Phenotypes 
In the sections 7.3.3, 7.3.2 and 7.6 different possible disease phenotypes were 
identified using various statistical approaches. In 7.3.3, regularized canonical 
correlation analysis could identify four possible BPD patient subgroups with 
each subgroup of patients correlated to certain clinical variables and 11 gene 
expressions, see the section for details. These results were compared to the 
CCA example in the statistics chapter using the same data set, however only 
utilizing 4 genes. The 4-gene and 11-gene cases were found to be quite similar 
in the sense that the subjects in two subgroups (BPD1/BPD2 and BPD4/BPD10) 
stayed closely together in both cases. This could indicate that these two 
subgroups were fairly robust. One subject in each of the other two subgroups 
switched group membership due to a different set of CCA chosen variables in 
each case.  
With so few clinical data for patients, the CCA output is only at best 
circumstantial evidence of 2-4 BPD phenotypes. Still, the approach of applying 
several (here two) gene sets to the same data and looking for consistent 
patient subgroups/phenotypes, is recommended. More clinical data for patients 
are needed to validate these results and possibly generate additional 
phenotype hypotheses.  
 
For the data set analyzed and results generated in section 7.3.2, recursive 
partitioning only subdivided the BPD patients into one major group consisting 
of 20 BPD patients (based on the expression values of GR and ARRB2 only) 
and one BPD patient outlier based on the expression values of GR, SERT, 
CREB2 and ADA (see figure 31). These results were generated when the BPD 
patients were compared to 20 DC and 21 SH ABS controls.  
In the statistics chapter, RP was used to divide the 299 ABS controls and 11 
BPD patients. In this case, RP identified two BPD subgroups consisting of more 
than one member; there was a subgroup of 5 BPD patients identified based on 
the expression values of GR and ERK2 only, and a subgroup consisting of two 
members based on the same gene expression adding CREB2 (figure 9). Again, 
due to the sparse clinical data for patients, it is difficult to validate these 
subgroup findings, and more both patient clinical and patient gene expression 
data is needed for this purpose. The RP results show that depending on which 
control and patient data you compare, different gene expression subgroups 
may emerge. If this is not just a RP overfitting issue, it indicates that the same 
patient group may be subdivided in various ways. To investigate this aspect, it 
would be of great assistance to have access to confirmed clinical 
phenotypes/subtypes. Having clinically defined phenotypes could be used to 
tune the statistical methods and validate the results. 
 
Both in statistics chapter (figure 10) and in section 7.6, heat maps were used 
to distinguish expression differences between both BPD subgroups and acute 
PTSD subgroups (figure 38 and figure 39). The different expression subgroups 
/ phenotypes are clearly seen on these plots. Furthermore, in the last part of 
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section 7.6, I demonstrated how SLR might be used to link the expression 
subgroups with clinical data for controls. Had sufficient patient clinical data 
been available, the same exercise might be done for patients, and disease 
putative disease phenotypes identified. Of course, they would have to be 
validated in further trials, and possible compared to clinically known 
phenotypes, if possible. 
In general, the clusters identified in such an unsupervised heat map manner 
may thus give clues to possible phenotypes among patients (and intermediate 
phenotypes in subjects at risk). These expression phenotypes would then have 
to be verified using a supervised approach like SLR with the clinical variables 
for these patients. It would be interesting to see how or if SLR would be able to 
separate, for instance, the two BPD or PTSD subtypes in figure 38 only 
considering these patients’ clinical variables. A further step would be to 
investigate whether these clinical variables and values would make sense to a 
psychiatrist.  
 
8.7 Bioinformatics predictions 
In section 7.1.1, bioinformatics was used to predict new possible biomarkers 
by looking into protein-protein interactions for protein complexes. New 
potential biomarkers were identified; primarily Hsp90, PP2A and NFkB (each 
interacting with at least three of the Lundbeck proteins), and secondary  
Ras, MHC Class I, Mek, Akt and Ap1 (interacting with maximum two of the 
Lundbeck selected proteins). 
 
The US Lundbeck group had investigated several possible biomarkers prior to 
the list of 29 genes described in chapter 3. The above bioinformatics 
predictions were of great interest to the US Lundbeck people. They considered 
in particular to measure PP2A (dephosphorylates ERK), Hsp90, NFkB and MHC 
Class I in the blood samples. A natural first step would be to see, if these 
genes are sufficiently expressed in blood to be measured reliably.  
 
Other sets of new potential biomarkers could have been obtained using other 
web applications than Ingenuity (like e.g. STRING or Inweb from CBS), 
because different PPI web applications use, for instance, different data sources, 
different quality of data, and protein data from different species. This might 
easily have resulted in other recommendations for new biomarkers.   
 
Also, if wanted, bioinformatics could have yielded other kinds of predictions 
like which genes have a transcriptional influence on other genes, which 
proteins activate or inhibit other proteins, etc. Such bioinformatics predictions 
could be done prior to any experiments in whole blood to better understand 
these aspects for the biology and pathology of affective disorders.  
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Bioinformatics was finally used to predict which of 29 genes selected by 
Lundbeck that would be altered in the yet un-analyzed patient group consisting 
of bipolar disorder (BD) patients. The predictions were based on two SNP 
studies (WTCC (210) and Baum et al. (59)) and NCBI’s SNP database. There 
were virtually no overlap between the 68 genes associated with these SNPs 
and the BD associated genes listed in chapter 2. With millions of SNPs present 
in the genome, overfitting is always an inherent issue, and thus, it is not 
surprising that there is so little overlap between the genes identified through 
various SNP studies and furthermore compared to e.g. gene expression 
studies. Nonetheless, three possible BD biomarkers related to 29 genes were 
identified via the PPI database STRING and via Ingenuity focusing on 
transcriptional interactions (see below); SYK, BDNF and THRB.  
At the level of transcription, the three BD associated proteins seemed to affect: 
Gs, IL-1 beta, CREB1 and ERK1, and thus expression differences between BD 
patients and controls might be expected to be seen in the above four gene 
expressions. These predictions have to be validated in future BD trials.  
 
Just like in the first bioinformatics task, the above predictions might have been 
different using other web applications than Ingenuity, STRING and NCBI’s SNP 
database for the reasons given there.  
 
Another way to do the bioinformatics BD predictions could have been to 
include all the BD disease related genes from chapter 2, and thus investigate 
how all these genes, together with the 68 genes mentioned above, interact 
with the 29 genes selected by Lundbeck on the protein level. 
 
Finally, it should be mentioned that the same kind of bioinformatics exercise 
that was done above with bipolar disorder could also be done with the 
borderline personality disorder and PTSD using the BPD and PTSD related 
genes mentioned in chapter 2 (plus additional SNP studies, if available and 
desired). In these cases, it would be possible to compare the bioinformatics 
predictions with the available qPCR blood data results. This way, we could 
learn about the value of such bioinformatics predictions, optimize the 
bioinformatics process and be better suited for future tasks and experiments.  
 
8.8 Gender differences 
In section 7.3.5 gender differences were explored in control groups using 
Pelora, SLR, univariate tests and Spearman correlations. There was a large 
overlap between the genes selected by either Pelora or SLR comparing all DC 
controls to all SH ABS controls, all DC males to all SH ABS controls and all DC 
females to all SH ABS controls. Furthermore, Pelora and SLR were not able to 
separate DC males versus DC females or control (DC, SH ABS and PTSD 
controls) males versus control (same combined control group) females with a 
satisfactory result. Spearman correlations between the former three 
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comparisons were also more than 96% in agreement. Univariate tests showed 
6 genes were significantly different expressed between the DC group split by 
gender and compared to the SH ABS. However, since there was only a very 
small overlap between the genes (only MR) selected by the classifiers and the 
6 significant genes, it was concluded that although some expression 
differences existed between the genders, they did not seem major.  
 
Pelora and SLR are linear classifiers. It is possible that using SVM in 
combination with varselrf would yield a more separable result comparing the 
DC males to the DC females or the male controls (DC, SH ABS and PTSD 
controls) to the female controls. This way, although the genders were not 
convincingly linearly separable, they could perhaps be convincingly (accuracy 
> 90% and significant compared to a permuted sample) separated with a 
nonlinear classifier. This would have to be investigated, and if the case, the 
succeeding analyses should possibly be done three ways (males only, females 
only, combined). However, given that all the patient data was either mostly 
only from women (BPD patients) or solely from men (acute PTSD), a proper 
gender investigation into the biology of affective disorder could not be carried 
out. More gender specific clinical data could have shed light on this important 
aspect as it is known that more women than men are affected by BPD and 
PTSD (see chapter 2). Thus, the influence of gender on patient groups in whole 
blood gene expression measurement remains to be determined. 
 
8.9 Temporal measurements of gene expressions  
In section 7.4, expression differences between three time points – Day 0 at 8 
am, Day 0 at 2 pm and Day 1 at 8 am - were investigated in the UK controls 
using repeated measured ANOVA. Five gene expression were found to differ 
significantly between the time points; CD8 beta, IL-8, MKP1, MR and ODC1. 
For IL-8 the significant difference was between the Day 0 and Day 1 
measurements, however the difference was caused by only five subjects, not 
the entire group. Removing these (IL-8 is a proinflammatory cytokine prone to 
noisy behavior), the significant difference disappeared. For the other four 
genes, the difference was between the morning and afternoon measurements.  
According to Pubmed, only MR was found to display a circadian pattern in man, 
however not in blood. Lundbeck wished to exclude genes displaying circadian 
patterns from the gene list. However, due to the few time point 
measurements, circadian effects could be neither be confirmed nor ruled out 
for the four genes. The conclusion was that even though the five genes were 
differently expressed between the three time points, they remained in the list 
of genes measured in the study.  
 
In my view, the time point measurements above highlight, nonetheless, the 
importance of the temporal aspect. Since expression difference do exist for 
some genes, it is another argument for pooling the control groups (across 
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various time measurements) in order to span the biological gene expression 
variability in controls.  
Ideally, the significant different time points for the five genes should be used 
as the basis for a test data set in a classification task separating controls from 
the patient groups. No matter the time of measurement, a control should still 
be classified as a control, and not as a patient simply due to the time of day 
the blood was sampled. This remains to be determined. Other possibilities, if 
time of day does matter for some gene expression, are either to exclude the 
genes from the study or try to incorporate the time aspect into clinical trials, if 
possible.  
 
Also, if possible, it is recommended to investigate any possible circadian effects 
for the five genes properly in order to be certain about whether to include or 
exclude the gene expressions. This aspect is included in the next chapter.  
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This final chapter presents different suggestions for further work. Some of the 
more interesting perspectives are  
• a suggestion for an experiment to confirm or rule out temporal gene 
expression oscillations. Large oscillations for a gene expression might 
mean that the gene expression is not suitable as a biomarker. 
Several of the gene expressions in the present study can potentially 
display circadian behavior as witnessed by the repeated measure ANOVA 
results and Ingenuity.  
I propose a simple 24-hour experiment with blood sampled every hour 
for a small number of depressed patients and healthy subjects. Not only 
should the 29 gene expressions be measured but I also propose to 
measure a limited number of so-called core clock components, as the 
literature points to a circadian component of mood disorder.  
• requirements for constructing a Bayesian gene regulatory network. With 
Bayesian networks, it is often possible to extract more information out of 
the genes selected in the various classification tasks. Actually, the 
ultimate goal is to construct a causal Bayesian network in order to 
predict gene regulatory behavior in whole blood in various affective 
disorders. The potential of the Bayesian network approach was clearly 
demonstrated on the protein level by Sachs and colleagues in the US 
(217).  
I spent a week at the University of Warwick, UK together with professor 
David Rand and David Wild investigating the possibility of constructing a 
Bayesian network with the available data and with the Sachs article in 
mind. The result became a wish to understand the mechanisms behind a 
successful Bayesian network model with the Lundbeck data, which 
should be obtained by making a simulated Bayesian network based on 
the available data. 
• suggestions for other classifier approaches. One suggestion involves the 
use of deterministic forests instead of random forests as the former 
produce a fixed set of genes every time the same classification tasks is 
executed. Another suggestion involves looking at classification 
probabilities, since they might be more informative when it comes to 
identify intermediate phenotypes. This section also contains additional 
classification oriented suggestions.   
• other ways of searching for blood biomarkers in affective disorders. Here, 
I propose the use of either microarrays to perform a genome-wide 
expression analysis in a hypotheses-free manner or to have custom 
microarrays designed focusing on specific important genes or pathways 
in order to reduce the number of false positives. 
• clustering simulations for disease subtyping. As a major future challenge 
involves disease subtyping, and only heat maps with hierarchical 
9. Perspectives 
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clustering have been investigated, I propose a simulation study to 
identify promising unsupervised clustering methods (as many different 
clustering techniques exist). 
 
 
In this last chapter, I choose to discuss perspectives on five issues related to 
the thesis; 
 
1. Temporal aspects of gene expression behavior. This includes a 
description of an experiment to confirm or rule out gene expression 
oscillations in blood.  
Furthermore, as an example of a systems biology approach, the 
dynamics of a minimal model involving the CREB proteins is included.  
 
2. The requirements for constructing a Bayesian gene regulatory network 
only using the available non-temporal blood measurements. 
 
3. Suggestions for other classifier approaches and classification tasks. 
 
4. Other ways of searching for new blood biomarkers in affective disorders. 
 
5. Unsupervised clustering simulations for subtyping purposes.  
 
9.1 Temporal aspects of gene expression behavior 
In section 7.4, four gene expressions were found to exhibit a significant 
difference between morning and afternoon measurements in whole blood; CD8 
beta, MKP1, MR and ODC1. Furthermore, according to Ingenuity, four other 
genes of interest to the present study are involved in the circadian rhythm (not 
in man, but in mouse and rat); IL-6, CREB1, SERT and ERK2. These findings 
could indicate that some, perhaps at least eight of the 29 ‘Lundbeck’ gene 
expressions, might exhibit a daily rhythm. This is difficult to confirm on the 
basis of the existing literature which is very restricted with respect to gene 
expression oscillations in whole blood in man.  
 
On the other hand, the literature points to a circadian component of mood 
disorders (218), (219), (220), involving the core clock components27; CLOCK 
(circadian locomoter output cycles kaput), PER1, PER2, PER3 (Period, 
drosophila, homolog of, 1, 2 and 3 respectively), CRY1, CRY2 (cryptochrome 1 
and 2 respectively), BMAL1 (aryl hydrocarbon receptor nuclear translocator-
like), REV-ERBα (nuclear receptor subfamily 1, group D, member 1) and RORα 
(RAR-related orphan receptor alpha) (221). Moreover, between 2-10% of all 
genes are assumed to be transcribed in a circadian manner (222).  
                                                 
27 “Core clock components are defined as genes whose protein products are necessary for the generation and 
regulation of circadian rhythms within individual cells throughout the organism” (221). 
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Taken together, this suggests that gene expression oscillations, both (part of) 
the 29 gene expressions and the core clock components, not only might occur 
in man, but be directly involved in the biological basis and pathology of 
affective disorders. In order to investigate whether circadian or ultradian28 
gene expression oscillations occur at all in whole blood and in affective 
disorders, I propose an experiment where a blood sample is obtained every 
hour for a 24-hour period. This sampling should be repeated two or three 
times to see if the results are consistent. Both the 29 gene expressions as well 
as the 9 core clock components could be measured, if the core clock 
components are expressed at detectable levels in whole blood and not show 
too much variability (see chapter 4). The obtained data should then be 
analyzed, starting by inspecting the multiple 24-hour plots for each gene 
expression. 
 
The experiment could be initialized with just a few healthy controls and a few 
MDD patients, hospitalized. Gene expressions should be normalized the same 
way as done in the present Lundbeck study (with 7 HKG).  
 
The reason for including the 9 core clock components in the above experiment 
is to examine how these clock components oscillate at the messenger RNA 
level in whole blood, if at all, in controls versus patients, and to relate their 
oscillations to oscillations occurring in any of the 29 gene expressions. This 
could shed light on the temporal dynamics (including amplitude and phase 
shift) of gene expression behavior in affective disorders and to the causal 
relations between the various gene expressions. This would add to the 
understanding of the molecular basis of affective disorders. Would these whole 
blood measurements indicate any disruptions in oscillatory behavior between a 
healthy and a disease state?  
The experiment could also indicate the variation of each gene expression 
during 24 hours, which either a) in case of large expression oscillations might 
mean that the oscillating gene expression is not suitable as a biomarker, or b) 
incorporated into a classifier, might improve the diagnostic classification 
performance. Including additional subjects could verify the results. 
 
Also, like in the Lundbeck study described in this thesis, it would be very 
informative to expand the above experiment with qPCR measurements from a 
few acute PSTD patients, some patients with trauma without PTSD, and a few 
BPD patients and remitted patients.  
 
If any of the gene expressions do indicate circadian or ultradian patterns, this 
might lead to the construction of a mechanism-based model to get a basic 
understanding of the biological mechanisms behind the oscillations, and predict 
qualitative behavior in various areas of the parameter space. A first step would 
                                                 
28 Recurrent cycles with a period of less than 20 hours. 
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be to perform further tissue specific investigations to identify important 
components that could be subject to mathematical modelling. Transitions with 
various parameter adjustments from the healthy state to the diseased state 
could then also be studied. A detailed description is beyond the scope of this 
thesis, but the interested reader is referred to the paper ‘Dynamics of a 
minimal model of interlocked positive and negative feedback loops of 
transcriptional regulation by cAMP-response element binding proteins’ (223). 
 
9.2 Bayesian gene regulatory networks 
The background for considering Bayesian networks is that I would like to 
extract more information out of the genes selected in the various classification 
tasks described in section 7.5. As a first approximation of the interactions 
between such a set of selected genes, I looked into the Spearman correlations 
between them. An example is shown in table 37 comprising four genes (ERK1, 
ERK2, GR, MKP1) separating the controls from the BPD and acute PTSD 
patients.  
 
 
Table 37: Spearman correlations between four genes (ERK1, ERK2, GR, MKP1) separating the 
controls from the BPD and the acute PTSD patients. Significant correlations (significantly 
different from zero) at the 1% level are encircled. The analyses were done in SPSS. 
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Table 37 indicates that, in general, the significance of the correlations depends 
on the group, and, thus, that different correlations exist among the genes 
depending on group. In theory this could add a little knowledge about which 
correlations that get strengthened or weakened comparing the various groups. 
Still, correlations are not very informative. On the other hand, Bayesian 
networks offer insight into a possible gene regulatory behavior.  
 
Now follows a brief introduction to Bayesian networks (BN) including reasons 
for considering these to explore interactions between the differentiating 
(classifier chosen) genes; 
 
• In a BN, biological knowledge from the literature (tissue) can be 
incorporated as prior knowledge and gene-gene interactions in blood 
(posterior knowledge of interest) inferred.  
 
• With a BN, a gene regulatory network of genes involved in affective 
disorders can then be examined. 
 
• Ideally, I would like to infer causal relationships, if any, between the 
genes. In a BN, this requires either time-series (that are not available) or 
intervention data (explained below). 
A BN with causal relationships may serve as a first step towards a 
dynamic model. 
 
• BNs “can represent complex stochastic nonlinear relationships among 
multiple interacting” genes (217). 
 
● BNs “are robust in the face of both noisy data and imperfectly specified 
hypotheses”. “They can handle missing values”, “are not limited to pair-
wise or linear interactions between genes” (226). 
 
● BNs “permit latent variables to represent unobserved factors” (226) and 
thus BNs can detect both direct and indirect causal connections.  
 
● BNs can combine data from multiple sources, e.g. questionnaire data, 
gene expression measurements and publicly available databases. 
 
● “Variables in a BN can be discrete or continuous” (226).  
 
A more thorough introduction to Bayesian inference for gene expressions is 
given in e.g. (224) and for graphical models (covering BNs) in (225). 
Furthermore, an interesting article on the subject is found in (226).  
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BN example 
In order to understand what it requires to construct a BN that may be used to 
examine the differentiating genes in the Lundbeck data, I now give an example 
from the literature of the use of BNs in a relevant biological context – this is 
from the Science paper ‘Causal Protein-Signaling Networks Derived from 
Multiparameter Single-Cell Data’ by Sachs et al. (217). BN had here 
“elucidated most of the traditionally reported signaling relationships and 
predicted novel interpathway network causalities” (217) using only static (non-
temporal) data. 
In figure 41, a “classic signaling network and points of intervention” (217) are 
shown.  
 
 
Figure 41 showing “a classical signaling network and points of intervention”. “Signaling nodes 
in color were measured directly” by flow cytometry. “Signaling nodes in gray were not 
measured, but were included to place the signaling nodes within contextual cellular pathways”. 
“Arcs are used to illustrate connections between signaling molecules; in some cases, the 
connections may be indirect”. For more details, see (217). 
 
A key point is the intervention data. In figure 42, observation-only (that is 
without any interventions) data was used to reconstruct the figure 41 signaling 
network. 
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Figure 42 shows inference results from observation data only. No arcs are recovered and the 
plot resembles a correlation network. This demonstrates that “intervention data is crucial for 
effective interference”. For more details, see (217). 
 
Observation data alone is clearly not enough to infer the underlying biological 
network. When the intervention data is included, almost the entire signaling 
network is recovered, see figure 43. 
 
 
 
Figure 43 shows inference results using observation as well as intervention data. Almost the 
entire original network is recovered and novel interpathway arcs predicted, that Sachs et al. 
verify experimentally. For more details, see (217). 
 
Static BNs are constrained to be acyclic, so any feedback loops can not be 
detected. This might be the reason for the missing arcs in figure 43. 
 
Also, it is worth noticing that  
 
• Causal influence could be inferred even though a protein was not 
perturbed (e.g. Raf -> Mek) 
 
• Most arcs were validated by literature studies (no a priori knowledge was 
used – only random restarts were utilized). 
 
• Arcs represented both direct and indirect causal connections, that is, in 
some cases the influence of one protein on another was mediated by a 
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protein that were not measured. 
 
 
The main differences between the Sachs’ approach and the Lundbeck data 
concerning possible inference of gene regulatory networks seemed to be; 
 
1. In the Lundbeck data, we are dealing with real-world conditions / non-
ideal interventions unlike in the Sachs' article, where intervention data is 
created with specific inhibitors and activators used to create 
perturbations. 
 
2. Clinical data set sizes are used with Lundbeck unlike in the Sachs' article 
where thousands of data points are collected in each experiment. 
 
3. Measurements are done on whole blood in the Lundbeck study that is, 
averaged over different cell types, unlike in the Sachs' article using good 
single-cell measurements.  
 
On the positive side, the Sachs’s article did point to the possibility of inferring 
gene regulatory networks based on incomplete measurements (not all 
variables were or could be measured) and static data only. A major question 
was then whether the different control and patient groups could be used as 
pseudo-intervention data. 
 
I spent a week at the University of Warwick, UK together with professor David 
Rand and David Wild looking into the possibility of using BNs to learn more 
about gene regulatory behavior in whole blood with the knowledge of the 
Sachs’s approach. Two suggestions were made to investigate whether the BN 
framework was likely to be successful for this task: 
 
1. Basically, modify the Sachs' data to match the available Lundbeck data 
(as much as possible) and see how much network can be inferred. 
 
2. Make a simulated BN model e.g. with 4 nodes matching the 4 genes 
separating the controls vs. BPD vs. acute PTSD patients, and then  
a. obtain distributions for each node sampled from the real gene 
expression data 
b. direct arcs (causality) 
c. simulate from the model and find out which perturbations give 
what information. 
 
In Warwick, I only managed to do some parts of suggestion 1 above and the 
more restrictions I put on the Sachs data (to match the Lundbeck data) the 
less gene regulatory network could get inferred (of course). However, two 
things were worth noticing: a) it was possible to infer part of a network, still 
and perhaps this small network could tell something about a pathway (or some 
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gene interactions) connected to the pathology of affective disorders. Of course 
it would have to be verified experimentally but the BN approach could give a 
hint about what to look for. b) The Sachs article dealt with protein 
measurements which was another obstacle in that protein expressions do not 
behave the same way as gene expressions. This meant that the Sachs BN 
model might not be suitable as a framework for deducting a regulatory 
network for the Lundbeck data.  
 
This leaves suggestion 2 - making a simulated BN model which I believe would 
be the best thing to do. However, as this was at the end of the thesis work, I 
did not have time to pursue this interesting endeavor. With a simulated BN 
model, one would be able to predict gene regulatory behavior in whole blood in 
various affective disorders. The simulated results would have to be 
experimentally verified, and could add to the understanding of the biological 
basis of affective disorders.  
 
9.3 Other classifiers and classification tasks 
Having worked with the different classifiers and classification tasks in chapter 6 
and observed the results in section 7.5, four perspectives come to my mind. 
 
First of all, random forests performed very well in classification tasks in chapter 
6 and showed, in general, excellent performance in section 7.5. However, 
random forests do not select a fixed set of genes, but the number of selected 
genes may vary (slightly) from each execution of the script. In order to obtain 
a fixed set of genes, deterministic forests might be a solution (227). They 
operate in a manner similar to random forests, have the same high 
performance, however, yield the same gene list every time for the same task. 
Deterministic forests are, however, not part of any R package at the present 
time, and would have to be either coded for optimal performance to the 
Lundbeck task or contact established with a possible software provider. 
 
A second aspect concerns the inclusion of clinical variables into classification 
tasks. This was briefly discussed in section 8.2 concerning SLR. As the path 
from micro (gene expressions) to macro (clinical descriptions) is quite long and 
complex, it is likely that the combination of clinical variables and gene 
expressions might yield a better classification performance that either set of 
variables. It could be quite interesting to identify a range of classifiers 
(including Bayesian classifiers) able to handle both set of variables and 
perform a simulation study to identify the most promising classifiers. These 
results should then be compared with the classification results obtained using 
only gene expressions. This way we could have an idea as to how much 
improvement in classification performance adding clinical variables could 
contribute with, if any.  
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A third perspective worth looking into deals with a combination of the search 
for intermediate phenotypes and classification probabilities for classification 
tasks involving gene expressions. So far, we have only focused on the discrete 
and typically binary classification outcome – e.g. control or patient. By 
considering classification probabilities, it could become easier to identify 
intermediate phenotypes. This could easily become relevant for subjects with a 
classification probability of ~40-60%. These individuals should have their 
clinical information checked to see how they differ clinically from the rest of 
their group, if at all.  
 
Finally, it should be mentioned that although treatment data was not available, 
the classifiers, identified in chapter 6, could be used to predict treatment 
response.  
 
9.4 Searching for blood biomarkers in affective disorders 
Lundbeck has collected blood samples from the different control and patient 
groups described in chapter 4. Half of the blood for each subject has been used 
to measure the gene expressions by qPCR. This leaves 2.5 ml of whole blood 
per subject to be used for other analyses. Below I briefly propose to use 
microarrays for identifying other putative blood biomarkers based on the 
remaining blood samples. 
 
While the Lundbeck study focused on a predetermined set of genes, with DNA 
microarrays Lundbeck could perform a genome-wide gene expression analysis 
in a hypotheses-free manner. Microarrays were briefly described in chapter 4. 
Microarrays have been used in number of mental disorders, see for instance, 
the review articles (228), (229) and (230) that also lists various benefits and 
drawbacks of this technology, see table 9 (chapter 4) for an overview.  
 
The DNA microarray technology could expand the number of possible blood 
biomarkers drastically compared with the original 29 gene expression 
biomarker list used by Lundbeck. Differentially expressed genes would need to 
be validated by qPCR. Due to the large ratio of measured gene expressions to 
the number of subjects, a large number of false positives (that partly can be 
diminished with multiple testing correction procedures) and overfitting are an 
inherent part of the analysis of microarray data. The latter is definitely also 
due to disease heterogeneity. Bioinformatics, e.g. with Ingenuity, would play a 
greater role than in the present study (chapter 3, section 7.1 and section 8.1). 
With many significant and differentially expressed genes, bioinformatics is 
crucial in the identification of the significant genes’ involvement in known 
metabolic or signaling pathways, in elucidating which other genes in a pathway 
that are significant, their function, etc.  
When it comes to statistical analyses and classification of microarray data, a 
wide range of the methods used in chapters 5 and 6 may be applied again, 
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since they are designed for microarray analysis purposes, e.g. random forests, 
Pelora, regularized CCA and heat maps besides the universal applicable 
univariate tests.  
 
As mentioned above, a large number of false positives are still to be expected 
with a genome-wide DNA microarray. Another possibility, that could reduce the 
number of false positives and overfitting, is to have custom arrays designed. 
Such custom-made arrays could monitor expression changes in specific 
pathophysiologically important genes or pathways. A disadvantage of custom 
arrays is that one is no more performing a hypotheses-free search for 
biomarkers but has introduced a bias in the selection of genes. Still, the 
custom array approach have been used with promising results in the 
assessment of human stress and depression in blood leukocytes, actually using 
only 2.5 ml of blood (94).  
 
9.5 Unsupervised clustering simulations 
A major future challenge is disease subtyping, and in section 8.6 I have 
suggested various approaches for this. The single most promising subtyping 
approach so far seems to be hierarchical clustering and heat maps. However, 
no systematic investigation into unsupervised clustering methods has been 
performed in this thesis. Many clustering algorithms exist with some of the 
most popular, besides hierarchical clustering, being “K-means, PAM (partioning 
around medoids), SOM (self-organizing maps), mixture model-based clustering 
and tight clustering” (231). In order to determine which clustering method that 
is best suitable for the Lundbeck data, a simulation study could be undertaken 
that could include the clustering methods above as well as AP clustering 
mentioned in chapter 5.  
 
It is beyond the scope of this thesis to go into details as how to evaluate 
different clustering algorithms. Some authors, see e.g. (231), evaluate 
clustering methods for microarray data by performing both a simulation study 
and looking at real data sets, like the approach taken in chapter 6. 
A popular similarity measure of two clusters is the weighted Rand index (231), 
but other measures exist as well (232). In the later reference, several 
suggestions, including simulated data sets, are given as how to perform cluster 
validation. Here it is stressed “that entirely objective cluster validation is 
possibly only on data with well-defined cluster structures”, which is why the 
evaluation of clustering algorithms should always include such data – 
simulated data as well as real data with well-defined structures, perhaps like 
the ones in the heat maps of figures 38 and 39. 
 
(233) 
(234)  
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Appendix 1: Three networks showing the 29 genes and interacting 
genes 
 
Below are shown the three networks from table 4 involving the 29 genes and 
interacting genes. Genes shown in grey are part of the 29 gene list.  
 
Ingenuity requires gene names to be entered via their Entrez gene name: 
ATF2=CREB2, NR3C1=GR, NR3C2=MR, DUSP1=MKP1, TSPO=PBR, 
MAPK1=ERK2, MAPK3=ERK1, INDO=IDO, SLC6A4=SERT, SLC18A2=VMAT2, 
GNAI2=Gi2 and GNAS=Gs. 
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Appendix 2: Significant biological functions among the 29 genes 
 
Output from Ingenuity (Ingenuity Systems®, www.ingenuity.com). 
Function  p-value Molecules 
Cell Cycle 9.61E-11-2.54E-04 
IL8, DPP4, MAPK1, MAPK3, MAPK8, IL6, NR3C1, ATF2, 
GNAS, MAPK14, ARRB1, DUSP1, CREB1, ADA, IL1B 
Inflammatory Disease 2.85E-10-2.4E-04 
IL8, DPP4, MAPK3, MAPK8, IL6, P2RX7, CD8A, NR3C1, 
ODC1, GNAI2, ARRB2, MAPK14, DUSP1, ADA, IL1B, 
SLC6A4, S100A10 
Cell Death 4.09E-10-2.49E-04 
DPP4, IL8, MAPK1, MAPK3, MAPK8, P2RX7, IL6, 
SLC18A2, CD8A, NR3C1, ODC1, ATF2, GNAS, ARRB2, 
MAPK14, DUSP1, CREB1, ADA, TSPO, IL1B, S100A10 
Cellular Growth and 
Proliferation 6.62E-09-2.54E-04 
DPP4, IL8, RGS2, MAPK1, MAPK3, MAPK8, P2RX7, IL6, 
CD8A, NR3C1, ODC1, ATF2, GNAI2, ARRB2, MAPK14, 
DUSP1, CREB1, ADA, IL1B, INDO, SLC6A4, NR3C2, 
S100A10 
Connective Tissue 
Disorders 6.9E-09-2.4E-04 
IL8, DPP4, MAPK3, MAPK8, IL6, P2RX7, NR3C1, ATF2, 
GNAI2, ARRB2, MAPK14, DUSP1, IL1B, SLC6A4, 
S100A10 
Skeletal and Muscular 
Disorders 6.9E-09-2.54E-04 
IL8, DPP4, MAPK1, MAPK3, MAPK8, IL6, P2RX7, NR3C1, 
GNAI2, GNAS, MAPK14, DUSP1, IL1B, SLC6A4, 
S100A10 
Cancer 8.17E-09-2.54E-04 
IL8, DPP4, MAPK1, MAPK3, MAPK8, P2RX7, IL6, CD8B, 
NR3C1, ODC1, ATF2, GNAI2, GNAS, ARRB2, MAPK14, 
ARRB1, DUSP1, CREB1, ADA, IL1B, NR3C2, S100A10 
Cellular Development 9.04E-09-2.54E-04 
DPP4, IL8, RGS2, MAPK1, MAPK3, MAPK8, IL6, P2RX7, 
CD8A, CD8B, NR3C1, ODC1, ATF2, ARRB2, MAPK14, 
DUSP1, CREB1, ADA, IL1B, S100A10 
Post-Translational 
Modification 1.25E-08-2.12E-04 
IL8, ARRB2, MAPK14, MAPK1, DUSP1, MAPK3, MAPK8, 
INDO, IL1B, IL6, CD8A, ODC1 
Cardiovascular Disease 1.43E-08-7.69E-05 
IL8, RGS2, MAPK1, MAPK3, MAPK8, IL6, SLC18A2, 
NR3C1, GNAI2, MAPK14, DUSP1, CREB1, IL1B, 
SLC6A4, NR3C2, S100A10 
Hematological System 
Development and 
Function 2.43E-08-2.37E-04 
IL8, DPP4, RGS2, MAPK1, MAPK3, MAPK8, P2RX7, IL6, 
CD8A, NR3C1, CD8B, GNAI2, GNAS, ARRB2, MAPK14, 
DUSP1, CREB1, ADA, IL1B, INDO 
Immunological Disease 3.83E-08-8.42E-05 
IL8, DPP4, MAPK3, MAPK8, P2RX7, IL6, CD8A, NR3C1, 
GNAS, MAPK14, DUSP1, ADA, IL1B, SLC6A4, S100A10 
Gene Expression 6.32E-08-1.49E-04 
IL8, MAPK1, MAPK3, MAPK8, IL6, NR3C1, ATF2, GNAS, 
ARRB2, ARRB1, MAPK14, DUSP1, CREB1, IL1B, NR3C2 
Hematological Disease 6.39E-08-1.43E-04 
DPP4, GNAS, IL8, MAPK14, MAPK8, ADA, IL1B, P2RX7, 
IL6, NR3C1 
Developmental Disorder 6.6E-08-4.29E-06 
GNAI2, DPP4, MAPK14, MAPK1, DUSP1, CREB1, 
MAPK8, ADA, IL1B, NR3C2, IL6, S100A10 
Organ Morphology 6.6E-08-2.17E-04 
GNAI2, GNAS, MAPK14, DUSP1, CREB1, MAPK8, IL1B, 
NR3C2, IL6, NR3C1 
Behavior 1.1E-07-1.49E-04 
RGS2, MAPK1, MAPK3, IL6, SLC18A2, NR3C1, GNAI2, 
ARRB2, ARRB1, CREB1, IL1B, SLC6A4, NR3C2 
Neurological Disease 1.9E-07-2.54E-04 
IL8, DPP4, MAPK8, IL6, P2RX7, SLC18A2, NR3C1, ATF2, 
PREP, GNAS, MAPK14, CREB1, ADA, TSPO, IL1B, 
SLC6A4 
Lipid Metabolism 2.63E-07-7.11E-05 
IL8, RGS2, MAPK1, MAPK8, P2RX7, IL6, NR3C1, GNAI2, 
GNAS, ARRB2, ARRB1, MAPK14, ADA, SLC6A4, IL1B, 
S100A10 
Molecular Transport 2.63E-07-2.54E-04 
IL8, RGS2, MAPK1, MAPK8, IL6, P2RX7, CD8A, 
SLC18A2, NR3C1, GNAI2, GNAS, ARRB2, MAPK14, 
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ARRB1, ADA, SLC6A4, IL1B, NR3C2, S100A10 
Small Molecule 
Biochemistry 2.63E-07-2.12E-04 
IL8, RGS2, MAPK1, MAPK3, MAPK8, IL6, P2RX7, 
SLC18A2, NR3C1, GNAI2, GNAS, ARRB2, ARRB1, 
MAPK14, DUSP1, ADA, INDO, SLC6A4, IL1B, S100A10 
DNA Replication, 
Recombination, and 
Repair 2.66E-07-2.54E-04 
GNAI2, IL8, ARRB2, ARRB1, DUSP1, MAPK8, ADA, IL1B, 
IL6, NR3C1 
Organismal Survival 5.66E-07-7.55E-07 
GNAI2, GNAS, DUSP1, CREB1, MAPK8, ADA, IL1B, 
NR3C2, IL6, SLC18A2, CD8A, NR3C1 
Metabolic Disease 6.12E-07-2.54E-04 
DPP4, GNAS, DUSP1, CREB1, ADA, SLC6A4, IL1B, 
NR3C2, IL6, NR3C1, S100A10 
Amino Acid Metabolism 6.25E-07-2.12E-04 MAPK14, MAPK1, DUSP1, MAPK3, MAPK8, INDO, IL6 
Connective Tissue 
Development and 
Function 1.01E-06-1.49E-04 
IL8, RGS2, ARRB2, MAPK14, MAPK1, MAPK3, CREB1, 
MAPK8, SLC6A4, IL1B, IL6, NR3C1 
Tissue Morphology 1.31E-06-2.02E-04 
IL8, MAPK3, IL6, P2RX7, NR3C1, ATF2, GNAI2, GNAS, 
MAPK14, CREB1, ADA, IL1B, SLC6A4, NR3C2 
Reproductive System 
Disease 1.32E-06-1.67E-04 
IL8, MAPK1, MAPK3, MAPK8, IL6, ODC1, ATF2, ARRB2, 
MAPK14, ARRB1, DUSP1, IL1B, S100A10 
Cellular Movement 1.57E-06-2.19E-04 
IL8, DPP4, MAPK1, MAPK3, MAPK8, IL6, CD8A, ODC1, 
GNAI2, GNAS, ARRB2, MAPK14, ARRB1, DUSP1, IL1B, 
S100A10 
Immune Response 1.57E-06-2.23E-04 
IL8, DPP4, RGS2, MAPK3, MAPK8, IL6, CD8A, NR3C1, 
GNAI2, GNAS, ARRB2, MAPK14, DUSP1, ADA, IL1B, 
INDO 
Psychological Disorders 2.03E-06-1.43E-04 RGS2, CREB1, IL1B, TSPO, SLC6A4 
Cell-To-Cell Signaling 
and Interaction 2.95E-06-2.54E-04 
GNAI2, GNAS, IL8, ARRB2, MAPK8, ADA, SLC6A4, IL1B, 
IL6, CD8A 
Immune and Lymphatic 
System Development 
and Function 2.95E-06-2.37E-04 
IL8, DPP4, RGS2, MAPK1, MAPK3, MAPK8, P2RX7, IL6, 
CD8A, NR3C1, CD8B, MAPK14, CREB1, ADA, IL1B, 
INDO 
Nutritional Disease 3.24E-06-4.82E-05 DPP4, MAPK8, SLC6A4, IL1B, NR3C2, IL6, NR3C1 
Organismal Functions 3.92E-06-2.09E-04 ARRB2, SLC6A4, IL1B, SLC18A2, NR3C1 
Endocrine System 
Disorders 7.15E-06-1.98E-04 
DPP4, GNAS, IL8, DUSP1, CREB1, IL1B, NR3C2, IL6, 
NR3C1, S100A10 
Endocrine System 
Development and 
Function 7.27E-06-1.98E-04 SLC6A4, IL1B, IL6, NR3C1 
Nervous System 
Development and 
Function 9.34E-06-2.08E-04 MAPK1, CREB1, SLC6A4, IL1B, IL6, ATF2 
Cell Signaling 1.09E-05-2.09E-04 
IL8, RGS2, MAPK1, MAPK3, MAPK8, P2RX7, IL6, CD8A, 
SLC18A2, ATF2, GNAI2, GNAS, ARRB2, ARRB1, 
MAPK14, ADA, IL1B, SLC6A4 
Nucleic Acid Metabolism 1.09E-05-2.09E-04 
GNAI2, GNAS, RGS2, ARRB2, ARRB1, ADA, IL1B, 
SLC6A4, SLC18A2 
Hepatic System 
Development and 
Function 1.18E-05-4E-05 MAPK1, MAPK8, IL1B, IL6 
Organismal Injury and 
Abnormalities 1.47E-05-1.12E-04 GNAS, IL8, DUSP1, MAPK8, SLC6A4, IL1B, P2RX7, IL6 
Hair and Skin 
Development and 
Function 1.81E-05-1.8E-04 IL8, MAPK8, IL6, NR3C1 
Dermatological Diseases 
and Conditions 1.83E-05-1.83E-05 GNAI2, IL8, DUSP1, IL1B, IL6, NR3C1, ODC1, ATF2 
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Cellular Compromise 2.14E-05-2.48E-04 CREB1, IL1B, IL6, ATF2 
Protein Trafficking 2.14E-05-2.14E-05 MAPK1, MAPK3 
Cell Morphology 2.18E-05-1.62E-04 
IL8, RGS2, ARRB2, MAPK14, MAPK1, MAPK3, CREB1, 
ADA, P2RX7, IL6, ODC1 
Carbohydrate 
Metabolism 2.51E-05-2.54E-04 GNAS, IL8, IL1B, IL6, P2RX7 
Gastrointestinal Disease 2.51E-05-2.51E-05 DUSP1, MAPK8, P2RX7, IL6 
Hepatic System Disease 2.51E-05-2.54E-04 IL8, DUSP1, MAPK8, IL1B, P2RX7, IL6 
Respiratory Disease 2.92E-05-4E-05 ADA, IL1B, IL6, CD8A, NR3C1 
Skeletal and Muscular 
System Development 
and Function 3.01E-05-1.98E-04 IL8, MAPK1, DUSP1, IL1B, IL6 
Cardiovascular System 
Development and 
Function 3.09E-05-3.09E-05 IL8, SLC6A4, IL1B 
Organismal 
Development 4.52E-05-4.52E-05 IL8, SLC6A4, IL1B 
Cellular Assembly and 
Organization 5.67E-05-1.62E-04 GNAI2, IL8, MAPK1, CREB1, SLC6A4, IL1B, IL6 
Renal and Urological 
Disease 7.11E-05-2.54E-04 MAPK1, MAPK8 
Embryonic Development 1E-04-1E-04 MAPK14, MAPK1, MAPK8, IL6 
Cellular Function and 
Maintenance 1.49E-04-1.49E-04 SLC6A4, IL1B 
Viral Function 1.8E-04-2.54E-04 IL8, IL1B, IL6 
Vitamin and Mineral 
Metabolism 1.95E-04-1.95E-04 IL8, IL1B, P2RX7, IL6, CD8A 
Genetic Disorder 1.98E-04-2.54E-04 GNAS, NR3C2, NR3C1 
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Appendix 3: Significant pathways involving the 29 genes 
 
Below the significant (below 1%) pathways are shown for various combinations of the 29 
genes. For the difference between the statistical significance (p-value) and ratio, see text after 
the table. Output from Ingenuity (Ingenuity Systems®, www.ingenuity.com). 
Pathway  -log(p-value) Ratio Molecules 
Glucocorticoid Receptor 
Signaling 
1.11E+01 4.15E-02 IL8, MAPK14, MAPK1, DUSP1, MAPK3, 
CREB1, MAPK8, IL1B, NR3C2, IL6, 
NR3C1 
IL-6 Signaling 8.67E+00 7.69E-02 IL8, MAPK14, MAPK1, MAPK3, MAPK8, 
IL1B, IL6 
cAMP-mediated 
Signaling 
8.46E+00 5.03E-02 GNAI2, GNAS, RGS2, MAPK1, DUSP1, 
MAPK3, CREB1, ATF2 
G-Protein Coupled 
Receptor Signaling 
7.69E+00 4.02E-02 GNAI2, GNAS, RGS2, MAPK1, DUSP1, 
MAPK3, CREB1, ATF2 
FGF Signaling 7.28E+00 7.14E-02 MAPK14, MAPK1, MAPK3, CREB1, 
MAPK8, ATF2 
PPARα /RXRα 
Activation 
6.73E+00 3.98E-02 GNAS, MAPK14, MAPK1, MAPK3, MAPK8, 
IL1B, IL6 
Acute Phase Response 
Signaling 
6.73E+00 4.07E-02 MAPK14, MAPK1, MAPK3, MAPK8, IL1B, 
IL6, NR3C1 
Neurotrophin/TRK 
Signaling 
6.22E+00 6.85E-02 MAPK1, MAPK3, CREB1, MAPK8, ATF2 
Ephrin Receptor 
Signaling 
6.00E+00 3.02E-02 GNAI2, GNAS, MAPK1, MAPK3, CREB1, 
MAPK8, ATF2 
Chemokine Signaling 5.92E+00 6.67E-02 GNAI2, MAPK14, MAPK1, MAPK3, MAPK8 
B Cell Receptor 
Signaling 
5.84E+00 4.05E-02 MAPK14, MAPK1, MAPK3, CREB1, 
MAPK8, ATF2 
p38 MAPK Signaling 5.39E+00 5.26E-02 MAPK14, DUSP1, CREB1, IL1B, ATF2 
T Cell Receptor 
Signaling 
5.36E+00 4.90E-02 MAPK1, MAPK3, MAPK8, CD8A, CD8B 
IL-10 Signaling 4.80E+00 5.88E-02 MAPK14, MAPK8, IL1B, IL6 
ERK/MAPK Signaling 4.75E+00 2.65E-02 MAPK1, DUSP1, MAPK3, CREB1, MAPK8, 
ATF2 
Aryl Hydrocarbon 
Receptor Signaling 
4.55E+00 3.29E-02 MAPK1, MAPK3, MAPK8, IL1B, IL6 
Xenobiotic Metabolism 
Signaling 
4.49E+00 2.40E-02 MAPK14, MAPK1, MAPK3, MAPK8, IL1B, 
IL6 
Fc Epsilon RI Signaling 3.96E+00 4.00E-02 MAPK14, MAPK1, MAPK3, MAPK8 
Synaptic Long Term 
Potentiation 
3.82E+00 3.60E-02 MAPK1, MAPK3, CREB1, ATF2 
EGF Signaling 3.68E+00 6.38E-02 MAPK1, MAPK3, MAPK8 
IL-2 Signaling 3.49E+00 5.66E-02 MAPK1, MAPK3, MAPK8 
Amyloid Processing 3.46E+00 5.77E-02 MAPK14, MAPK1, MAPK3 
Synaptic Long Term 
Depression 
3.41E+00 2.45E-02 GNAI2, GNAS, MAPK1, MAPK3 
Hepatic Cholestasis 3.41E+00 2.47E-02 IL8, MAPK8, IL1B, IL6 
SAPK/JNK Signaling 3.27E+00 2.72E-02 MAPK1, MAPK3, MAPK8, ATF2 
Parkinson's Signaling 3.13E+00 1.18E-01 MAPK14, MAPK8 
PDGF Signaling 3.09E+00 4.05E-02 MAPK1, MAPK3, MAPK8 
Calcium Signaling 3.02E+00 1.96E-02 MAPK1, MAPK3, CREB1, ATF2 
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NRF2-mediated 
Oxidative Stress 
Response 
2.96E+00 2.22E-02 MAPK14, MAPK1, MAPK3, MAPK8 
TGF-β Signaling 2.94E+00 3.61E-02 MAPK1, MAPK3, MAPK8 
Nicotinate and 
Nicotinamide 
Metabolism 
2.90E+00 2.33E-02 MAPK1, MAPK3, MAPK8 
PPAR Signaling 2.83E+00 3.16E-02 MAPK1, MAPK3, IL1B 
IGF-1 Signaling 2.83E+00 3.26E-02 MAPK1, MAPK3, MAPK8 
Estrogen Receptor 
Signaling 
2.61E+00 2.54E-02 MAPK1, MAPK3, NR3C1 
Circadian Rhythm 
Signaling 
2.59E+00 6.25E-02 CREB1, ATF2 
Serotonin Receptor 
Signaling 
2.50E+00 4.35E-02 SLC6A4, SLC18A2 
Hepatic Fibrosis / 
Hepatic Stellate Cell 
Activation 
2.39E+00 2.29E-02 IL8, IL1B, IL6 
Insulin Receptor 
Signaling 
2.38E+00 2.26E-02 MAPK1, MAPK3, MAPK8 
Inositol Phosphate 
Metabolism 
2.38E+00 1.73E-02 MAPK1, MAPK3, MAPK8 
Apoptosis Signaling 2.30E+00 2.21E-02 MAPK1, MAPK3, MAPK8 
Toll-like Receptor 
Signaling 
2.18E+00 3.92E-02 MAPK14, MAPK8 
PI3K/AKT Signaling 2.08E+00 1.70E-02 MAPK1, MAPK3, MAPK8 
 
The ratio is calculated by taking the number of genes from the 29 gene set 
that participate in a pathway, and dividing it by the total number of Ingenuity 
genes in that pathway. The ratio indicates the percentage of genes in a 
pathway that were also found in the 29 gene list. The ratio is therefore useful 
for determining which pathways overlap the most with the 29 genes. 
  
The p-value measures how likely the observed association between a specific 
pathway and a certain combination of the 29 genes would be if it was only due 
to random chance. If a p-value is very small one can be confident that the 
corresponding pathway is significantly associated with the 29 genes.  
 
The ratio indicates the strength of the association, whereas the p-value 
measures its statistical significance.  
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Appendix 4: The US ABS questionnaire 
 
Official Use ONLY 
Identification number:   __  __  __  __  __  __ 
To be used for blood sample labeling  
 
Today’s Date (mm/dd/yy) __  __ / __  __ / __  __ 
Time of blood collection  __  __ : __  __ am / pm (circle one) 
 
IT IS IMPORTANT THAT YOU COMPLETE THE ENTIRE QUESTIONNAIRE  
(ALL THE INFORMATION WILL REMAIN ANONYMOUS!) 
THANK YOU FOR YOUR TIME AND COOPERATION. 
 
 
Age:   __  __    
Month  / year of birth (mm/yy): __  __ / __  __ 
 
Gender:  
 Male  
 Female 
 
Weight:   __  __  __ lbs. 
Height:    __  __ ft.   __  __ inches 
 
Race or Ethnic Background:  
 Native American / American Indian 
 African American / Black 
 White / Caucasian 
 Asian (including Native Hawaiian/Other Pacific Islander) 
 Hispanic 
 If none of the above categories apply, please specify your race or ethnic 
background________________________________________. 
 
Marital Status: (CHECK ONLY ONE) 
 Never married/single 
 Never married, live with partner 
 Married, live with spouse 
 Separated 
 Divorced 
 Widowed 
 
Employment Status: (CHECK ONLY ONE) 
 Unemployed 
 Full-time employee 
 Part-time employee 
 Homemaker, stay at home parent 
 Self-employed 
 Retired 
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Current Occupation: (CHECK THE ONE MOST APPROPRIATE) 
 Manual worker 
 Clerical 
 Skilled /Craftsman (e.g. Carpenter, Construction Worker)   
 Skilled / Office Worker 
 Manager 
 Professional 
 
Tobacco use: (CHECK ALL THAT APPLY) 
 Cigarettes 
 Cigar 
 Pipe 
 Chewing tobacco 
 
Frequency of your tobacco use: (CHECK THE ONE MOST APPROPRIATE) 
 None ever 
 None, past 12 months 
 Less than 1 per week 
 1 to 10 per day 
 10 to 20 per day 
 Greater than 20 per day 
 
Frequency of your alcohol use: (CHECK THE ONE MOST APPROPRIATE) 
 None ever 
 None, past 12 months 
 Less than 1 drink per week 
 Less than 1 drink per day 
 1 to 5 drinks per day  
 6 to 10 drinks per day 
 More than 10 drinks per day 
 
Amount of your caffeine intake (including coffee, tea, caffeinated soda):  
(CHECK THE ONE MOST APPROPRIATE) 
 None ever 
 None, past 12 months 
 Less than 1 cup per week 
 Less than 1 cup per day 
 1 to 2 cups per day  
 2 to 5 cups per day 
 Greater than 5 cups per day 
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What type of drugs have you taken at ANY time in your life? (CHECK ALL THAT 
APPLY) 
 Tranquilizers, sleeping pills 
 Antidepressants 
 Anxiolytics 
 Pain killers 
 Anti-migraine drugs 
 Anti-inflammatory drugs (e.g. aspirin, ibuprofen, acetaminophen…) 
 Drugs against allergies 
 Statins (cholesterol-lowering drugs) 
 Drugs to treat high/low blood pressure  
 Drugs to treat diabetes 
 Drugs to treat thyroid disease 
 Marijuana / Cannabis (grass, pot, weed, bud, Mary Jane, dope, indo, hydro) 
 Amphetamine / Methamphetamine type stimulants (speed, goey, whizz, uppers, 
ice, glass, crystal meth Meth, poor man's cocaine)  
 Cocaine (blow, nose candy, snowball, tornado, wicky stick, crack, rock) 
 Ecstasy (E, Adam, XTC, eccies, the love drug, the hug drug, go, X) 
 GHB (Liquid Ecstasy, Scoop, Easy Lay, Georgia Home Boy, Grievous Bodily Harm, 
Liquid X, and Goop) 
 LSD / Hallucinogens (PCP, acid, trips, blotters, mellow, tabs) 
 Inhalants (glue, solvents, aerosols) 
 Methaqualone (Disco Biscuits, Lemmon 714, Lennons, Lovers, Ludes, Mandies, 
Mandrake, Q, Quaalude, Qualudes, Soaper, Vitamin Q)  
 Heroin/morphine (smack, thunder, hell dust, big H, nose drops) 
 OxyContin  (Hillbilly heroin, Oxy, Oxycotton) 
 Ketamine  (jet, super acid, Special "K", green, K, cat Valium) 
 Steroids (e.g. Prednisone, Dexamethasone, Anadrol, Oxandrin, Dianobol, 
Winstrol, Durabolin, Depo-Testosterone, Equipoise, other) 
 
If you have taken drugs that are not listed above, please list them below: 
 __________________________________________ 
__________________________________________ 
__________________________________________ 
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What type of drugs have you taken DURING THE LAST 3 MONTHS?  
(CHECK ALL THAT APPLY)  
 Tranquilizers, sleeping pills 
 Antidepressants 
 Anxiolytics 
 Pain killers 
 Anti-migraine drugs 
 Anti-inflammatory drugs (e.g. aspirin, ibuprofen, acetaminophen…) 
 Drugs against allergies 
 Statins (cholesterol-lowering drugs) 
 Drugs to treat high/low blood pressure 
 Drugs to treat diabetes 
 Drugs to treat thyroid disease  
 Weight control pills 
 Antibiotics 
 Vitamins 
 Marijuana/Cannabis (grass, pot, weed, bud, Mary Jane, dope, indo, hydro) 
 Amphetamine / Methamphetamine type stimulants (speed, goey, whizz, uppers, 
ice, glass, crystal meth Meth, poor man's cocaine)  
 Cocaine (blow, nose candy, snowball, tornado, wicky stick, crack, rock) 
 Ecstasy (E, Adam, XTC, eccies, the love drug, the hug drug, go, X) 
 GHB (Liquid Ecstasy, Scoop, Easy Lay, Georgia Home Boy, Grievous Bodily Harm, 
Liquid X, and Goop) 
 LSD / Hallucinogens (PCP, acid, trips, blotters, mellow, tabs) 
 Inhalants (glue, solvents, aerosols) 
 Methaqualone (Disco Biscuits, Lemmon 714, Lennons, Lovers, Ludes, Mandies, 
Mandrake, Q, Quaalude, Qualudes, Soaper, Vitamin Q) 
 Heroin/morphine (smack, thunder, hell dust, big H, nose drops) 
 OxyContin  (Hillbilly heroin, Oxy, Oxycotton) 
 Ketamine  (jet, super acid, Special "K", green, K, cat Valium) 
 Steroids (e.g. Prednisone, Dexamethasone, Anadrol, Oxandrin, Dianobol, 
Winstrol, Durabolin, Depo-Testosterone, Equipoise, other) 
 
If you have taken drugs that were not listed above, please list them below: 
__________________________________________ 
__________________________________________ 
__________________________________________ 
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Please answer the following questions regarding your general medical history 
Indicate all that you EVER experienced in your life: (CHECK ALL THAT APPLY)  
 Chronic Pain 
 Chronic inflammation (Ulcerative colitis, Crohn’s disease, Rheumatiod arthritis)  
 Cardiovascular disorder 
 Diabetes 
 Regular Headaches, migraines 
 Sexually transmitted diseases (e.g. clamydia, gonorrhea, HPV, HIV, Syphilis, 
Genital Herpes) 
 Other chronic infections 
 Allergies 
 Chronic gastric problems 
 Tumors/Cancer, specify 
__________________________________________ 
__________________________________________ 
 
 Other, please specify 
__________________________________________ 
__________________________________________ 
__________________________________________ 
                    
Current medical problems:  Indicate all that you are CURRENTLY experiencing or 
being treated for: (CHECK ALL THAT APPLY) 
 Chronic Pain 
 Chronic inflammation (Ulcerative colitis, Crohn’s disease, Rheumatoid arthritis)  
 Cardiovascular disorder 
 Diabetes 
 Gastric problems 
 Headaches, migraines 
 Sexually transmitted diseases (e.g. clamydia, gonorrhea, HPV, HIV, Syphilis, 
Genital Herpes) 
 Other chronic infections  
 Allergies 
 Tumors/Cancer, specify 
 Other, please specify 
__________________________________________ 
__________________________________________ 
__________________________________________ 
 
Have you ever been hospitalized? 
 No 
 Yes 
 
If yes, how often in last 12 months, please provide reason(s) 
__________________________________________ 
__________________________________________ 
__________________________________________ 
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Have you ever had surgery? 
 No 
 Yes 
 
If yes, please provide reason(s) and year the surgery took place 
___________________________________________  / ___________ (yy) 
___________________________________________  / ___________ (yy) 
___________________________________________  / ___________ (yy) 
___________________________________________  / ___________ (yy) 
___________________________________________  / ___________ (yy) 
 
 
When did you last see a doctor? (CHECK ONE) 
 In last 4 weeks 
 In last 6 months 
 In last year 
 In last 5 years 
 In last 10 years 
 More than 10 years ago 
 Never 
 
 
 
Indicate if you have experienced any of the following during the LAST 2 WEEKS and 
the frequency in which you experienced it: 
 Feeling low: 
 Every day  Most days  Sometimes  Never 
 
 Lack of energy: 
 Every day  Most days  Sometimes  Never 
 
 Less interest in things or unable to enjoy things you used to enjoy: 
 Every day  Most days  Sometimes  Never 
 
 Difficulties concentrating: 
 Every day  Most days  Sometimes  Never 
 
 Sleep problems, e.g. problems falling asleep, problems staying asleep, 
early morning awakening:  
  Every day  Most days  Sometimes  Never 
 
 Anxiety: 
  Every day  Most days  Sometimes  Never 
 
 Cannot cope with daily problems, suicide considered:  
  Every day  Most days  Sometimes  Never 
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Indicate if you have experienced changes in any of the following and the level of 
change: 
 Appetite:  
 Increased   Decreased    Unchanged 
  Decreased (unintentionally) 
 
 Weight:  
 Increased   Decreased    Unchanged 
 Decreased (unintentionally) 
 
 Sexual Interest:  
 Increased   Decreased    Unchanged 
 
Have you EVER experienced ANY of the following? (CHECK ALL THAT APPLY) 
 Severe depression, severe mania 
 Panic attacks 
 Severe anxiety 
 Severe obsessive or compulsive thoughts 
 Alcohol abuse 
 Substance abuse other than alcohol 
 Psychotic episodes 
 
Have you EVER been treated for ANY of the following? (CHECK ALL THAT APPLY) 
 Depression, Mania 
 Panic attacks 
 Anxiety disorder 
 Obsessive-compulsive disorder 
 Alcohol abuse 
 Substance abuse other than alcohol 
 Psychotic episodes 
 
 
Has anyone in your family EVER experienced or been treated for one of the following 
disorder(s)? (PLEASE CHECK ALL THAT APPLY, THEN SELECT WHICH MEMBER OF THE 
FAMILY EXPERIENCED OR WAS TREATED FOR THE DISORDER). 
 
 Depression:  
 Mother  Daughter  Sister 
 Father  Son   Brother 
 Grandmother  Aunt   Granddaughter 
 Grandfather  Uncle   Grandson 
 
 Anxiety: 
 Mother  Daughter  Sister 
 Father  Son   Brother 
 Grandmother  Aunt   Granddaughter 
 Grandfather  Uncle   Grandson 
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 Alcohol abuse: 
 Mother  Daughter  Sister 
 Father  Son   Brother 
 Grandmother  Aunt   Granddaughter 
 Grandfather  Uncle   Grandson 
 
 Other substance abuse: 
 Mother  Daughter  Sister 
 Father  Son   Brother 
 Grandmother  Aunt   Granddaughter 
 Grandfather  Uncle   Grandson 
 
 Schizophrenia/psychosis: 
 Mother  Daughter  Sister 
 Father  Son   Brother 
 Grandmother  Aunt   Granddaughter 
 Grandfather  Uncle   Grandson 
 
 Suicide: 
 Mother  Daughter  Sister 
 Father  Son   Brother 
 Grandmother  Aunt   Granddaughter 
 Grandfather  Uncle   Grandson 
 
 Dementia: 
 Mother  Daughter  Sister 
 Father  Son   Brother 
 Grandmother  Aunt   Granddaughter 
 Grandfather  Uncle   Grandson 
 
Has anyone in your family EVER experienced or been treated for one of the following 
disorder(s)?  (PLEASE CHECK ALL THAT APPLY, THEN SELECT WHICH MEMBER OF 
THE FAMILY EXPERIENCED OR WAS TREATED FOR THE DISORDER). 
 
 Amyotrophic Lateral Sclerosis: 
 Mother  Daughter  Sister 
 Father  Son   Brother 
 
 Parkinson’s disease:  
 Mother  Daughter  Sister 
 Father  Son   Brother 
 
 Multiple Sclerosis: 
 Mother  Daughter  Sister 
 Father  Son   Brother 
 
 Huntington's Chorea: 
 Mother  Daughter  Sister 
 Father  Son   Brother 
 
183
Appendices 
 
Indicate your exercise frequency and duration: 
 Daily 
 Less than 30 min   30 min to 1 hour   Greater than 1 hour 
 
 2-3 x/week  
 Less than 30 min   30 min to 1 hour   Greater than 1 hour 
 
 Once per week  
 Less than 30 min   30 min to 1 hour   Greater than 1 hour 
 
 Once per month  
 Less than 30 min   30 min to 1 hour   Greater than 1 hour 
 Never 
 
Please indicate your normal daily rhythm: (CHECK THE MOST APPROPRIATE) 
 Rotating/split shift worker  
 Normal bedtime after midnight 
 Normal bedtime before midnight 
 
Prior or current stressful live events can influence some blood parameters.  Please 
Indicate if any of the following events happened in your life BEFORE AGE 15. (CHECK 
ALL THAT APPLY) 
 Death of both parents 
 Death of one parent 
 Divorce of parents 
 Death of a close family member 
 Major personal injury or illness (e.g. cancer) 
 Death of a close friend  
 Gain of new family member (e.g. new sibling) 
 Major change in health or behavior of a close family member 
 Major change in finances 
 Major change in living conditions (e.g. change in residence, schools) 
 
 
Indicate if any of the following events happened in the LAST 12 MONTHS.  
(CHECK ALL THAT APPLY) 
 Death of spouse/partner 
 Divorce 
 Death of a close family member 
 Marital separation/separation from partner 
 Fired from work 
 Major personal injury or illness 
 Jail term 
 Death of a close friend 
 Pregnancy (including miscarriage or abortion) 
 Gain of a new family member (e.g. birth of a child) 
 Major change in health or behavior of a close family member 
 Major change in finances 
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 Retirement 
 Change to a different line of work 
 Marriage 
 Child leaving home 
 Major change in living conditions (e.g. change in residence) 
 Outstanding personal achievement 
 Minor violations of the law 
 
 
Please provide the time of your last 3 meals:  
__  __: __  __ am / pm (circle one) 
__  __: __  __ am / pm (circle one) 
__  __: __  __ am / pm (circle one) 
 
 
 
 
FOR WOMEN ONLY  
 
 
Are your menstrual cycles: (CHECK ONE) 
 Regular?   
 Irregular?  
 
Date of your last menstrual period: _____/_____  (dd/mm) 
 
Are your currently pregnant? (CHECK ONE)  
 Yes       
 No 
 
Indicate the number of past pregnancies: (CHECK ONE) 
 1  
 2 
 3  
 4  
 5  
 Greater than 5 
 
Did you give birth in the past year? (CHECK ONE) 
 Yes   
 No 
 
Are you currently breastfeeding? (CHECK ONE)  
 Yes 
 No  
 
 
 
Thank you for your cooperation! 
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Appendix 5: Coding table with clinical variables and covariates 
 
The table lists the coding of clinical variables and covariates from the US ABS 
questionnaire. The same coding was applied to the first cohort of borderline 
disorder patients.  
 
 Scoring questionnaire variables for ABS and borderline samples 
Variable Score Comment 
age as reported on questionnaire   
gender as reported on questionnaire   
BMI calculated from height and 
weight 
  
alcohol 
quantity 
score 
< 1 drink per day = 0, > 1 drink 
per day = 1 
  
tobacco 
frequency 
score 
< 1 per week = 0,  > 1 per day 
= 1 
  
feeling low 
score 
never = 0, sometimes = 1, most 
days = 2, every day = 3 
  
enjoyment 
score 
never = 0, sometimes = 1, most 
days = 2, every day = 3 
  
sleep 
problems 
score 
never = 0, sometimes = 1, most 
days = 2, every day = 3 
  
anxiety score never = 0, sometimes = 1, most 
days = 2, every day = 3 
  
concentration 
score 
never = 0, sometimes = 1, most 
days = 2, every day = 3 
  
sexual 
interest score 
unchanged  = 0, increased = 2, 
decreased = 3 
  
energy score never = 0, sometimes = 1, most 
days = 2, every day = 3 
  
coping score never = 0, sometimes = 1, most 
days = 2, every day = 3 
  
appetite 
change score 
unchanged  = 0, decreased = 0, 
increased = 2, decreased 
unintentionally = 3 
people that change eating habits on purpose need to 
be scored differently than people who change 
unintentionally. 
weight 
change score 
unchanged  = 0, decreased = 0, 
increased = 2, decreased 
unintentionally = 3 
people who lose weight on purpose need to be 
scored differently than people who lose weight 
unintentionally. 
Lifetime 
treatment 
no personal treatments for 
depression or anxiety = 0, any 
treatments = 1 
mostly depression/anxiety but also includes some 
alcohol or substance abuse. 
Lifetime drug 
use  
no drugs or only prescription 
drug use  = 0, use of any drugs 
of abuse = 1 
on the questionnaire the "drugs of abuse" start with 
marijuana and end with ketamine 
3 month 
drugs 
no drugs or "harmless" drugs  = 
0, prescription drugs only = 1, 
drugs of abuse = 2 
"harmless" drugs are allergy meds, weight pills, 
vitamins, NSAID, antibiotics, prescription drugs are 
antidepressants, pain killers, diabetes drugs, etc 
Appendices 
Lifetime 
experiences 
no personal episodes of 
depression , anxiety, panic = 0, 
any episodes = 1 
mostly depression/anxiety but also includes some 
alcohol or substance abuse. 
Early life 
stress score 
sum of boxes checked for 
stressful events before the age 
of 15. The top item (death of 
both parents) has a value of 20 
and the bottom item in the list 
(major change in living 
conditions) has a value of 11. 
also called ELS in tables, scoring adapted from the 
literature (105). 
Recent stress 
score 
sum of boxes checked for 
stressful events experienced in 
the past 12 months. The top 
item in the list (death of spouse) 
has a value of 20 and the 
bottom item in the list (minor 
violations of the law) has a value 
of 2. 
also called RS in tables, scoring adapted from the 
literature (105). 
Symptom 
score sum 
sum of scores for 10 symptoms 
(feeling low, energy, interest, 
concentration, sleep problems, 
anxiety, coping, appetite 
change, weight change, sex 
interest 
lowest score is 0 and highest possible is 30, 
sometimes we also created a 7 symptom score which 
does NOT include appetite, weight and sex. 
Depression / 
Anxiety / 
suicide            
(family 
history) 
no relatives with any disease = 
0, any secondary relative with 
any of the diseases = 1, any 
primary relative with any of the 
diseases = 2 
Secondary relative is uncle, aunt, grandparent, 
grandchild; primary relatives are mother, father, 
children, sibling; there is no consideration for the 
number of relatives affected. 
alcohol abuse 
(family) 
no relatives with any disease = 
0, any secondary relative with 
any of the diseases = 1, any 
primary relative with any of the 
diseases = 2 
sometimes we combine alcohol and substance abuse 
together but the scoring is the same method 
schizophrenia 
/ psychosis 
(family) 
no relatives with any disease = 
0, any secondary relative with 
any of the diseases = 1, any 
primary relative with any of the 
diseases = 2 
  
Substance 
abuse 
(family) 
no relatives with any disease = 
0, any secondary relative with 
any of the diseases = 1, any 
primary relative with any of the 
diseases = 2 
sometimes we combine alcohol and substance abuse 
together but the scoring is the same method 
vegetative 
symptom 
score 
0 = no symptoms, 1 = some 
symptoms, 2 = more symptoms, 
3 = most symptoms 
this score combines three symptoms often 
associated with melancholic depression (weight loss, 
appetite loss, and sleep problems). The scoring is 
shown below. 
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 Scoring mechanism: 
 
1) score the "Weight change" category as follows: 
unchanged = 0 
increased = 1 
decreased unintent = -1 
decreased intent = 1 
 
2) score the "appetite change" category as follows: 
unchanged = 0 
increased = 1 
decreased unintent = -1 
decreased intent = 1 
 
3) sum these two scores then convert as follows: 
all zeros stay zero 
all positive values become zero 
all negative values switch sign 
 
4) score the "sleep problems" category as follows: 
never = 0 
all others = 1 
 
5) add the values for steps 3 and 4 
(the range is zero to 3) 
(basically looking for weight loss, appetite loss, and 
sleep disturbances) 
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Appendix 6: Simulation study – phase 1 tasks 
 
Below are tables showing the various tasks performed in phase 2 together with 
file names explained below. 
 
Run Gene file name Response file 
name 
Number of 
contributing 
variables 
Data 
size  
Correlation 
among 
explanatory 
variables 
Inclusion 
criteria 
Gene-
gene 
interaction 
1 Gene00100.csv Response1.csv 1 100 0 Threshold - 
2 Gene001000.csv Response2.csv 1 1000 0 Threshold - 
3 Gene00100.csv Response3.csv 1 100 0 Interval - 
4 Gene001000.csv Response4.csv 1 1000 0 Interval - 
5 Gene00100.csv Response5.csv 2 100 0 Threshold Sum 
6 Gene001000.csv Response6.csv 2 1000 0 Threshold Sum 
7 Gene00100.csv Response7.csv 2 100 0 Interval Sum 
8 Gene001000.csv Response8.csv 2 1000 0 Interval Sum 
9 Gene00100.csv Response9.csv 2 100 0 Threshold Product 
10 Gene001000.csv Response10.csv 2 1000 0 Threshold Product 
11 Gene00100.csv Response11.csv 2 100 0 Interval Product 
12 Gene001000.csv Response12.csv 2 1000 0 Interval Product 
13 Gene00100.csv Response13.csv 2 100 0 Threshold Ratio 
14 Gene001000.csv Response14.csv 2 1000 0 Threshold Ratio 
15 Gene00100.csv Response15.csv 2 100 0 Interval Ratio 
16 Gene001000.csv Response16.csv 2 1000 0 Interval Ratio 
17 Gene05100.csv Response17.csv 2 100 0.5 Threshold Sum 
18 Gene051000.csv Response18.csv 2 1000 0.5 Threshold Sum 
19 Gene05100.csv Response19.csv 2 100 0.5 Interval Sum 
20 Gene051000.csv Response20.csv 2 1000 0.5 Interval Sum 
21 Gene05100.csv Response21.csv 2 100 0.5 Threshold Product 
22 Gene051000.csv Response22.csv 2 1000 0.5 Threshold Product 
23 Gene05100.csv Response23.csv 2 100 0.5 Interval Product 
24 Gene051000.csv Response24csv 2 1000 0.5 Interval Product 
25 Gene05100.csv Response25.csv 2 100 0.5 Threshold Ratio 
26 Gene051000.csv Response26.csv 2 1000 0.5 Threshold Ratio 
27 Gene05100.csv Response27.csv 2 100 0.5 Interval Ratio 
28 Gene051000.csv Response28.csv 2 1000 0.5 Interval Ratio 
 
 
Separate Studies 
 
Different magnitudes of 2 contributing variables 
 
Run Gene file name Response file 
name 
Number of 
contributing 
variables 
Data 
size  
Special 
feature 
Inclusion 
Criteria 
Gene-
gene 
interaction 
7 Gene00100.csv Response7.csv 2 100 
21 XX ≈  Interval Sum 
30 Gene00100a.csv Response30.csv 2 100 
12 10 XX ⋅≈  Interval Sum 
31 Gene00100b.csv Response31.csv 2 100 
12 100 XX ⋅≈  Interval Sum 
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Fraction of data points being classified as Y = 1 
 
Run Gene file name Response file 
names  
Number 
of con. 
variables 
Data 
size  
Special 
feature 
Inclusion 
Criteria 
Gene-
gene 
interaction 
32 Genefrac05100.csv Response32.csv 1 100 05.0100
}0{# 1 =≥X
 
Threshold - 
33 Genefrac20100.csv Response33.csv 1 100 20.0100
}0{# 1 =≥X  Threshold - 
34 Genefrac50100.csv Response34.csv 1 100 50.0100
}0{# 1 =≥X  Threshold - 
35 Genefrac051000.csv Response35.csv 1 1000 05.01000
}0{# 1 =≥X
 
Threshold - 
36 Genefrac201000.csv Response36.csv 1 1000 20.01000
}0{# 1 =≥X  Threshold - 
37 Genefrac501000.csv Response37.csv 1 1000 50.01000
}0{# 1 =≥X  Threshold - 
 
 
2 populations with different mean values in gene no. 1 
 
Run Gene file 
name 
Response file 
names  
Number 
of con. 
variables 
Data 
size  
Inclusion Criteria Gene-gene 
interaction 
38 Mydif6.csv Response38.csv 1 100 
)1,3(~0
)1,3(~1
1
1
+=
−=
NXifY
NXifY
 
- 
39 Mydif4.csv Response38.csv 1 100 
)1,2(~0
)1,2(~1
1
1
+=
−=
NXifY
NXifY
 
- 
40 Mydif2.csv Response38.csv 1 100 
)1,1(~0
)1,1(~1
1
1
+=
−=
NXifY
NXifY
 
- 
41 Mydif1.csv Response38.csv 1 100 
)1,5.0(~0
)1,5.0(~1
1
1
+=
−=
NXifY
NXifY
 
- 
42 Mydif05.csv Response38.csv 1 100 
)1,25.0(~0
)1,25.0(~1
1
1
+=
−=
NXifY
NXifY
 
- 
 
 
 
Overview of gene files 
 
Gene file name Distribution 
Gene00100.csv ),0(~ 30 INX ; data points=100 
Gene001000.csv ),0(~ 30 INX ;data points=1000 
Gene05100.csv 5.0;1);,0(~ 30 ==Σ ijiiNX σσ ;  
data points=100 
Gene051000.csv 5.0;1);,0(~ 30 ==Σ ijiiNX σσ  
data points=1000 
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Gene00100a.csv 
.303)1,0(~
);1,10(~);1,1(~ 21
−=iforNX
NXNX
i
 
data points=100 
Gene00100b.csv 
.303)1,0(~
);1,100(~);1,1(~ 21
−=iforNX
NXNX
i
 
data points=100 
Genefrac05100.csv 100 data points: 
301);1,0(~ −=iNX i  
05.01001 =}0{# ≥X   
Genefrac20100.csv 100 data points:  
301);1,0(~ −=iNX i ; 
20.0100
}0{# 1 =≥X  
Genefrac50100.csv 100 data points: 
301);1,0(~ −=iNX i  
50.0100
}0{# 1 =≥X  
Genefrac051000.csv 1000 data points: 
301);1,0(~ −=iNX i  
05.01000
}0{# 1 =≥X   
Genefrac201000.csv 1000 data points:  
301);1,0(~ −=iNX i ; 
20.01000
}0{# 1 =≥X  
Genefrac501000.csv 1000 data points: 
301);1,0(~ −=iNX i  
50.01000
}0{# 1 =≥X  
Mydif6.csv 100 data points: 
302);1,0(~
10051);1,3(~
501);1,3(~
1
1
−=
−=+
−=−
iNX
jNX
jNX
i
j
j
 
Mydif4.csv 100 data points: 
302);1,0(~
10051);1,2(~
501);1,2(~
1
1
−=
−=+
−=−
iNX
jNX
jNX
i
j
j
 
Mydif2.csv 100 data points: 
302);1,0(~
10051);1,1(~
501);1,1(~
1
1
−=
−=+
−=−
iNX
jNX
jNX
i
j
j
 
Mydif1.csv 100 data points: 
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302);1,0(~
10051);1,5.0(~
501);1,5.0(~
1
1
−=
−=+
−=−
iNX
jNX
jNX
i
j
j
 
Mydif05.csv 100 data points: 
302);1,0(~
10051);1,25.0(~
501);1,25.0(~
1
1
−=
−=+
−=−
iNX
jNX
jNX
i
j
j
 
 
 
Overview of response files 
 
Response file name Inclusion criteria 
Response1.csv 
Response2.csv 
Response32.csv 
Response33.csv 
Response34.csv 
Response35.csv 
Response36.csv 
Response37.csv 
0
1
=Yelse
10 =⇒≥ YX
 
Response3.csv 
Response4.csv 
0
167.067.0 1
=
=⇒≤≤−
Yelse
YX
 
Response5.csv 
Response6.csv 
Response17.csv 
Response18.csv 
0
021
=
⇒≥+
Yelse
XX 1=Y
 
Response7.csv 
Response8.csv 
Response19.csv 
Response20.csv 
0
19521
=
=⇒
Yelse
Y.0≤95.0 +≤− XX
 
Response9.csv 
Response10.csv 
Response21.csv 
Response22.csv 
0
1021
=
=⇒≥⋅
Yelse
YXX
 
Response11.csv 
Response12.csv 
Response23.csv 
Response24.csv 
0
14.04.0 21
=
=⇒≤⋅≤−
Yelse
YXX
 
Response13.csv 
Response14.csv 
Response25.csv 
Response26.csv 0
10
2
1
=
=⇒≥
Yelse
Y
X
X
 
Response15.csv 
Response16.csv 
Response27.csv 
Response28.csv 0
111
2
1
=
=⇒≤≤−
Yelse
Y
X
X
 
Response30.csv 
0
11121
=
=⇒≥+
Yelse
YXX
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Response31.csv 
0
110121
=
=⇒≥+
Yelse
YXX
 
Response38.csv 
100510
5011
≤≤=
≤≤=
iifY
iifY
i
i
 
Response105.csv 
Response117.csv 
(N=100) 0
1054321
=
=⇒≥+−−+
Yelse
YXXXXX
 
Response107.csv 
Response119.csv 
(N=100) 0
195.095.0 54321
=
=⇒≤+−−+≤−
Yelse
YXXXXX
 
Response109.csv 
Response121.csv 
(N=100) 0
1054321
=
=⇒≥⋅⋅⋅⋅
Yelse
YXXXXX
 
Response111.csv 
Response123.csv 
(N=100) 0
14.04.0 54321
=
=⇒≤⋅⋅⋅⋅≤−
Yelse
YXXXXX
 
Response113.csv 
Response125.csv 
(N=100) 
0
10
543
21
=
=⇒≥+−
+
Yelse
Y
XXX
XX
 
Response115.csv 
Response127.csv 
(N=100) 
0
111
543
21
=
=⇒≤+−
+≤−
Yelse
Y
XXX
XX
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Appendix 7: Simulation study – phase 2 tasks 
 
Below are tables showing the various tasks performed in phase 2 together with 
file names explained below. 
 
Run Gene file name z-score 
standardized 
data 
Response file 
name 
Number of 
contributing 
variables 
Data 
size  
Inclusion 
criteria 
Gene-gene 
interaction 
1 allcombined_z.csv Yes Response1.csv 1 263 Threshold - 
2 allcombined_z.csv Yes Response2.csv 1 263 Interval - 
3 allcombined_z.csv Yes Response3.csv 2 263 Threshold Sum 
4 allcombined_z.csv Yes Response4.csv 2 263 Interval Sum 
5 allcombined_z.csv Yes Response5.csv 2 263 Threshold Product 
6 allcombined_z.csv Yes Response6.csv 2 263 Interval Product 
7 allcombined_z.csv Yes Response7.csv 2 263 Threshold Ratio 
8 allcombined_z.csv Yes Response8.csv 2 263 Interval Ratio 
9 allcombined_z.csv Yes Response9.csv 5 263 Threshold Sum 
10 allcombined_z.csv Yes Response10.csv 5 263 Interval Sum 
11 allcombined_z.csv Yes Response11.csv 5 263 Threshold Product 
12 allcombined_z.csv Yes Response12.csv 5 263 Interval Product 
13 allcombined_z.csv Yes Response13.csv 5 263 Threshold Ratio 
14 allcombined_z.csv Yes Response14.csv 5 263 Interval Ratio 
 
 
 
Separate studies 
 
Random y 
 
Run Gene file name z-score 
standardized 
data 
Response file 
name 
Number of 
contributing 
variables 
Data 
size  
Inclusion 
criteria 
Gene-gene 
interaction 
15 allcombined_z.csv Yes Response15.csv 0 263 - - 
 
 
Fraction of data points being classified as Y = 1 
 
Run Gene file name z-score 
standardized 
data 
Response file 
name 
Number of 
contributing 
variables 
Special 
feature 
Data 
size  
Inclusion 
criteria 
16 allcombined_z.csv Yes Response16.csv 1 05.0100
}{# 11 =≥αX  263 Threshold 
17 allcombined_z.csv Yes Response17.csv 1 20.0100
}{# 21 =≥αX  263 Threshold 
18 allcombined_z.csv Yes Response18.csv 1 50.0100
}{# 31 =≥αX  263 Threshold 
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Actual data 
 
Run Gene file name z-
score 
data 
Response file 
name 
Number of 
contributing 
variables 
Special 
feature 
Data 
size  
Inclusion 
criteria 
Gene-
gene 
interaction 
19 allcombined.csv No Response19.csv 2 Different 
magnitudes 
263 Threshold Sum 
20 allcombined.csv No Response20.csv 2 Equal 
magnitudes 
263 Threshold Sum 
21 allcombined.csv No Response21.csv 2 Different 
magnitudes 
263 Threshold Ratio 
22 allcombined.csv No Response22.csv 2 Equal 
magnitudes 
263 Threshold Ratio 
23 allcombined.csv No Response23.csv 2 Different 
magnitudes 
263 Threshold Product 
24 allcombined.csv No Response24.csv 2 Equal 
magnitudes 
263 Threshold Product 
25 allcombined.csv No Response25.csv 2 Different 
magnitudes 
263 Interval Sum 
26 allcombined.csv No Response26.csv 2 Equal 
magnitudes 
263 Interval Sum 
 
 
3 groups/classes 
 
Run Gene file name z-score 
standardized 
data 
Response file 
name 
Number of 
contributing 
variables 
Data 
size  
Inclusion 
criteria 
Gene-gene 
interaction 
27 allcombined.csv Yes Response27.csv 1 263 Interval - 
28 allcombined.csv Yes Response28.csv 2 263 Interval Sum 
29 allcombined.csv Yes Response29.csv 2 263 Interval Ratio 
30 allcombined.csv Yes Response30.csv 2 263 Interval Product 
31 allcombined.csv Yes Response31.csv 5 263 Interval Sum 
32 allcombined.csv Yes Response32.csv 5 263 Interval Ratio 
33 allcombined.csv Yes Response33.csv 5 263 Interval Product 
 
 
Overview of gene files 
 
Gene file name Description  
allcombined_z.csv Data set consisting of DC+SH ABS + BP + PTSD controls + PTSD acute, 7 
HKG, 25 genes; z-score standardized data; N=263 (variables in columns, 
samples in rows) 
allcombined.csv Data set consisting of DC+SH ABS + BP + PTSD controls + PTSD acute, 7 
HKG, 25 genes; N=263 (variables in columns, samples in rows) 
 
Overview of response files 
 
Response file name Inclusion criteria 
Response1.csv 
 0,101 ==⇒≥ YelseYX  
Response2.csv 
 0,167.067.0 1 ==⇒≤≤− YelseYX  
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Response3.csv 
 0,1032 ==⇒≥+ YelseYXX  
Response4.csv 
 0,195.095.0 32 ==⇒≤+≤− YelseYXX  
Response5.csv 
 0,1054 ==⇒≥⋅ YelseYXX  
Response6.csv 
0,14.04.0 54 ==⇒≤⋅≤− YelseYXX  
Response7.csv 
 0,10
7
6 ==⇒≥ YelseY
X
X
 
Response8.csv 
 0,111
7
6 ==⇒≤≤− YelseY
X
X
 
Response9.csv 
0,1012111098 ==⇒≥+−−+ YelseYXXXXX  
Response10.csv 
 0,195.095.0 12111098 ==⇒≤+−−+≤− YelseYXXXXX  
Response11.csv 
 0,101716151413 ==⇒≥⋅⋅⋅⋅ YelseYXXXXX  
Response12.csv 
 0,14.04.0 1716151413 ==⇒≤⋅⋅⋅⋅≤− YelseYXXXXX  
Response13.csv 
 0,10
222120
1918 ==⇒≥+−
+
YelseY
XXX
XX
 
Response14.csv 
 0,111
222120
1918 ==⇒≤+−
+≤− YelseY
XXX
XX
 
Response15.csv Random y; no combination of any variables 
Response16.csv 05.0100
}{# 11 =≥αX )(.*7.1 11 Xdevst=, α  which yields ~ 5% Y=1 
Response17.csv 20.0100
}{# 21 =≥αX )(.*8.0 12 Xdevst=, α  which yields ~ 20% Y=1 
Response18.csv 50.0100
}{# 31 =≥αX )(.*15.0 13 Xdevst, −=α  which yields ~ 50% Y=1 
Response19.csv 
0=Y,1= elseY))()(( 24232423 ⇒+≥+ XXXX μμ .  
NB! X23 ≈ 150*X24 
Response20.csv 
0,1))()(( 25242524 ==⇒+≥+ YelseYXXXX μμ .  
NB! X24 ≈ X25 
Response21.csv 
0,1
)(
)(
24
23
24
23 ==⇒≥ YelseY
X
X
X
X
μ
μ
.  
NB! X23 ≈ 150*X24 
Response22.csv 
0,1
)(
)(
25
24
25
24 ==⇒≥ YelseY
X
X
X
X
μ
μ
.  
NB! X24 ≈ X25 
Response23.csv 
0,1)()( 24232423 ==⇒⋅≥⋅ YelseYXXXX μμ  
NB! X23 ≈ 150*X24 
Response24.csv 
0,1)()( 25242524 ==⇒⋅≥⋅ YelseYXXXX μμ .  
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NB! X24 ≈ X25 
Response25.csv 
0,1))()((5.1))()((5.0 242324232423 ==⇒+⋅≤+≤+⋅ YelseYXXXXXX μμμμ .  
NB! X23 ≈ 150*X24 
Response26.csv 
0,1))()((5.1))()((5.0 252425242524 ==⇒+⋅≤+≤+⋅ YelseYXXXXXX μμμμ  
NB! X24 ≈ X25 
Response27.csv 
0,25.0,15.0 11 ==⇒≥=⇒−≤ YelseYXYX  
Response28.csv 
0,21,11 2121 ==⇒⋅≥+=⇒−≤+ YelseYXXYXX  
Response29.csv 
0,275.0,175.0
4
3
4
3 ==⇒≥=⇒−≤ YelseY
X
X
Y
X
X
 
Response30.csv 
0,225.0,125.0 6565 ==⇒≥⋅=⇒−≤⋅ YelseYXXYXX  
Response31.csv 
0
25.0,15.0 11109871110987
=
=⇒≥+−−+=⇒−≤+−−+
Yelse
YXXXXXYXXXXX
 
Response32.csv 
0
275.0
,175.0
161514
1312
161514
1312
=
=⇒≥+−
+
=⇒−≤+−
+
Yelse
Y
XXX
XX
Y
XXX
XX
 
Response33.csv 
0
205.0
,105.0
2120191817
2120191817
=
=⇒≥⋅⋅⋅⋅
=⇒≤⋅⋅⋅⋅
Yelse
YXXXXX
YXXXXX
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Appendix 8: BD associated genes according to WTCC and Baum 
 
In the table below, the 68 genes putatively associated with BD according to the WTCC study 
and according to the Baum article, are listed. 
AK3L1 DTNBP1 LOC283547 SOX5 
AK3L2 EARS2 LOC730018 SVEP1 
AKAP10 ERN2 LOC731264 SYK 
AOF1 ESRRG LOC731914 SYN3 
BDNF FAM126A LRRC7 SYNE1 
C14orf58 GABRB1 MYH9 TBC1D21 
CAPN6 GALNTL4 NDUFAB1 TDRD9 
CDC25B GGA2 NPAS3 THRB 
CMTM8 GRIK2 NRG1 THSD7A 
COG7 GRIN2B NXN TRDN 
CSF2RB GRM3 PALB2 UBPH/UBFD1
DAOA GRM4 PAX5 VGCNL1 
DCTN5 GRM7 PLK1 ZBTB44 
DFNB31 KCNC2 PTPRE ZNF274 
DGKH KCNQ3 PTPRG ZNF490 
DISC1 KLHDC1 RNPEPL1 ZNF659 
DPP10 LAMP3 SORCS2 ZNF678 
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Appendix 9: Gene ratios 
 
In the table below, 97 gene ratios are listed. They are formed partly on a biological basis, 
partly on a data driven basis; high (>0.8) and low (<0.3) Spearman correlations.  
Ratio 1 IDO/SERT Ratio 49 ERK1/ERK2 
Ratio 2 ERK1/MAPK8 Ratio 50 ARRB1/MAPK8 
Ratio 3 ERK1/MAPK14 Ratio 51 ARRB1/P2X7 
Ratio 4 ERK2/MAPK8 Ratio 52 MAPK14/IL-1 beta 
Ratio 5 ERK2/MAPK14 Ratio 53 PREP/SA100A10 
Ratio 6 (ERK1+2)/MAPK8 Ratio 54 S100A10/P2X7 
Ratio 7 (ERK1+2)/MAPK14 Ratio 55 ERK1/ARRB1 
Ratio 8 (ERK1+2)/(MAPK8+MAPK14) Ratio 56 CREB/ERK1 
Ratio 9 ERK1/(MAPK8+MAPK14) Ratio 57 CREB/PREP 
Ratio 10 ERK2/(MAPK8+MAPK14) Ratio 58 GR/RGS2 
Ratio 11 Gi2/ARRB1 Ratio 59 ARRB1/S100A10 
Ratio 12 Gi2/ARRB2 Ratio 60 CREB2/MAPK8 
Ratio 13 Gs/ARRB1 Ratio 61 CREB2/S100A10 
Ratio 14 Gs/ARRB2 Ratio 62 ERK1/GR 
Ratio 15 (Gi2+Gs)/ARRB1 Ratio 63 GR/MAPK8 
Ratio 16 (Gi2+Gs)/ARRB2 Ratio 64 MAPK8/MR 
Ratio 17 (Gi2+Gs)/(ARRB1+ARRB2) Ratio 65 ERK2/ARRB1 
Ratio 18 Gi2/(ARRB1+ARRB2) Ratio 66 CREB/MR 
Ratio 19 Gs/(ARRB1+ARRB2) Ratio 67 MAPK8/S100A10 
Ratio 20 Gi2/CREB Ratio 68 MR/PREP 
Ratio 21 Gi2/CREB2 Ratio 69 ARRB2/IL-1 beta 
Ratio 22 Gs/CREB Ratio 70 ERK2/RGS2 
Ratio 23 Gs/CREB2 Ratio 71 MAPK8/PREP 
Ratio 24 (Gi2+Gs)/CREB Ratio 72 MKP1/RGS2 
Ratio 25 (Gi2+Gs)/CREB2 Ratio 73 RGS2/IL-1 beta 
Ratio 26 (Gi2+Gs)/(CREB+CREB2) Ratio 74 ARRB1/GR 
Ratio 27 Gi2/(CREB+CREB2) Ratio 75 IL-8/ADA 
Ratio 28 Gs/(CREB+CREB2) Ratio 76 PBR/IL-6 
Ratio 29 Gi2/RGS2 Ratio 77 ODC1/PBR 
Ratio 30 Gs/RGS2 Ratio 78 IL-8/IDO 
Ratio 31 (Gi2+Gs)/RGS2 Ratio 79 IL-8/SERT 
Ratio 32 Gi2/Gs Ratio 80 IL-8/IL-6 
Ratio 33 GR/MR Ratio 81 IDO/IL-6 
Ratio 34 MKP1/(ERK1+ERK2+MAPK8+MAPK14) Ratio 82 IL-8/MR 
Ratio 35 MKP1/(ERK1+ERK2) Ratio 83 MPK1/ADA 
Ratio 36 MKP1/(MAPK8+MAPK14) Ratio 84 IL-8/ODC1 
Ratio 37 MKP1/ERK1 Ratio 85 IL-8/CD8 alpha 
Ratio 38 MKP1/ERK2 Ratio 86 PBR/SERT 
Ratio 39 MKP1/MAPK8 Ratio 87 IL-8/MAPK14 
Ratio 40 MKP1/MAPK14 Ratio 88 IL-8/PREP 
Ratio 41 ERK2/Gi2 Ratio 89 IL-8/CD8 beta 
Ratio 42 ERK1/Gi2 Ratio 90 SERT/IL-6 
Ratio 43 CREB/ARRB2 Ratio 91 ADA/ODC1 
Ratio 44 ERK2/GR Ratio 92 CREB2/IL-8 
Ratio 45 Gi2/GR Ratio 93 RGS2/ADA 
Ratio 46 PREP/P2X7 Ratio 94 Gs/IL-8 
Ratio 47 ERK2/Gs Ratio 95 ODC1/IL-6 
Ratio 48 ARRB2/ERK1 Ratio 96 CD8 beta/PBR 
  Ratio 97 ODC1/CD8 alpha 
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Appendix 10: Summary ABS controls and DC controls 
 
The table below was created by Joseph Tamm based on the statistical analysis, I did in section 7.3.1, and based on visual trends 
noted with the graphical software Spotfire. An explanation is given after the table.  
 Correlation between clinical variables and gene expression in two control groups (ABS and DC)   
ABS subjects                
DC subjects                
  CREB2 DPP4 ERK1 ERK2 GR Gs MAPK8 MAPK14 MKP1 MR PBR RGS2 S100A10 SERT VMAT2 
Family History (D/A/S)   Inc **         Inc **                 
Family History (D/A/S)                               
                                
Tobacco use                           Dec ***   
Tobacco use                           trend down   
                                
Lifetime experiences (D/A) Inc *** Inc ***   Inc ** Inc ***   Inc ***         Inc **     Inc ** 
Lifetime experiences (D/A)   Inc ***     trend up             trend up       
                                
Lifetime treatments (D/A) Inc ** Inc ***     Inc **   Inc ***   Inc **             
Lifetime treatments (D/A)         trend up Inc **     trend up             
                                
Appetite Change   Inc **                       Dec **   
Appetite Change                           trend down   
                                
Sleep Problems   Inc **                           
Sleep Problems   Inc **                           
                                
10 Symptom score (*)   Inc ***         Inc ***   trend up   Dec **         
10 Symptom score (*)     Inc ** Inc ***         Inc **   Inc **         
                                
Vegetative symptoms   Inc **                           
Vegetative symptoms                               
                                
Recent stress   Inc **                           
Recent stress                               
                                
Appendices 
Early life stress                               
Early life stress                         Inc ***     
                                
Interest in sex         Inc **           trend down         
Interest in sex               Inc **   Dec ** Inc **         
D/A/S = Depression / Anxiety / Suicide 
** indicates importance on the 1% significance level, while *** indicates importance on the 0.1% significance level. 
(*) The 10 symptom score is as close to the symptom score sum in the ABS controls as possible. The scores were then binned into 
two bins based on a threshold value of 25. 
 
Important points to keep in mind regarding the table: 
A) Sometimes there are few subjects in groups, especially in the DC data set.  
B) Neither the questions nor the questionnaires were the same in the two studies.   
 
Joseph did the following: 
1) Using mine univariate analyses on ABS and DC subjects, he noted which combinations of genes and variables produced a p value 
< 0.01. To keep the table manageable in size (for viewing), he omitted all of the genes and variables where nothing interesting was 
happening. 
 
2) Next he looked in Spotfire to see if the statistical results made sense (a believable pattern). Most of the time they did, but if not, 
he excluded that combination. He also noted if gene expression increased or decreased with the variable in question. 
 
3) Whenever a gene/variable combination in ABS produced a significant p value, but DC did not, he looked at the DC scatter plot to 
see if there was a trend toward the ABS result. Likewise, if DC had a significant p value but ABS did not, he looked at the ABS data 
to see if there was a similar trend. This was the most subjective part of the process. 
 
4) In the table, whenever ABS and DC produced the same results for a gene/variable combination, he colored the cells green. Thus, 
DPP4 expression increases in both control groups when people have any lifetime experiences of depression/anxiety. Whenever the 
control groups produced clearly opposite results, he colored the cells red (see PBR). Whenever only one control group produced a 
significant change (for example DPP4 and family history), he colored the cells orange.  
 
Results:  
The table reflects results for 377 combinations of gene expression / question response. 
That's 13 questions (includes age and BMI which are not shown) times 29 genes = 377 
 
23 combinations yield different results for ABS vs DC (2 are red and 21 are orange) …so 6% of the combinations produce 
differences. 9 combinations display changes in the same direction in both subject groups (green). 345 combinations are unchanged 
in both groups … 9+345=354 … so 94% of the combinations produce the same pattern. 
Therefore, DC and ABS are showing very similar expression trends. 
 
201 
